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Abstract
Expression of chemokines CXCL10 and CCL2 is elevated within inflammatory 
lesions in the central nervous system (CNS) of multiple sclerosis (MS) patients, 
particularly in astrocytes. These chemokines play a critical role in the recruit­
ment of inflammatory cells into the CNS during inflammation. However, the 
cerebrospinal fluid of MS patients also shows high levels of CXCL10  a t the time 
of relapse but by contrast CCL2 is decreased. In the present study, the mecha­
nisms controlling the synthesis and release of these two chemokines in MS were 
assessed in vitro using primary human brain astrocytes isolated from MS and 
non-MS individuals.
Pro-inflammatory cytokines (interleukin -1/3 , tum our necrosis factor and interferon- 
7 ) increased the expression of both CCL2  and CXCL10 by astrocytes at the 
mRNA and protein level, as determined by real time PC R  and enzyme linked 
immunosorbent assays (ELISA), respectively. CCL2 binding to astrocytes was 
then determined to evaluate any autocrine action on astrocytes in a single astro­
cyte preparation. CCL2 bound constitutively and following cytokine treatm ent. 
CCL2-binding was not the result of the interaction with its receptor since astro­
cytes did not express CCR2 on this astrocyte culture. CCR2-independent binding 
of CCL2 was confirmed by the absence of intracellular signalling, evidenced by the 
lack of calcium influx as well as of Erk and Akt phosphorylation, in CCL2-treated 
astrocytes. Even though astrocytes expressed CXCR3, similar negative results on 
calcium influx and downstream signalling pathways were observed for CXCL10. 
D6  chemokine decoy receptor expression was then assessed in vitro and in situ 
to further investigate the mechanism(s) of chemokine binding to astrocytes. Cul­
tured astrocytes constitutively expressed the D 6  decoy receptor a t the mRNA and 
protein level, bu t levels were unchanged following cytokine treatm ent. D 6  was ex­
pressed in situ in MS normal appearing white m atter and in control brain tissue, 
at both  the mRNA and protein level. D6  expression was detected on neurons 
and microglia bu t not astrocytes using imunohistochemical methods. Incubation 
of frozen brain sections with biotinylated CCL2  resulted in partial co-localisation 
with D6  staining.
Altogether, these results suggest a role for astrocytes in regulating inflamma­
tion through synthesis and secretion of CCL2 and CXCL10. Subsequently, CCL2 
binding to  astrocytes, either by binding to D6 decoy receptor or by alternative 
mechanisms, may establish a chemokine gradient in the CNS, and direct the mi­
gration of leukocytes.
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CHAPTER 1
Introduction
1.1 Central nervous system  (CNS) overview
1.1.1 O rganisation of the CNS
The central nervous system (CNS), composed of the brain and spinal cord, con­
trols the human body by interpreting information involved in different functions 
such as thinking, movement, learning, memory. The CNS is composed of different 
cell types: neurons, neuroglial cells (oligodendrocytes, microglia, and astrocytes), 
endothelial cells, pericytes, smooth muscle cells, ependymal cells. [Purves et al., 
2001].
1.1.1.1 Neurons
Neurons are both  the structural and functional units of the CNS. They enable 
the transmission of different signals to all parts of the body in response to  external 
stimuli. The ability of neurons to propagate signals all over the body lies on the 
existence of supporting cells called neuroglia.
1.1.1.2 Oligodendrocytes
Oligodendrocytes are small cells with many processes th a t produce a myelin 
sheath which surrounds nerve fibress. This myelin sheath plays an im portant role
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in the transmission of signals along the axon. I t acts as an insulating sheath and 
prevents ion exchange with the outside environment, which is necessary for the 
propagation of the nerve signal [Simons and Trotter, 2007]. There are gaps be­
tween two myelin sheaths known as the Nodes of Ranvier where ion exchange takes 
place to create depolarization, necessary for nerve signal propagation: the action 
potential. The action potential at one node is sufficient to  excite a response at the 
next node, so the nerve signal can propagate faster by these discrete jum ps rather 
than  the continuous propagation of depolarization/repolarization along the mem­
brane. This enhanced signal transmission is called saltatory conduction [Hartline 
and Colman, 2007]. The myelin sheath also provides a supportive framework and 
provides nutrients for the neurons. One oligodendrocyte is able to produce myelin 
sheaths to  several neurons [Purves et al., 2001].
1.1.1.3 Microglia
Microglia, the resident macrophages of the brain, are the smallest neuroglia 
cells and account for approximatively 20% of the glia cells in the brain [Kreutzberg, 
1995]. They represent the main cell type th a t provide immuno-surveillance to  the 
CNS [Kreutzberg, 1996].
Activation of microglia cells following injury is a graded process in response to 
injury by:
•  changing their morphological phenotype
• increasing m igratory activity
•  proliferating
•  secreting chemokines, proteases and others inflammatory mediators
•  presenting antigen
These responses are responsible for the clearance of toxic molecules released by 
damaged and dying neurons and other cell types in the CNS [Bohatschek et al., 
2001, Carson et al., 1998, Raivich et al., 1999]. W hen microglia are activated
in a number of CNS diseases, they express increased levels of MHC II molecules 
[Minagar et al., 2002] which can, during inflammation, activate lymphocytes and 
produce pro-inflammatory mediators th a t could exert a damaging or a protective 
effect on adjacent axons, myelin and oligodendrocytes [Raivich and Banati, 2004, 
Carson, 2 0 0 2 ].
1.1.1.4 Astrocytes
Astrocytes are the most abundant glial cells within the brain and represent 
one th ird  of the mass of the brain [Kandel, 1991]. Two different types of astro­
cytes have been observed depending on their localization in the CNS and their 
antigenic profile and function [Holley et al., 2003]. Type 1 astrocytes or fibrous 
astrocytes are localized in the white m atter and are in contact w ith myelinating 
axons [Karasek et al., 2004]. They have a star-shape with cytoplasmic exten­
sions th a t surround most of the synapses within the CNS. Astrocytes express glial 
acidic fibrillary protein (GFAP), an astrocytic marker, which is a component of 
the cytoskeleton, defining and maintaining the shape of the astrocyte [Eng, 1985]. 
Astrocytes also express S100/?, a calcium-binding astrocytic protein [Ridet et al., 
1997]. Type 2 astrocytes or protoplasmic astrocytes are localized in the grey m at­
ter and surround the node of Ranvier. It is characterised by S100/3 staining and 
a variable GFAP staining [Mi and Barres, 1999, Karasek et al., 2004]. For many 
years, astrocytes have been considered to have limited function within the CNS. 
However they are involved in the development on the CNS (synapse formation), 
the formation and maintenance of the blood brain barrier, support of neurons, 
regulation of neurotransm itters, hormones and homeostasis, and communication 
with other cells as discussed below.
Development of the CNS:
Astrocytes have been recently shown to have active control of synaptogenesis. It 
was assumed for a long time th a t neurons were the only player in synapse forma­
tion [Scheiffele, 2003]. However, it has been shown th a t there is a delay between 
the arrival of neurons in the CNS and synapse formation which corresponds to 
the tim e in which astrocytes develop, suggesting the involvement of astrocytes in 
synaptogenesis [Pfrieger and Barres, 1997]. Direct evidence was obtained in vitro. 
Using retinal ganglion cells (RGCs) in culture, it was dem onstrated th a t there 
is a 7 fold increase in synapse formation in the presence of astrocytes, and the 
synapses were functional [Nagler et al., 2001, Ullian et al., 2001].
Astrocytes are involved in the differentiation of stem cells into neurons [Song 
et al., 2002]. Enriched cultures of neurons from the hippocampus were prepared 
and it was shown th a t adult neural stem cells cultured with astrocytes signifi­
cantly increased the number of neurons by 1 0  fold compared to  the control (stem 
cells plated on laminin-coated substrate). Therefore astrocytes are sufficient to 
induce neurogenesis [Song et al., 2002].
Formation of the blood brain barrier (BBB):
One of the special feature of the CNS is the lim itation of immune response to 
prevent accidental inflammation, which might be deleterious for the whole organ­
ism. The CNS is separated from the blood by the blood brain barrier, which is 
composed of three elements: endothelial cells, pericytes and astrocytes (figure 1 .1 ) 
[Correale and Villa, 2007]. Endothelial cells form a continuous layer by forming 
tight junctions and adherens junctions between adjacent endothelial cells (ECs). 
ECs are thus tightly held together to form a barrier separating the blood from 
the CNS [Ballabh et al., 2004]. BBB selectively blocks toxic molecules, drugs 
and infectious agents, to protect the brain [Ballabh et al., 2004]. Paul Erlich in 
the early 1900s was the first to show the properties of the BBB by intravenous 
injection of vital dyes leading to the staining of almost the entire body except the
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Fig. 1.1: S ch em a tic  r e p re s e n ta t io n  o f th e  s t r u c tu r e  o f th e  B B B .
ECs, held together by adherens and tight junctions are wrapped by pericytes 
and astrocyte end-feet to form a physically impermeable barrier (taken from 
http: /  /  www.medicalook.com/hmnan_ anatomy /  organs/Blood_brain_ barrier.htm l).
10
brain. However, the BBB is not fully impermeable and allows the influx or 
efflux of molecules through transporters for normal brain function. For instance, 
the BBB allows the transport, from the blood to the CNS of glucose and large 
amino acids such as leucine via Glut-1 transporter and L-system carrier LI, re­
spectively [Abbott, 2002]. Pericytes (PCs) are cells of microvessels th a t wrap 
around the endothelial cells on the CNS side of the BBB [Lai and Kuo, 2005]. 
They are the least-studied component from the BBB but appear to  play a reg­
ulatory role in brain angiogenesis, endothelial cell tight junction formation, and 
blood-brain barrier differentiation [Balabanov and Dore-Duffy, 1998, Dore-Duffy 
et al., 1993, Lindahl et al., 1997, Ramsauer et al., 2002], as well as contributing to 
the microvascular vasodynamic capacity and structural stability [Bandopadhyay 
et al., 2001, Rucker et al., 2000].
Astrocytes form an integral part of the BBB by covering more than  90% of the 
BBB with end-feet to form a lacework of fine lamellae around the endothelial 
cells. This close contact is im portant for the induction and the maintenance of 
the BBB. In vivo experiments have shown th a t im plantation of astrocytes into an 
area with normally leaky vessels induces tightening of the endothelium, highlight­
ing the role of astrocytes in the induction of the BBB properties [Hayashi et al., 
1997, Kuchler-Bopp et al., 1999, Hurwitz et al., 1993].
Regulation of neurotransmitters and hormones:
Astrocytes not only have supportive and structural functions bu t also act as mod­
ulators of function by regulating glutam ate concentration a t the synapse, to  reg­
ulate neurotransmission. G lutam ate is a strong excitatory amino acid in the 
brain and is cleared from the synapse by two transporters [Simard and Neder- 
gaard, 2004]. G lutam ate transporter 1 (GLT1 also called EAAT2) and the Na+- 
dependent g lu tam ate/aspartate  transporter (GLAST also called excitatory amino 
acid transporter 1 or EAAT1) are highly expressed in the astrocytic processes 
highlighting the ability of astrocytes to take up glutam ate from the extracellular 
milieu [Rauen et al., 1998, Rothstein et al., 1996, Anderson and Swanson, 2000]. 
GLAST acts as a water channel and is involved in the regulation of water in the
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CNS [MacAulay et al., 2002]. GLT1 appears to limit oedema, resulting from is­
chemia, w ithin the brain [Namura et ah, 2002].
Astrocytes also induce the release of neuropeptides such as atrial natriuretic 
peptide (ANP) which appears to regulate the fluid and ionic environment in the 
CNS [Krzan et al., 2003]. Astrocytes have also been shown respond to  neuroactive 
molecules released by neurons such as histamine and acetylcholine [Shelton and 
McCarthy, 2000]. The fact th a t astrocytes release these gliotransm itters, modu­
late the synaptic transmission and respond to neuroactive molecules has led to the 
concept of the tripartite  synapse and highlight the preponderant role of astrocytes 
as a regulator of neuronal function but also the bi-directional signalling between 
neurons and astrocytes [Perea and Araque, 2005].
Support of neurons:
Considering the position of astrocytes in the CNS and the metabolism of astro­
cytes, it is not surprising to see th a t astrocytes provide support to  the axon. As 
previously said, the transporter EAAT1 and 2 are able to  take up glutam ate from 
the synapse, which is converted into glutamine, under the action of glutamine 
synthase. Glutamine is released into the synaptic com partm ent where it is used 
by neurons as a source of energy [Anderson and Swanson, 2000, McKenna, 2007]. 
Astrocytes, which are in close contact with the capillaries in the brain, possess 
high numbers of glucose transporters 1 a t the end-feet processes and are capable 
of glycolysis and oxidation of glucose, the main source of energy within the brain. 
I t was thought th a t glucose was the only source of energy for neurons obtained 
from the extracellular compartment by the cerebral circulation. However, it has 
been proposed th a t neurons can use lactate by oxidation as a source of energy 
[Bouzier-Sore et al., 2006]. They also showed th a t neurons preferentially use lac­
ta te  as their main oxidative substrate. In astrocytes, glucose is converted into 
lactate by an oxidative pathway before uptake by neurons, via a specific moncar- 
boxylate transporter present on neurons
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As well as providing energy for neurons, astrocytes also produce neurotrophic 
factors including nerve growth factor (NGF) or basic fibroblast growth factor 
(bFGF) th a t promote neuronal development, differentiation and survival [Kale- 
hua et al., 2004].
Regulation of homeostasis
Astrocytes are involved in the regulation of ion concentration (including K+ , Na+, 
C l") in the extracellular com partment in the CNS th a t enables normal neuronal 
function.
To control the K+ concentration in the extracellular com partm ent, astrocytes take 
up K+ by:
•  inward rectifying channels
•  Na+/K + pump
• K+/N a +/C l“ co transporter [Simard and Nedergaard, 2004].
Astrocytes are able to  redistribute intracellular K+ via gap junctions th a t connect 
astrocytes and to regulate intracellular K+ via outward rectifying channels (Kir 
4.1, rSloKCa, Kv 1.5) th a t expel K+ into the perivascular space. They are ex­
pressed on the end-feet th a t surround synapses and blood vessels [Higashi et al., 
2001, Price et al., 2002, Roy et al., 1996].
Na+ is taken up by:
•  the co transporter Na+K+2C1-
• 2Na+/C a 2+ exchanger
•  H+/N a+ antiport.
Efflux of Na+ is controlled by Na+/K + pump and the 2Na+/C a 2+ exchanger 
[Simard and Nedergaard, 2004].
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The concentration of Cl-  is controlled by influx of Cl-  by inward rectifying 
channels, co transporter Na+K+2C1“ and C1” /H C 0 3  " exchanger. Cl-  can be 
extruded by outward rectifying anion currents [Simard and Nedergaard, 2004]. 
Therefore astrocytes play an im portant role in the regulation of neuronal activity 
by regulating ion homeostasis at the synapse.
To conclude on the role of astrocytes, in vitro and in vivo studies have shown 
th a t astrocytes have a more complex role in the CNS than  just a structural role. 
They are also involved in the development, maintenance and function of the CNS.
1.2 M ultiple Sclerosis (MS)
1.2.1 D efin ition
MS is an inflammatory autoimmune disease th a t mainly affects the white m at­
ter of the CNS. It is classified as a putative autoimmune disease due to the accu­
mulation of immunological cells, autoreactive T-lymphocytes and monocytes, in 
the CNS. These cells specifically attack the myelin sheath resulting in inflamma­
tion and demyelination leading to plaque formation and axonal damage. These 
plaques impair nerve transmission to muscles and other organs, rendering them  
unable to carry out their normal function [Minagar et al., 2004].
1.2.2 E pidem iology
MS can be diagnosed at any age but is most commonly diagnosed in people 
between 20 to  40 years old [Sospedra and M artin, 2005]. In the UK, the incidence 
of MS is 1:1000 and affects more women than  men with a ratio of 3:2 [Alonso et 
al. 2007]. Many studies have shown th a t MS is not present a t the same incidence 
all over the world [Kurtzke, 1977]. It can be seen on the world map (figure 1.2) 
th a t MS is indeed highly prevalent in Northern Europe (UK, Germany and Scan­
dinavia), N orth America, Australia and New Zealand (between 60-200/100,000)
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compared to low risk areas such as Japan (6-20/100,000). This suggests tha t the 
disease seems to  be preferentially present in the western tem perate latitudes. In 
comparison, Eastern regions and regions below 40° and above 60° latitude are not 
affected by the disease at the same rate [Kurtzke, 1977].
1.2.3 Cause of MS
This specific distribution of MS in the world has not be fully explained, how­
ever various factors including environmental factors e.g. infections, diet and sun 
exposure levels as well as genetic component or a combination of both have been 
implicated.
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Fig. 1.2: G eo g ra p h ic a l d is t r ib u t io n  o f M S.
MS is highly prevalent in Northern Europe (UK, Germany and Scandinavia), 
North America, Australia and New Zealand. The high prevalence is represented 
by purple colour whereas medium, low and unknown prevalence are represented 
by violet, blue and white colours respectively. This means tha t the disease seems 
to be preferentially present in the western tem perate latitudes (obtained from 
http://w w w .liendess.net/grf/m s_w elt_06_e.gif).
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1.2.3.1 Diet
I t has been shown th a t the prevalence of MS is reduced where environmental 
supplies of vitam in D are higher. It is well known th a t the active hormonal form 
of vitam in D (1,25-dihydroxyvitamin D) is a natural immunoregulator with anti­
inflammatory effects. Vitamin D seems to reduce the risk of developing MS by 
about 40% and reduce the exacerbation of the disease [Brown, 2006].
Direct evidence using an animal model of MS, experimental autoimmune en­
cephalomyelitis (EAE) (section 1.3), was obtained by adm inistration of 1,25- 
dihydroxy vitam in D to rats, which resulted in protection and reduction in the 
disease activity. V itamin D deficiency results from insufficient exposure to sun­
light and a low vitam in D 3 diet [VanAmerongen et al., 2004].
1.2.3.2 Viral or bacteria theory
Recently, growing evidence has suggested th a t a viral or bacterial infection 
could explain the incidence of the disease by activating T  cells resulting in so 
called molecular mimicry (see section 1.2.6 .2). It has been shown th a t almost 
100 % of transgenic mice expressing a TC R  th a t is specific for myelin basic pro­
tein (MBP), a component of myelin, developed spontaneous EAE when they were 
housed in a non virus free environment but not in a sterile environment [Gover- 
man et al., 1993].
Among viruses th a t are pathogenic, the human herpes viruses are good candi­
dates and have been widely studied including, human herpes virus 6  (HHV6 ) and 
Epstein-Barr virus (EBV). A study was conducted to  determine the frequency of 
human herpesvirus 6  (HHV-6 ) on autopsy material from 64 MS lesions, 44 normal 
appearing white m atter in CNS of MS patients (NAWM), 41 healthy brains and 
46 brains with other neurological disease [Cermelli et al., 2003], They found tha t 
15.9% of NAWM samples, 21.7% of patients w ith non-MS neurologic disorders and 
26.8% of control patients were positive for HHV- 6  DNA sequences, versus 57.8% 
of MS plaques (P<0.0005). This result was confirmed by a study on NAWM, le-
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sional tissue and normal control brain samples [Opsahl and Kennedy, 2005]. They 
showed th a t bo th  NAWM and lesional tissues presented higher amounts of HHV6 
mRNA and th a t HHV6  mRNA was present on oligodendrocytes by double mRNA 
FISH analysis. Therefore these studies show th a t HHV6  might play a role in the 
pathogenesis of MS.
Relevance of EBV in MS pathogenesis was obtained by looking a t antibody 
directed against EBV in MS patient sera. In a study of 271 patients (108 MS 
patients and 163 healthy patients), anti-EBV antibodies were elevated in patients 
with MS and MS patients reactivate EBV infections more frequently and this cor­
relates w ith a relapse [Wandinger et al., 2000, Hollsberg et al., 2005].
Among bacteria, Chlamydia pneumoniae has been implicated in MS patho­
genesis but this issue is still controversial. Collaborative reports from two lab­
oratories (Vanderbilt University Medical center (VMUC) and the University of 
South Florida (USF)) have shown the presence of C pneumoniae in the CSF of 
MS patients. Indeed they showed th a t the prevalence of C. pneumoniae was 72 
(VMUC) and 61% (USF) in 18 CSF of MS patients, compared to  CSF of 11 pa­
tients with other neurological disorder patients with a prevalence of 7 (VMUC) 
and 16 % (USF) [Sriram et al., 2002]. However, other study failed to  identify any 
association of this bacteria with MS using 70 CSF from MS patients and 30 CSF 
from other neurological disorders [Chatzipanagiotou et al., 2003]. Further work is 
needed to  clearly associate C. pneumoniae w ith MS.
1.2.3.3 Genetics and MS
Genetic involvement in MS is primarily suggested by high risk groups and 
incidence in specific ethnic populations, regardless of the geographic localization 
of the population. For instance, observations have shown th a t MS is mainly a 
disease of Caucasians [Cournu-Rebeix et al., 2001]. Further evidence for a genetic 
aetiology in MS is illustrated by twin study. Concordance rates in twin study are
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higher in monozygotic than  dizygotic twins [Dyment et al., 2004].
To date, the hum an leukocyte antigen (HLA) genes remain the strongest genetic 
factor influencing MS susceptibility. HLA-DRB1*15 has been found to be con­
sistently expressed in the MS population and confers a 2 to 3 fold increase in 
the risk of developing MS [Oksenberg and Barcellos, 2005, Lincoln et al., 2005] 
The exact mechanism whereby HLA DRB1 affects the susceptibility of MS re­
mains unclear bu t it seems th a t it is linked to  the binding/presentation of antigen 
and T  cell repertoire determ ination by negative selection [Stratm ann et al., 2003, 
Wucherpfennig, 2005].
1.2.3.4 Migration studies
M igration studies showed th a t children born to parents immigrating from 
South Africa or West Indies (low prevalence of MS) to the UK have high prevalence 
of MS similar to the general population of England [Elian et al., 1990] highlighting 
the im portance of the environmental factors. It was also shown th a t populations 
migrating before the age of 15 from high risk to  low risk acquired a low risk status 
to develop MS bu t not if there are above 15 [Hammond et al. 2000].
Therefore, whether MS develops in an individual is due to  a combination 
of different factors rather than a unique factor such as genetic predispostion or 
environmental factor i.e. MS is a multifactorial disease.
1.2.4 T im e course of disease
This disease is unusual as people with MS do not follow the same pattern  
of clinical manifestations. Indeed, MS is characterised by a number of disease 
courses (figure 1.3):
•  Relapsing-remitting
•  Secondary progressive
• Prim ary progressive
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1.2.4.1 Relapsing-remitting MS (RR-MS)
This type of disease course is the most common. It is characterised by suc­
cessions of relapse and remission. Relapse is considered as an aggravation of the 
disease in term s of symptoms or degree of disability. I t is followed by a remission 
state th a t corresponds to a complete or partial regression of symptoms. A relapse 
is considered to be more than  24 hours duration and is separated from the previ­
ous relapse by a t least 1 month. Usually the patient recovers completely after the 
first relapse and prolonged symptoms appear after several relapses as the disease 
progresses [Weinshenker, 1994, Hohol et al., 1995].
1.2.4.2 Secondary progressive MS (SP-MS)
RR-MS is usually followed by secondary progressive MS. This is a progressive 
evolution of the disease with increasing neurological disability over tim e [Wein­
shenker, 1994, Hohol et al., 1995]. It is difficult to determine the exact time when 
this second form appears but it seems to correlate with the appearance of active 
inflammatory demyelinating lesions seen on MRI (magnetic resonance imaging) 
[De Stefano et al., 2000].
1.2.4.3 Primary progressive MS (PP-MS)
2 0 % of patients are affected by this form and this corresponds to  a rapid clinical 
decline. No acute attacks or remissions occur in this form of MS. This course is 
the most severe form of MS [Kremenchutzky, 2003]. MRI gadolinium scans show 
th a t PP-MS has less cerebral lesions and fewer lesions per unit of time, compared 
to the SP-MS [Thompson et al., 1991] and th a t in PP-M S the axonal loss is partly 
independent of demyelination [Bitsch et al., 2000] suggesting different pathological 
mechanisms compared to other forms of MS.
20
1.2.5 D iagnosis o f MS
W hen a patient presents with symptoms including fatigue, visual problems 
and depression, neurologists use a variety of tools to confirm the diagnosis [Poser 
and Brinar, 2004].
1.2.5.1 Magnetic resonance imaging (MRI)
Imaging technologies such as MRI are used to  confirm a diagnosis of MS. The 
contrast in MRI is due to the different relaxation times of water protons in different 
environments within the body. Protons with short relaxation times give rise to 
brighter images. In order to enhance the contrast in a magnetic resonance image 
it is sometimes necessary to  administer a ’’contrast agent” which will localise in a 
particular region of the body such as gadolinium (Gd) [Caravan, 2006]. It helps 
to  distinguish new lesions from old lesions on MRI resulting from myelin loss.
1.2.5.2 Visual evoked potentials
Because demyelination of the optical nerve is the most common initial symp­
tom  in MS, the visual evoked potential (VEP) which measures the speed of the 
brain’s response to visual, auditory and sensory stimuli can be helpful for the diag­
nosis of MS, characterised by a delay in the latency of the nerve signal [Weinstock- 
G uttm an et al., 2003].
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Fig. 1.3: T im e  co u rse  o f M S.
Diagram representing the different types of the MS progression modified from 
http://www.chum sweb.org/pics/m s_class.jpg. There are three type of MS: re­
lapsing remitting, secondary progressive and primary progressive MS
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1.2 .5 .3  C S F  an a ly sis
The pa tien t’s cerebrospinal fluid is examined for cellular and chemical abnor­
malities often associated with MS. The rationale underpinning the use of CSF 
testing is the determ ination of whether there is clonal synthesis of immunoglob­
ulin G (IgG) in the CNS com partment (intrathecal synthesis) resulting from the 
disruption of the BBB and the expansion of specific B cells in the CNS resulting 
in the synthesis of IgG. The screening of CSF against cDNA expression phage 
display or random peptide libraries did not show any common antigen recognition 
but showed some reactivity for oligodendrocytes or viruses, although it accounted 
for a minority of bands [Compston and Coles, 2 0 0 2 ].
Using isoelectrofocussing, the presence of a characteristic pattern  called oligoclonal 
bands of immunoglobulin can be identified, which are usually evident in relapsing- 
rem itting MS [Pender, 2005]. Increased CSF cell numbers are also linked to  active 
disease but are not unique to MS.
1.2.6 P athophysiology of the disease
In MS there are different types of lesion with different levels of axonal damage.
1 .2 .6 . 1  D iffe ren t ty p e  o f  lesions in  M S
A c u te  lesions are the precursors of the MS plaque characterized by perivas­
cular infiltration of inflammatory cells (essentially monocytes and lymphocytes), 
oedema, myelin swelling and activation of endothelial cells [Trapp et al., 1999, 
Lassmann, 1998]. These lesions might have variable axonal damage [Lassmann, 
1998, 2003].
C h ro n ic  a c tiv e  lesions are older plaques with areas of active inflammation 
and demyelination usually at the margin of these plaques. They are characterized 
by perivascular lymphocyte infiltration, myelin breakdown leading to decreased 
numbers of oligodendrocytes, phagocytosis of myelin debris by foamy macrophages
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and reactive astrocytosis. Variable axonal damage may be present [Oleszak et al., 
2004].
C h ro n ic  in a c tiv e  p la q u e s  are old plaques sharply delimited from adjacent 
normal appearing white m atter with reactive gliosis, loss of oligodendrocytes, 
variable axonal loss and sometimes persistent immunological cells (monocytes, 
lymphocytes). A th in  rim of perivascular collagenous fibrosis might be present in 
long-standing lesions and there is disruption of the BBB [Oleszak et al., 2004].
S h ad o w  p la q u e s  consist of variable size and delimited plaques with demyeli­
nation and incomplete remyelination surrounding the principal plaque [Oleszak 
et al., 2004].
Although the aetiology of MS is still not fully resolved, many studies have 
focussed on the mechanism of the tissue damage in the disease.
1 .2 .6 .2 In it ia l  s ta g e  o f M S: se lf-reac tiv e  ly m p h o c y te s
The initial stage of the disease is proposed as the activation of self-reactive 
lymphocytes in the lymph node. Two theories have been proposed [Sospedra and 
M artin, 2005]:
E x is te n c e  o f  m y e lin  a u to re a c tiv e  T  ly m p h o c y te s
Self tolerance, a fundamental property of the immune system, is a result-of the 
existence of negative selection of self reactive lymphocytes in the thymus called 
central tolerance and peripheral tolerance, which corresponds to  the incapacity of 
autoreactive T  cells to  be activated. During negative selection, there is intrathym ic 
expression of many tissue-specific antigens from ’’ectopic” or ’’promiscuous” genes, 
which play a m ajor role in determining the antigen repertoire [Klein et al., 2000]. 
Indeed, in the thymus, lymphocytes th a t recognize these antigens, presented by 
the T  cell receptor (TCR) to the MHC class II, are deleted; this is negative se­
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lection. This selection is not complete as it has been shown th a t autoreactive T 
cells are present in the blood of healthy patients [Ota et al., 1990, Wekerle et al., 
1996].
Since both  healthy controls and MS patients show the the presence of autore­
active T  cells which recognised epitopes from MBP (myelin basic protein) and 
PLP (proteolipid protein), 2 m ajor components of myelin [Bielekova et al., 2000, 
von Budingen et al., 2001], then the development of MS is not solely due to  the 
presence of autoreactive T  cells.
Therefore the question is what is the difference between the autoreactive T cells of 
healthy controls and MS patients th a t could explain the incidence of the disease. 
Studies have shown th a t the IL-2 receptor (CD25), a hallmark receptor for ac­
tivated T  cells, was more highly expressed on MBP-reactive T  cells from MS 
patients than  from normal patients. Therefore T  cells in MS patients are in a 
greater activation state  [Zhang et al., 1994, Hellings et al., 2001]. It has been 
also shown th a t T  cells from peripheral blood in MS patients, bu t not normal 
individuals are less dependent on B7 costimulation for their activation [Lovett- 
Racke et al., 1998, Racke et al., 2000]. B7 is the second costimulatory signal which 
functions to induce the secretion of IL-2 from activated T-cells. These findings 
suggest th a t the explanation for the expansion of self reactive T  cells in MS lies in 
the less stringent requirement of these cells for activation and on their enhanced 
activation state.
Negative selection is not the only mechanism for inducing self tolerance. A 
subset of lymphocytes, so called regulatory T cells (Tregs) have been shown to 
inhibit the activation of autoreactive T  cells in the thymus [Sakaguchi et al., 2006]. 
They are characterised by their cell surface expression of CD4 and CD25 as well 
as the expression of the transcription factor Foxp3 [Viglietta et al., 2004]. Foxp3 
belongs to the forkhead/winged helix family and is responsible for the develop­
ment of the Tregs [Fontenot et al., 2003].
The role of Tregs in MS pathogenesis has been obtained by comparing the func­
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tion of Tregs in MS patients and healthy control. I t was shown th a t Tregs failed 
to suppress the proliferation of CD25-  T  cells in MS bu t not in healthy controls 
[Viglietta et al., 2004]. This was confirmed by another study where Tregs from 
healthy or MS patients were co-cultured with CD4+CD25- T  cells. Healthy Tregs 
induced 80% inhibition of CD25-  T  cells compared to MS Tregs (20%) [Baecher- 
Allan and Hafler, 2004]. These results clearly indicate a role for Tregs in the 
pathogenesis of MS.
Molecular mimicry
The second theory is based on molecular mimicry in which infectious agents mimic 
epitopes of autoantigen (figure 1.4). Upon infection by bacteria or virus, lympho­
cytes are activated in the lymph node by APC th a t present antigenic peptide from 
the infectious agent [Markovic-Plese et al., 2004, Wucherpfennig, 2001]. As these 
antigens mimic self antigens (MBP, PLP), the immune response is then directed 
at self tissue. In MS a number of infectious agents have been proposed bu t none 
of them  have been directly linked to the initiation of MS (see 1.2.3).
Effect of activated T lymphocytes in the CNS
Activated T  cells migrate into the CNS under the influence of chem oattractant 
molecules called chemokines (see section 1.4). Studies have shown th a t upon 
activation, T  lymphocytes can induce neuronal death in vitro and in vivo, inde­
pendently of their antigen specificity [Giuliani et al., 2003, Newman et al., 2001]. 
Encephalitogenic CD4+ T  lymphocytes, using two-photon microscopy, have been 
shown to possess m igratory capacities within the CNS and to  interact w ith the 
soma and processes of neurons leading to neuronal death. The capacity to induce 
this neuronal death is due to  the expression of TN F related apoptosis-induced 
ligand (TRAIL) on T  lymphocytes [Nitsch et al., 2004, Aktas et al., 2005].
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1.2.6.3 BBB and cell migration into the CNS
In MS, immune cells readily cross the BBB and gain access to the CNS, leading 
to inflammation and demyelination, through the interaction with endothelial cell 
adhesion molecules at the blood-brain barrier [Engelhardt and Ransohoff, 2005]. 
This is a critical step in the pathogenesis of inflammatory diseases including MS. 
Inter cellular adhesion molecules-1 (ICAM-1 ), vascular cell adhesion molecule-1 
(V-CAM1) and E-selectin have been shown to be im portant molecules in this pro­
cess [Dore-Duffy et al., 1993, Elovaara et al., 1998, Rieckmann et al., 1997]. ICAM- 
1 is a 90 KDa surface glycoprotein with 5 extracellular Ig domains th a t binds to 
the membrane bound integrin receptors LFA-1 (leukocyte function-associated-1) 
(C D lla /C D 18) on the surface of activated leukocytes [Lee and Benveniste, 1999, 
Staunton et al., 1988]. V-CAM-1 also belongs to the immunoglobulin superfam­
ily but has 7 extracellular IgG domains. It binds to integrins including VLA-4 
(very late antigen 4) th a t is constitutively expressed by mononuclear cells [Elices 
et al., 1990, May et al., 2000, Sheremata et al., 2005]. Both I-CAM and V-CAM 
have been shown to be more highly expressed on endothelial cells from MS brain 
compared to control brain [Washington et al., 1994]. The selectin family, consist­
ing of L-selectin, E-selectin and P-selectin, are a group of type I transm em brane 
glycoproteins which have been shown to be expressed by microvascular endothe­
lial cells in MS lesions [Lee and Benveniste, 1999, W ashington et al., 1994]. By 
over-expressing adhesion molecules, activated leukocytes are able to  interact with 
the BBB via E-selectin, this is ’’rolling” [Ley et al., 1998]. As soon as the interac­
tion between VCAM-1 and LFA-4 occurs, lymphocytes stop rolling and strongly 
adhere to  the BBB. In  vivo, the involvement of adhesion molecules in leukocyte 
entry into the CNS parenchyma has been clearly dem onstrated by the adm inistra­
tion of antibodies against VLA-4 which blocked the transendothelial m igration of 
lymphocytes and monocytes in EAE [Yednock et al., 1992]. These two processes, 
adhesion and migration, are regulated by molecules th a t play a m ajor role in the 
pathogenesis of MS: the chem oattractant cytokines or chemokines (see section 
1.4.1).
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Lymphocytes are then able to enter into the CNS by diapedesis. Entry is facili­
ta ted  by the synthesis of MMPs produced by CNS resident cells including endothe­
lial cells and microglia [Zozulya et al., 2007, Cossins et al., 1997]. These enzymes 
disrupt the BBB and basement membrane thereby facilitating the transm igration 
of lymphocytes into the CNS [Chavarria and Alcocer-Varela, 2004]. MHC class II+ 
CNS resident cells th a t present myelin sheath peptides can then reactivate myelin- 
specific CD4+ T  lymphocytes, so called epitope spreading [McMahon et al., 2005], 
which increases the expression of inflammatory mediators such as IL2, TN F and 
IFN 7  resulting in more tissue damage due to  increased cell activation and release 
of secondary antigens [Chitnis, 2007] (figure 1.5).
Evidence for a role of CD8 + cells in MS pathogenesis was obtained from the pres­
ence of expended clones of CD8 + found in MS lesions as well as blood and CSF 
from MS patients [Skulina et al., 2004, Babbe et al., 2000]. Moreover, it was 
shown in vitro th a t CD8 + cells interact with neurons resulting in neuronal death 
through Fas/FasL [Medana et al., 2000]. These activated lymphocytes produce 
inflammatory mediators which attack the myelin sheath resulting in inflammation, 
axonal damage and neuronal death [Bar-Or et al., 1999].
1.2.6.4 Inflammation
In the body, direct tissue injury is followed by recruitm ent of peripheral blood 
mononuclear cells followed by wound healing and angiogenesis [Lo et al., 1999]. 
In the CNS, neuroinflammation involves T  cells as discussed in section 1.2.6 and 
glia cells. Microglia cells are also involved in inflammation through antigen pre­
sentation and synthesis of pro-inflammatory mediators [Farber and Kettenm ann, 
2005, Muzio et al., 2007]. Oxidative myelin destruction induced increased levels of 
7-ketocholesterol (7KC), a myelin breakdown product, which has been shown to 
accumulate in the brain in MS patients and correlate w ith disability and neuronal 
death in EAE. 7KC does not induce direct neuronal death but has an effect on 
migration and induces a neurotoxic phenotype in microglia, leading to  neuronal 
death [Diestel et al., 2003].
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Inflammation is not solely detrimental and can have some protective effects. A 
recent study on knock-out (KO) /52-microglobulin mice lacking m ature CD8 +  lym­
phocytes has shown an aggravation of the disease and increased neuronal damage, 
highlighting the potential anti-inflammatory role of this T  lymphocyte subset in 
MS [Linker et al., 2005].
Secretion of neurotrophins by T-cells such as brain-derived neurotrophic factor 
(BNDF), neurotrophin-3 (NT-3), NT-4 IL-4 and IL-10, have the potential to in­
duce neuronal recovery and neuronal development in vitro and in vivo [Chitnis, 
2007, Hohlfeld, 2004, Kerschensteiner et al., 1999, Lu et al., 2005].
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Fig. 1.4: P ro p o sed  m olecular m im icry  m echanism  in M S for th e  in d u c­
tio n  of au to im m unity .
In the lymph node the potentially autoreactive T cells are activated by antigen 
presenting cells (APC) which present viral peptide (mimic self antigen) through 
MHC class II. These activated T cells migrate into the CNS and are reactivated 
by self peptide leading to the immune response against self tissue. Image obtained 
and modified from Holmes et al. (2005).
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Fig. 1.5: A m odel of th e  m olecu lar pa thogenesis  of m u ltip le  sclerosis.
Myelin autoreactive T cells are activated in the periphery and chem oattracted into 
CNS by chemokine/chemokine receptor interactions. Activated cells adhere to the 
blood-brain-barrier (BBB) endothelium via E selectin molecules (rolling). Firm  
adhesion stops the rolling through the interaction between ICAM-1 and LFA-1. 
Chemokines are involved in this process by acting on firm adhesion, locomotion, 
diapedesis, and chemotaxis [Savarin et al. 2007]. Activated T cells cross BBB 
basement membrane and migrate into CNS parenchyma (diapedesis) which is 
facilitated by m atrix metalloproteinases. Auto reactive T cells in the CNS mediate 
damage to myelin and axonal injury through the synthesis of pro-inflammatory 
cytokines and activation of glia cells.
31
1.2.6.5 Demyelination-axonal damage
Demyelination is a characteristic feature of MS plaques. Demyelination oc­
curs w ith the destruction of both the myelin sheath and oligodendrocytes. Myelin 
destruction is under the influence of autoreactive activated T-cells th a t have mi­
grated into the CNS and macrophages (cellular immunity) and plasma cells th a t 
secrete antibodies directed against myelin (humoral immunity). There are several 
mechanisms for myelin destruction [Sospedra and M artin, 2005].
T  cells can bind directly to myelin epitopes when presented by the MHC class II 
molecules expressed by activated microglia th a t result in the production of T h l 
cytokines from T  cells leading to the destruction of myelin [Carson, 2002].
One other mechanism is the fixation of myelin specific antibodies from invading 
B-cells th a t activate the complement and opsonization by macrophages. As well, 
release of cytotoxic mediators from immune cells and glial cells create further de­
myelination [Bruck and Stadelmann, 2003].
Axonal damage can be visualized by accumulation of amyloid precursor protein 
(APP) in axons a t sites of recent axon damage [Kuhlmann et al., 2 0 0 2 ]. This 
accumulation is prominent in early disease and correlates with the extent of ac­
cumulation of T  cells and macrophages into lesions. Several mechanisms are re­
sponsible for the axonal damage. As discussed in section 1.2.6 .3, CD8 + T  cells 
have been shown to induce neuronal death through the Fas/Fas Ligand pathway 
but not perforin. Neurons are resistant to  perforin secreted by CD8 + lympho­
cytes [Medana et al., 2000]. This finding contradicted a study by M urray (1998) 
where it was shown th a t Theiler’s virus encephalomyelitis mice model in perforin 
KO mice showed protection against the axonal damage but not for demyelination 
[Murray, 2002].
G lutam ate has been shown to play a role in neuronal death as discussed in sec­
tion 1.1.1.4. Indeed, evidence was obtained from a study using of excitatory amino 
acid receptor antagonist, which resulted in the protection of axons in EAE mouse 
model [Pitt et al., 2000] (see section 1.3).
Finally, as discussed above in this section, antibodies against myelin from acti­
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vated B cells and complement result in axonal damage in the same way described 
for the demyelination [Mead et al., 2002].
1.2.6.6 Astrocytes in MS: scar formation
Cellular damage in the CNS leads to a response from glia cells and results in 
the formation of scar tissue also known as reactive gliosis. This scar formation 
involves different cell types including: astrocytes, microglia, oligodendrocyte pre­
cursor cells (OPC) and some meningeal cells [Fawcett and Asher, 1999].
The glial scar produces many signals to block the migration of oligodendro­
cytes precursor cells (OPC). Astrocytes around the lesion induced secretion of 
chemokine CXCL1 [Omari et al., 2006], which promotes OPC proliferation but 
acts as a stop signal for OPC migration [Tsai et al., 2 0 0 2 ].
O ther evidence was obtained in post-mortem CNS tissue where oligodendrocytes 
were present with multiple processes for remyelination but failed to interact with 
viable neurons leading to the absence of demyelination [Chang et al., 2002]. This 
is supported by the fact th a t astrocytes produce specific molecules (proteoglycans) 
th a t inhibit the growth of neurons [Silver and Miller, 2004].
The structure of the glia scar evolves with time and the cell types involved. In its 
final form, the glial scar is mainly formed by astrocytes due to enlargement of the 
astrocyte cell body and processes, called astrogliosis or astrocytic proliferation to 
replace the damaged tissue [Fawcett and Asher, 1999]. The astrocyte fine pro­
cesses are tightly apposed one to each other by gap and tight junctions limiting 
extracellular space. The number of plaques are not directly correlated with the 
evolution of the disease as they can be located in a region of the brain th a t has 
little effect on brain function. In contrast, if the scar is in an region controlling 
movement for example this leads to disability [Silver and Miller, 2004].
Astrocytes are not only involved in the scar formation in MS. They are also 
involved in the migration of immune cells into the CNS by increasing the perme­
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ability of the BBB [Williams et al., 2007]. Astrocytes have been shown to express 
m atrix metalloproteases (MMPs) th a t will disrupt the extracellular m atrix and the 
tight junction between endothelial cells, which facilitates extravasation of immune 
cells into the CNS [Yang et ah, 2007]. Once in the CNS, T  cells are reactivated 
by their interaction with local APCs such as microglia or dendritic cells th a t con- 
stitutively express MHC class II molecules [Wu et ah, 2007].
Astrocytes have also been shown to be non professional APCs [Williams et ah, 
2007]. Indeed, IFN - 7  have been shown to be the most potent inducer of MHC 
class II expression and the induction of cell surface co-stimulatory molecules in as­
trocytes, which convert them  into effective antigen presenting cells (APC) [Dong 
and Benveniste, 2001]. The expression of MHC class II by astrocytes was also ob­
served in vivo in post-mortem brain tissue [Zeinstra et ah, 2000]. Double labelling 
immunohistochemistry showed th a t astrocytes expressed MHC class II molecules 
in MS lesions but not in control suggesting the potential role for astrocytes to 
act as APCs. However the ability of astrocytes to  act as APCs is controversial. 
Absence of expression of the co-stimulatory signal B7.1 and 7.2 by astrocytes but 
not by microglia in MS lesions has shown the incapacity of astrocytes to  present 
antigen to immune cells [De Simone et ah, 1995, Aloisi et ah, 1995]. These findings 
are in contradiction with a study where astrocytes have been shown to express 
both  B7.1 and B7.2 molecules in chronic active plaques using double labelling 
immunofluorescence [Zeinstra et al., 2003].
Therefore astrocytes have a dual role during MS. On the one hand it increases 
tissue damage by increasing the recruitment of immune cells into the CNS and 
activation of T  cells. On the other hand, they are involved in the scar formation 
to  repair tissue damage following inflammation.
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1.3 Experim ental autoimmune encephalomyeli­
tis (EAE): model for MS
Experimental autoimmune encephalomyelitis (EAE) is an inflammatory de- 
myelinating disease th a t is used as a model for the study of MS. It has been 
extensively used to better understand the pathophysiology of MS and presents 
the same pathological characteristics as MS (local inflammation and demyelina- 
tion as a result of activated T  cells) [Dogan and Karpus, 2004, Elhofy et al., 2002]. 
There are three type of EAE depending on the method of induction of EAE (pep­
tide or brain homogenate injection and viral infection).
1.3.1 Induction of EAE
EAE can be induced by immunizing susceptible strains of mice with a mixture 
of immunodominant peptides from myelin proteins such as myelin basic protein 
(MBP), myelin olygodendrocyte glycoprotein (MOG) or proteolipid protein (PLP) 
emulsified with complete Freund’s adjuvant [Amor et al., 1996, Tuohy et al., 1992]. 
It can also be induced by transferring CNS antigen specific reactive CD4-I- T  cells 
into animals [Mokhtarian et al., 1984], term ed passive transfer of the disease. The 
disease course in EAE varies depending on the strains of animal injected and the 
immunogen used. For example, in S JL /J  mice injection of PLP or MBP induced 
the relapsing-remitting form of EAE whereas C57bl/6 mice are resistant to EAE 
induction by MBP but develop a chronic form of EAE (CREAE) by injecting 
MOG peptide [Dogan and Karpus, 2004, Elhofy et al., 2002].
Another animal model for MS can be obtained following viral infection. Theiler’s 
murine encephalomyelitis virus (TMEV) is a single strand RNA virus th a t belongs 
to the Picornaviridae family. Intrathecal TM EV inoculation in susceptible mice 
strains (SJL) induces a biphasic disease of the CNS, characterized by an early 
acute disease and a late chronic demyelinating disease [Lipton, 1975, Tsunoda 
and Fujinami, 1996].
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1.3.2 P hysiopathology of EAE
As in MS, the initial stage of EAE starts w ith the activation and differenti­
ation of T h l cells in the lymph nodes by the injection of the immunodominant 
peptide from myelin proteins. These cells migrate into the CNS by overexpress­
ing of adhesion molecules such as VLA-4 (a4/31 integrin), LFA-1 and ICAM-1 . 
Treatm ent of mice with an antibody, anti VLA-4, induced a reduction in bind­
ing of T  cells to  the cerebrovascular endothelium, thereby inhibiting EAE [Kent 
et al., 1995, Baron et al., 1993]. Similar to anti-VLA-4, treatm ent of mice with 
antibodies directed against LFA-1  and ICAM-1 resulted in protection from EAE 
[Kobayashi et al., 1995]. W hen T  cells re-encounter the peptide (MBP or MOG), 
they are reactivated and secrete pro-inflammatory molecules including IFN 7  and 
TN F resulting in axonal damage and neuronal death. It has been shown th a t the 
expression of IFN 7  within the CNS increased during relapse and decreased during 
remission [Begolka et al., 1998]. Overexpression of IFN 7  in myelinating oligoden­
drocytes of transgenic mice resulted in a progressive demyelinating disease [Renno 
et al., 1998]. Glabinski et al. (2004) showed th a t injection of soluble TN F recep­
tor (sTN F):Fc/p80 fusion protein ameliorated relapsing-remitting EAE [Glabinski 
et al., 2004]. Similar findings were observed with the injection of TNFR-IgG [Ko- 
rner et al., 1997]. They found th a t adm inistration of TNFR-IgG prior to onset 
of disease signs completely prevented the neurological deficit or markedly reduced 
its severity compared to the untreated EAE model.
1.3.3 A dvantages and disavantages of EA E as a m odel for 
MS
There is debate on the validity of the EAE model in increasing understanding 
of MS pathogenesis.
None of the EAE models truly represent MS therefore the model is an imprecise 
method for the understanding of MS and for the development and test of new
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therapies [Sriram and Steiner, 2005]. Other researchers argue th a t use of the 
EAE model is necessary to simplify the questions concerning a highly complex 
disease such as MS. Once genes and proteins are identified in MS, the EAE model 
can be used to  understand their biological significance. Use of KO EAE animal 
models or neutralizing antibody injection in EAE models are useful methods to 
elucidate the role of specific molecules. EAE models have given great input in 
the understanding of the disease and have led to six medications th a t received 
the approval by the US Food and Drug adm inistration (FDA) for MS treatm ent. 
Although the animal models are valuable tools to  understand the pathology of 
disease, they are not perfect [Steinman and Zamvil, 2006], hence in vitro approach 
in this study.
The recruitm ent of immune cells to the CNS is an im portant feature in both MS 
and EAE. This cell recruitment is under the control of chem oattractant cytokines 
called chemokines [Elhofy et al., 2002].
1.4 Chemokines and their receptors
1.4.1 Chem okines
Chemokines are small molecules (8-10 KDa) th a t belong to  the family of pro- 
inflammatory mediators called cytokines involved in chem oattraction [Rossi and 
Zlotnik, 2000]. They are produced in various tissues including brain and have 
additional functions, other than solely chem oattraction. I t has been shown th a t 
they are involved in the differentiation of T  cells [Luther and Cyster, 2001], in 
leukocyte activation, angiogenesis and anti-microbial functions [Adams and Lloyd, 
1997, Coelho et al., 2007]. The importance of the role of chemokines is also 
highlighted by the fact th a t they are highly conserved, they show 20 to  70% 
homology in amino acid sequence [Rossi and Zlotnik, 2000].
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1.4.2 C hem okine classification
Chemokines have been subdivided into four classes (a, /?, S and 7 ) depending 
on their structure and especially on the relative position of the N-terminal cys­
teine residues [Murphy, 2002]. In the 7  family there is only one cysteine residue 
whereas in the /?, a  and 5 the first two cysteines are respectively separated by 
0 , 1 and 3 amino acids respectively. CC (/?) and CXC (a) are the largest fami­
lies. Each class of chemokines acts on different population of cells [Ambrosini and 
Aloisi, 2004]. CXC chemokines are divided into 2  subclasses depending on the 
presence or absence of a three amino acid ELR motif (glutamic acid - leucine - 
arginine) a t the N-terminal part. The ELR-CXC chemokines include CXCL8  and 
CXCL1 th a t stim ulate angiogenesis and act specifically on neutrophils whereas 
non ELR-chemokines such as CXCL9, CXCL10, CXCL11  stim ulate the migration 
of monocytes and lymphocytes [Laing and Secombes, 2004]. CC chemokines act 
on cells involved in innate and adaptive immune responses including monocytes, 
eosinophils, basophils, monocytes and activated T  cells [Laing and Secombes, 
2004]. XC chemokines or lymphotaxin a ttrac t resting T  cells and is the only 
chemokine with this structure identified to  date. It binds specifically to  the orphan 
chemokine receptor previously named GPR5/XCR1 and acts on T  lymphocytes 
and NK cells [Laing and Secombes, 2004]. CX3C chemokine is represented by only 
one chemokine called fracktaline or CX3CL1, which can be found both  in a soluble 
and membrane bound form, where it functions as an adhesion molecule. Produced 
by neurons and endothelial cells, it acts on T  cells, monocytes, im m ature dendritic 
cells, microglia and NK cells [Laing and Secombes, 2004].
1.4.3 C hem okine receptors
Chemokines exert their biological function via interaction with chemokine re­
ceptors, which are members of the G protein coupled receptor family (GCPRs) 
(figure 1.6) [Cartier et al., 2005, Rossi and Zlotnik, 2000]. GPCRs are subdivided 
into three subfamilies but they all share structural features. They are character­
ized by a polypeptide chain composed of approximately 350 amino acids. They
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have seven transm em brane spanning cc-helical segments, connected by intracellu­
lar (ICL) and extracellular (ECL) loops with a relatively short acidic N terminal 
domain with glycosylation sites. Cysteine bonds are present in the N term inal do­
main and in each of the 3 extracellular loops. The DRYLAIVHA m otif sequence, 
which is im portant for signal transduction, is well-conserved in the second in tra­
cellular loop and the intracellular domain contains serine and threonine th a t act as 
phosphorylation sites for receptor regulation [Gether, 2000, Murdoch and Finn, 
2000]. Chemokine receptors belong to the A family of GPCRs and have been 
identified in the last 10 years. They possess 50% homology amongst themselves 
and less than  30% homology with the other G protein coupled receptor families 
[Kristiansen, 2004].
1.4.4 C hem okine receptor classification
The nomenclature for chemokine receptors follows th a t used for chemokines 
by adding ”R” for receptor. Four classes of receptor have been identified (XCR, 
CXCR, CCR and CX_3CR), summarized in Table 1 .1  w ith their respective ligands 
and functions. The XCR and CX3CR families contain only one receptor, XCR1 
and CX3CR1. The CXCR family consist of up to  6  receptors (CXCR1-6) and the 
CCR family is composed of CCR1- CCR10 [Murphy, 2002].
Interaction between chemokines and their receptors are complex and show some 
redundancy in the system. Each chemokine can bind several receptors and one 
chemokine can bind to more than one chemokine receptor.
1.4.4.1 Silent chemokine receptors
The chemokine system includes at least three ’’silent” receptors, DARC, D6 
and CCX-CKR, each w ith distinct specificity and tissue distribution. DARC binds 
to 11  chemokines belonging to  the CXC and CC chemokine family, D 6  binds to 
9 pro-inflammatory chemokines from the CC family and CCX CKR binds CXC 
homeostatic chemokines (CCL19, CCL2 1 , CCL25 and CXCL13) [Haraldsen and 
Rot, 2006]. Although they bind different ligands, they all share the ability to bind
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Extracellular
C-termlnus
Fig. 1.6: Schem atic re p re se n ta tio n  of a fam ily A re c ep to r in  th e  cell by 
cry sta l s tru c tu re : G p ro te in  coupled re c ep to r (G P C R ).
It is composed of three extracellular loops (ECL) and intracellular loops (ICL) 
with seven transm embrane domains. The N-terminal domain is required for ligand 
binding and the C-terminal domain is required for signalling. O btained from 
Kristiansen (2004).
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N a m e M a in  ag o n is ts M a in  F u n c tio n s
C X C  su b g ro u p
CXCR1 CXCL8 Neutrophil migration; innate immunity; acute inflam­
mation
CXCR2 CXCL1-
3;CXCL5-8
Neutrophil migration; innate immunity; acute inflam­
m ation and angiogenesis
CXCR3 CXCL9-11 T  cell migration;adaptive immunity; T h l inflamma­
tion
CXCR4 CXCL12 B cell lymphopoiesis; bone marrow myelopoietis; cen­
tra l nervous system and vascular development; HIV 
infection
CXCR5 CXCL13 B cell trafficking; lymphoid development
CXCR6 CXCL16 T  cell migration
C C  s u b g ro u p
CCR1 CCL3; CCL5; 
CCL7; CCL8 ; 
CCL13-16; 
CCL23
T cell and monocyte migration; innate and adaptive 
immunity; inflammation
CCR2 CCL2; CCL7; 
CCL8 ; CCL13
T cell and monocyte migration; innate and adaptive 
immunity; T h l inflammation
CCR3 CCL5; CCL7; 
CCL8 ; CCL1 1 , 
CCL13; CCL15; 
CCL24; CCL26
Eosinophil, basophil, and T  cell migration; allergic 
inflammation
CCR4 CCL17, CCL22 T  cell and monocyte migration; allergic inflammation
CCR5 CCL3; CCL4; 
CCL5; CCL8 , 
CCL14
T cell and monocyte migration; innate and adaptive 
immunity; HIV infection
CCR6 CCL20 Dendritic cell migration
CCR7 CCL19, CCL21 T cell and dendritic cell migration; lymphoid devel­
opment; prim ary immune response
CCR8 CCL1; CCL4; 
CCL17
T cell trafficking
CCR9 CCL25 T cell homing to  gut
CCR10 CCL26-28 T  cell homing to  skin
C X 3C a n d  C  su b g ro u p s
CX3CRI CX3CLI T  cell and NK cell trafficking and adhesion; innate 
and adaptive immunity; T h l inflammation
XCR1 XCL1-2 T  cell trafficking
Tab. 1.1: T h e  fo u r c lasses o f ch em o k in e  re c e p to r ,  th e i r  m a in  ag o n is ts  
a n d  fu n c tio n s .
The nomenclature of the chemokine receptor follows the nomenclature of the 
chemokines. There are four classes of receptor (CXC, CC, CX3C and C). This 
table summarises the different ligands for each receptor as well as their function. 
Obtained from M urphy et al. (2002). 4 1
chemokines w ithout inducing any signalling or m igratory function. The func­
tion of these receptors is to compete with the natural receptor, sequester the 
ligand and internalise it for targeting to  the degradation pathway [Nibbs et al., 
2003].
The DARC receptor has been found to be expressed on erythrocytes of Duffy anti­
gen positive subjects but also on endothelial cells. The DARC receptor may have 
a dual function. I t seems to  facilitate the transport of chemokines through the 
vascular endothelium and controls the level of circulating chemokines [Nibbs et al., 
2003]. D 6  binds most inflammatory CC chemokines and shuttles from the plasma 
membrane to endocytic compartments where they are targeted for degradation. 
The receptor is detectable on placenta and on endothelial cells of lymphatic af­
ferent vessels in skin, gut and lung [Weber et al., 2004]. CCX-CKR receptor is 
expressed on T  lymphocytes and im mature dendritic cells [Gosling et al., 2000]. 
As yet, there are no publications on the ability of this receptor to  internalize the 
ligand.
1.4.5 Chem okine-chem okine receptor interaction
Regarding the high affinity chemokine and chemokine receptor interaction, the 
role of the extracellular loops and N-terminal domain of the receptors has been 
determined through mutagenesis experiments of the receptor. A report on one iso­
form of CCR2, CCR2B, has shown th a t replacement of the first extracellular loop 
of CCR2B with the corresponding region of CCR1 decreased the binding affinity 
for CCL2 about 10-fold. It was shown th a t this segment contains two distinct 
domains; one involved in the binding of CCL2 , whereas the other is involved in 
receptor activation and signal transduction [Han et al., 1999]. Involvement of the 
N-terminal domain of chemokine receptors in binding of its ligand has been con­
firmed by replacing the hexapeptide Thr-Thr-Xaa-Phe-Asp-Tyr in the N-terminal 
domain of CCR2 by alanine. This segment has been shown to be conserved be­
tween CCR1 and CCR2  th a t binds CCL2  and RANTES. It contains a sulphation 
site, highlighting the biological importance of this segment [Preobrazhensky et al.,
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2000]. CCR5 has also been shown to be post-translationally modified by sulpha- 
tion of tyrosine and shown to contribute to  the binding of CCL3 and CCL4 [Farzan 
et al., 1999].
In a study on CXCR2, serine or leucine residues were substitu ted  for cysteine 
in the extracellular domains, and 7 transm em brane domain. These substitutions 
resulted in the inability of CXCR2  to  bind CXCL8 , indicating the involvement 
of the three extracellular domains and transm em brane domains. However, they 
did not dram atically impair the expression of the receptor a t the cell surface and 
showed minor effects on CXCR2 trafficking [Limatola et al., 2005].
1.4.6 C hem okine-glycosam inoglycan interaction
As well as binding to their cognate receptor and ’’silent” receptors a t high 
affinity, chemokines bind to cell surface proteoglycans with lower affinity. Proteo­
glycans consist of glycosaminoglycans (GAGs), long linear polysaccharides and a 
protein core [Johnson et al., 2005]. Proteoglycans are expressed ubiquitously on 
cell surfaces and in the extracellular m atrix and present high diversity due to the 
polysaccharide composition, with a length th a t can vary from 1 to 25, 000 disac­
charide units, and the protein core also has diversity. The fact th a t chemokines 
bind to the proteoglycan is not surprising because of the highly negative charge, 
and hence have favorable interaction with chemokines th a t are prim arily basic. 
However, the interaction between chemokines and proteoglycan seems to show 
some specificity. For instance, CCL2 has greater affinity for chondroitin sulphate 
>  derm atan sulphate >  heparan sulphate >  heparin [Kuschert et al., 1999]. These 
interactions are im portant for establishment of chemokine gradients, for the re­
cruitm ent of immunological cells and also for the modulation of the presentation 
of chemokines to their receptors and their protection from proteolytic cleavage 
[Johnson et al., 2005].
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1.4.7 C hem okine receptors intracellular signalling path­
ways
W hen chemokines bind to their receptor, it induces cell migration. Treatment 
with pertussis toxin (PTX), a specific inhibitor of G proteins, inhibits cell mi­
gration, highlighting the im portance of G protein signalling in chemokine effects 
[Cartier et al., 2005]. Upon binding of the ligand to the receptor, conformational 
changes occur in the receptor. The trimeric G protein composed of an a  and 
/? 7  subunit is dissociated due to  the replacement of GDP by GTP. Downstream 
signalling pathways are mostly triggered by the f3 subunit. Because of the re­
dundancy of the system, a receptor can activate various intracellular pathways, 
depending on its ligand. I t is well known th a t it is mostly (3 subunits tha t activate 
downstream signalling pathways including the phosphoinositide-specific phospho- 
lipase C (PLC) and phosphoinositide 3 kinase(PI3K) (figure 1.7):
1.4.7.1 Phosphoinositide-specific phospholipase C pathway (PLC)
PLC activation leads to the generation of diacylglycerol (DAG) and inositol
1,4,5 triphosphate (IP3) which, upon binding to its receptor on the endoplasmic 
reticulum, releases intracellular calcium. The increase in intracellular calcium 
following chemokine binding to  its receptor is a well-known feature [Kiselyov 
et al., 2003]. This calcium release is often monitored to  determine the effect 
of chemokines on their receptor. DAG in conjunction with an increase in intracel­
lular calcium, activates protein kinase C (PKC). PKC activation by chemokines is 
required for certain responses, such as the respiratory burst of neutrophils [Thelen, 
2001].
1.4.7.2 Phosphoinositide 3 kinase pathway(PI3K)
Activation of PI-3K triggers the accumulation of phosphatidylinositol 3,4,5- 
trisphosphate (PtdIns(3,4,5)P3). Protein Kinase B (PKB) migrates to the mem­
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brane and binds to PtdIns(3,4,5)P3 activating the P K B /A K t and Erk pathways.
The P K B /A kt subfamily of the mammalian cAM P-dependent, cGMP-dependent, 
protein kinase C family of kinases (AGO) consists of three members, PKBcn/Aktl, 
PKB/?/Akt2 and PKB 7 /A k t3  and are activated by phosphorylation of two residues, 
T hr308 and Ser473 [Alessi et al., 1996, Walker et al., 1998]. They share strong sim­
ilarities in a kinase domain and pleckstrin homology (PH) domain, which is a 
specialized lipid binding domain [Alessi et al., 1996]. They are regulated by the 
signalling of the phosphatidylinositol phosphate 3 kinase (PI3Kinase), which is ac­
tivated by growth factors, and G PCR agonists [Hirsch et al., 2007, Radeff-Huang 
et al., 2004, Vanhaesebroeck and Alessi, 2000]. Akt has many targets including 
cell polarization, chemotaxis and cell survival [Cartier et al., 2005].
Mitogen-Activated-Protein-Kinases (MAPKs) are serine-threonine protein ki­
nases th a t are activated by a variety of molecules including cytokines, growth fac­
tors, neurotransm itters, hormones, cell adhesion molecules and chemokines [Choi 
et al., 2001]. The M APKs are subdivided into three different groups; the extra­
cellular signal-regulated kinase (Erk), c-jun kinase (JNK) and p38 MAPK .
Erk is a well characterised signalling kinase, and is activated by phosphoryla­
tion on threonine and tyrosine residues by mitogen-activated protein k inasel/ 2  
(M EK1/2) [Chang and Karin, 2001]. Erk has six different isoforms, however the 
most common are Erk 1 and 2, which share many similarities and have a RMM 
of 44 and 42 KDa respectively [Chang and Karin, 2001]. Erk activation induces 
proliferation/differentiation [Cartier et al., 2005].
The intracellular pathways of chemokines are complex as one receptor is able 
to activate different second messengers depending on its ligand consequently trig­
gering several downstream pathways [Thelen, 2001].
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Ligand
Chemokine receptor
PI3K PLC
PKB/AKT
Chemotaxis
Erk
Proliferation/differentiation
Increase of calcium
PKC activation
Fig. 1.7: Signalling pathw ays do w n stream  of chem okine re c ep to r ac tiv a ­
tion .
Following binding, G/Ty dissociates from the G PCR and induces activation of 
phospholipase C (PLC) resulting in an increase in intracellular calcium and ac­
tivation of protein kinase C (PKC). It also activates phosphoinositide 3 kinase 
pathway(PI3K) which activates Erk and PK B /A kt, responsible for cell prolifera­
tion/differentiation and chemotaxis respectively.
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1.4.8 Function o f chem okines
1.4.8.1 Leukocyte recruitment
The most studied action of chemokines is their role in recruitm ent of leuko­
cytes, which occurs in inflammatory disorders including MS [Baggiolini, 1998]. 
The recruitm ent process can be subdivided into three steps, rolling, firm adhesion 
and diapedesis (section 1.2.6.3). Wan et al. (2003) have shown the involvement 
of chemokines in the interaction of leukocytes with the endothelium. CCL3 and 
CCL2 caused a dose-dependent increase in leukocyte rolling, adhesion and recruit­
ment, which was inhibited by an antibody directed against selectin [Wan et al., 
2003]. O ther evidence was obtained from the EAE model. For example, Huang 
et al. (2006) showed th a t EAE mice deficient for CX3CR1 presented a marked 
reduction in the migration of NK cells within the CNS compared to W T EAE 
mice [Huang et al., 2006].
1.4.8.2 Differentiation of T lymphocytes
Studies indicate th a t chemokines regulate the differentiation of T  lymphocytes. 
Dey et al. (2007) have shown th a t in Leishmania donovani-infected BA LB/c mice, 
CCL2  and CCL3, both induced the expression of the pro-inflammatory cytokine, 
IL-12, and the suppression of the anti-inflammatory cytokines IL-10 and trans­
forming growth factor-beta (TGF/?) in infected macrophages. The chemokine 
treatm ent lead also to an increase in IFN7 , TN F and inducible nitric oxide syn­
thase in both  liver mononuclear cells as well as in splenocytes, which reflect the 
switch of CD4+ T cells from Th2 to T h l [Dey et al., 2007].
Chemokines may also affect the differentiation of immune cells by regulating 
the migration of antigen presenting cells into the lymph node. It was found th a t 
mice deficient for CCR2 had a 70% decrease in IFN 7  producing cells in the drain­
ing lymph nodes compared to  W T mice [Peters et al., 2000]. They also showed 
in vitro th a t both  dendritic cells from CCR2-/- and W T mice stim ulated with
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LPS produced IL12, the cytokine th a t induces a T h l phenotype. This suggests 
an impaired traffic of APC into the lymph node resulting in the decrease in IFN 7  
producing cells (T h l cells). Therefore, CCL2 plays an indirect role on the differ­
entiation of naive T cells into a T h l phenotype by regulating the number of IL12 
producing cells (DCs) in the lymph node.
1.4.8.3 Activation of dendritic cells
Dendritic cells are key players in the immune response by activating B cells 
and T  cells. In vivo and in vitro studies has shown th a t CCL19, acting on CCR7, 
directly activates dendritic cells (DCs) th a t have previously encountered pathogen- 
associated signals, by increasing co-stimulatory molecules (CD40, B7.1 and B7.2) 
and pro-inflammatory cytokine production, resulting in the activation of naive T 
cells into T h l cells [Marsland et al., 2005]. CCR5, triggered by cyclophilin derived 
from T.gondii, is another example of chemokine effects on DCs. It has been shown 
th a t CCR5 activation induced activation of DCs by increasing the production of 
pro-inflammatory cytokines and particularly IL-12, resulting in activation of a 
T h l response and clearance of the pathogen. However this response can induce 
immunopathology if exaggerated [Marsland et al., 2005].
1 .4.8.4 CNS development
Chemokines have a role in neurogenesis. It has been shown recently th a t 
CXCL12 and its receptor CXCR4 control the development of distinct brain re­
gions. Inactivation of CXCR4 in mice resulted in loss of motoneurons and dorsal 
root ganglions and therefore in the reduction of innervation of fore and hindlimbs 
in the developing mouse [Odemis et al., 2005]. In  vivo studies on CXCR4 or 
CXCL12 KO mice showed strong abnormalities of the cerebellar and hippocam pal 
morphology, possibly due to the perturbation of neuronal precursor cell m igration 
[Lu et al., 2002]. These mice also showed defects in B cell development, homing 
of haematopoietic precursors to the bone marrow and cardiac and vascularization 
problems and died soon after birth  [Ma et al., 1998, Tachibana et al., 1998]. This
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example dem onstrates the im portance of chemokines in CNS development and 
brain morphogenesis.
1.4.8.5 Control of angiogenesis by chemokines
Angiogenesis is the process of new blood vessel formation and is under the 
control of various factors including CXC chemokines. The CXC chemokine family 
has disparate effects on angiogenesis. The ELR+ CXC chemokines have angio­
genic effects whereas the ELR-  CXC chemokines have angiostatic effects on the 
endothelium. CXCL1, 2, 3, 5, 6 , 7 and 8  promote angiogenesis through the bind­
ing to their putative receptor, CXCR2  and CXCL4, 9, 10, 11 and 14 exert their 
inhibitory effect on angiogenesis through CXCR3 [Strieter et al., 2005]. The an­
giogenic factor in a local environment can exert this effect directly or in a serial 
manner. The angiogenic effect of VEGF on endothelial cells is an example of a 
serial manner effect where it activates Bcl2, the anti apoptotic molecule th a t lead 
to the up-regulation of CXCL8  by endothelial cell (EC) [Karl et al., 2005], which 
then acts in a paracrine and autocrine way to m aintain the angiogenic phenotype 
on EC. Therefore the local balance of these chemokines in regulating angiogenesis 
might be im portant.
1.4.9 Chem okines and chem okine receptors in M S
The evidence implicating chemokines and their receptors in MS pathology are 
mainly shown by descriptive and observational analysis using CNS tissue or CSF 
from MS patients [Kieseier et al., 2002].
1 .4.9.1 Chemokines in MS
Distribution of chemokines and chemokines receptors have been assessed in 
post-mortem brain tissue using immunohistochemistry and in situ  hybridization. 
It is not surprising to  see th a t both a- and /^-chemokines, the two largest classes 
of chemokine, are mostly implicated in MS pathology. There is accumulation in 
the perivascular space of various CC chemokines including CCL3, CCL4, CCL5
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and CCL7 [Ambrosini and Aloisi, 2004, Muller et al., 2004]. In acute and chronic 
lesions, three members of the CC chemokine family (CCL2 , CCL7 and CCL8 ) 
were highly expressed in the centre of MS lesions with strong staining of astrocytes 
compared to control brains. In demyelinating lesions, it has been shown th a t there 
is a high level of expression of:
•  CCL2 associated with astrocytes and macrophages
• CCL3 associated with astrocytes and macrophages
•  CCL4 associated with macrophages and microglia
•  CCL5 associated with endothelial cells and astrocytes
•  CXCL9 and CXCL10 associated with macrophages in the centre of the lesion 
and reactive astrocytes in the surrounding parenchyma [Balashov et al., 
1999, Cartier et al., 2005, Simpson et al., 1998, Tanuma et al., 2006]
This present study focussed on two chemokines: CCL2 and CXCL10, both 
implicated in MS.
1.4.9.2 CCL2 expression in MS
CCL2 was the first MCP chemokine, belonging to the /^-chemokine family, to 
be identified. It promotes migration of various cell types including: monocytes, 
activated T-cells, basophils and NK cells. This chemokine exerts its effects by 
binding to CCR2 [McManus et al., 1998]. The expression level of this chemokine 
has been extensively studied in brain, CSF and serum in MS.
CCL2 is expressed in MS CNS tissue and especially in acute MS lesions com­
pared to control brain, where no expression is detected [McManus et al., 1998]. 
Immunohistochemistry and in situ hybridization has dem onstrated th a t CCL2 was 
abundantly expressed by astrocytes within active, chronic-active MS lesions com­
pared to normal appearing white m atter (NAWM) tissue [McManus et al., 1998].
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CCL2 immunoreactivity in astrocytes correlated with the level of inflammation in 
the lesion. It has also been shown th a t reactive and hypertrophic astrocytes in ac­
tive and chronic-active lesions highly expressed CCL2 showing a strong correlation 
with inflammation [Simpson et ah, 2000a, Van Der Voorn et ah, 1999]. Simpson 
et al. (1998) reported th a t reactive astrocytes in the adjacent NAWM around 
lesions were strongly immunoreactive for CCL2. Strong expression of CCL2 by 
astrocytes at the edge of lesions could be explained by the fact th a t expression 
of CCL2 by reactive and hypertrophic astrocytes forms a chemotactic gradient, 
allowing the recruitment of inflammatory cells to lesions. The correlation with 
inflammation was confirmed by the absence of expression of CCL2 in the NAWM 
[Van Der Voorn et al., 1999].
CCL2 levels in CSF have been extensively studied in people with MS. M ahad 
et al. (2002) showed by ELISA th a t the concentration of CCL2 in the CSF of MS 
patients was significantly reduced (around 450pg/ml) compared to people w ith un­
explained headache (850pg/ml), non inflammatory neurological disease (around 
900pg/ml) and neurological inflammatory disease controls (around 800pg/m l). 
The concentration of CCL2 in the CSF correlated significantly and positively 
with the time of relapse (n=21; p<0.01, r=0.58) highlighting the role for CCL2 
in the pathogenesis of MS [Mahad et al., 2002b]. The discrepancy between CCL2 
expression in the CNS and reduction in the CSF is not fully resolved as yet. A 
recent study suggested th a t CCR2+ immune cells would consume CCL2 in the 
CSF explaining the decrease [Mahad et al., 2006].
The decreased of level of CCL2 in the CSF in MS was confirmed by several 
other studies. Narikawa et al (2004) showed th a t CCL2 is significantly lower 
(p<0.05) in the CSF of MS patients (125.6 ±  11.3pg/ml) than  controls (174.0 ±  
9.2pg/ml) [Narikawa et al., 2004]. In the Scarpini study (2002), they compared 
the level of CCL2 in the CSF from active RR-MS, stable RR-MS, SP-MS and 
PP-MS with patients with no neurological disease (CON), patients w ith other
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neurological disease (OND) and patients with non inflammatory neurological dis­
eases (NIND). The level of CCL2 in the CSF was significantly reduced in all MS 
clinical subtypes (active RR-MS: 371 ±  49pg/ml, stable RR-MS: 495± 90pg/ml 
and SP-MS: 557 ±  94pg/ml) compared to control (865 ±  95pg/m l), OND (887 ±  
70pg/ml) and inflammatory patients (1802±535 pg/m l) [Scarpini et al., 2002].
The level of CCL2 in the serum has also been analysed but gave contradictory 
evidence. In one study, CCL2 was decreased in active RR-MS (361±35 pg/m l), 
stable RR-MS (383 ±  69pg/ml), SP-MS (442 ±  38pg/ml) and PP-M S (390 ±  
llO pg/m l) compared to CON (1038 ±  65pg/ml) and OND (1374 ±  146pg/ml) 
and OIND (1206 ±  269 pg/ml)[Scarpini et al., 2002]. In a second study, no 
difference between the expression of CCL2 in MS and normal individuals was 
observed [Kivisakk et al., 1998].
1.4.9.3 Function of CCL2 during inflammation in the CNS
CCL2 has been extensively studied in EAE to understand its role in the patho­
genesis of MS. CCL2 expression levels in the spinal cord, using ELISA, correlated 
with the severity and timing of attacks in relapsing EAE, induced in both  rats 
and mice [Kennedy et al., 1998]. The intrathecal synthesis of CCL2 was as­
sessed by RT-PCR at early time points in mice with and w ithout EAE (PLP 
induction)[Glabinski et al., 1995]. It was shown th a t CCL2 synthesis correlated 
with histological inflammation. In situ  hybridization, using an antisense probe for 
CCL2, showed strong staining for astrocytes, but not for inflammatory leukocytes, 
indicating the cellular source of CCL2 in early evolution of EAE lesions. Thus 
intrathecal synthesis of CCL2 by astrocytes, was required for leukocyte entry, sug­
gesting a role in amplification of inflammation rather than  initiation [Glabinski 
et al., 1995]. Use of anti-CCL2 treatm ents using either antibody or DNA vac­
cination [dos Santos et al., 2005, Youssef et al., 1999], reduced the severity of 
the disease in relapsing EAE. CCL2 KO mice showed a significant reduction in 
macrophage recruitment within the CNS [Huang et al., 2001].
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Many in vitro studies have examined the effect of the interaction between 
CCL2 and its receptor. In vitro studies on foetal and murine astrocytes have 
shown th a t similarly to the recruitm ent of monocytes in inflammation sites, foetal 
human astrocytes sense and respond to gradients of CCL2 [Andjelkovic et al.,
2002]. It was proposed th a t this chemotactic effect could either promote the 
recruitm ent of astrocytes at lesion sites within the brain or affect the position 
of astrocytes at the BBB [Dorf et al., 2000]. Chemokines released by ra t brain 
endothelial cells [Harkness et al., 2003] may help to guide astrocytes towards mi­
crovessels and ensure the development of the BBB [Cancilla, 1993]. In addition to 
actively responding to chemokines, astrocytes might regulate the chemokine ac­
tion via internalization of CCL2 via CCR2 as shown by decreased CCL2 binding 
to human foetal astrocytes with increasing concentrations of CCL2 [Andjelkovic 
et al., 1999b].
CCL2, via interaction with CCR2, seems to increase the permeability of the 
BBB by perturbing the tight junctions of endothelial cells, through activation of 
Rho and Rho kinase pathways facilitating the penetration of inflamm atory cells 
into the CNS [Stamatovic et al., 2003]. Chemokines also act on the extravasion of 
immune cells by increasing the production of metalloproteinase enzyme (MMPs) 
by monocytes and macrophages resulting in destabilization of the BBB such as 
MMP9 [Cossins et al., 1997, Rosenberg, 2002, Sellebjerg and Sorensen, 2003]. In­
deed CCL2 has been shown to increase secretion of pro-MMP9 by the monocytic 
cell line (THP-1 cells) in a dose dependent manner using zymography gels and 
densitometry [Robinson et al., 2002],
Nevertheless, CCL2 seems to have a more complex role than  solely promoting 
inflammation by recruiting inflammatory cells into the CNS. Kalehua et al. (2004) 
have shown th a t CCL2 is involved in neuronal recovery in the hippocam pus in 
mice. Immunohistochemical analysis has shown th a t intrahippocam pal injection
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of kainic acid results in a late and unexpected increase in CCL2 expression by 
reactive astrocytes after 21-45 days. Microarray experiments on cDNA of rodent 
astrocytic cell line (CTX TNA2 cell line) showed th a t stim ulation by CCL2 leads 
to secretion of bFGF, th a t would facilitate neuronal cell differentiation and pro­
mote survival of neurons in vitro [Kalehua et ah, 2004]. Further evidence on 
the protective effect of CCL2 on neuronal apoptosis, induced by N-methyl-D- 
aspartic acid (NMDA), was obtained by an in vitro study where mixed culture 
of human neurons and astrocytes induced a reduction in neuronal apoptosis fol­
lowing treatm ent with CCL2 but not for CXCL10 [Eugenin et al., 2003]. The 
co-treatm ent of NMDA with CCL2 on mixed cultures of neurons and astrocytes 
induced a reduction in glutam ate release compared to NMDA only [Eugenin et al.,
2003]. Therefore astrocytes seem to protect neurons from glutam ate excitotoxic- 
ity by regulating the level of glutam ate through transporters (GLT1 and GLAST) 
[MacAulay et al., 2 0 0 2 ].
Despite the contradictory evidence, CCL2 seems to play an active role in MS. 
The reason why CCL2 is highly expressed in active demyelination lesions and the 
level of CCL2 decreased in the CSF of MS patients at the time of relapse remains 
unclear.
1 .4.9.4 CXCL10 expression in MS
CXCL10 belongs to the a-chemokine family and promotes the recruitm ent of 
T  lymphocytes through binding to its receptor, CXCR3. The role of CXCL10 in 
the pathogenesis of MS has been elucidated by studying the level of expression of 
this chemokine in the CSF and serum of MS patients.
Studies on brain tissue of control individuals and in NAWM of MS patients 
showed th a t no reactivity was observed [Balashov et al., 1999]. In active MS 
lesions, expression of CXCL10 has been reported by several groups [Balashov
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et al., 1999, Simpson et al., 2000b, Sorensen et al., 1999]. CXCL10 was highly 
expressed on macrophages and lymphocytes bu t not in silent and silent/inactive 
lesions [Simpson et al., 2000b]. CXCL10 is not only expressed by macrophages 
and lymphocytes, studies have reproducibly localized CXCL10 immunoreactivity 
to reactive astrocytes within active demyelinating MS lesions, suggesting astro­
cytes as a potential cellular source of CXCL10 in the CNS [Sorensen et al., 1999, 
Simpson et al., 2000b].
In the CSF, CXCL10 has been shown to be present in significantly higher 
levels in patients with relapsing rem itting MS (RR-MS), secondary progressive 
MS (SP-MS) and prim ary progressive MS (PP-MS) compared to controls (CON), 
other neurological disorders (OND) and other inflammatory neurological disorders 
(OIND). Scarpini et al. (2002) showed th a t CXCL10 was more highly expressed 
in active RR-MS (453 ±  63pg/ml), stable RR-MS (293 ±  43pg/m l) SP-MS (424 
±  130pg/ml) and OIND (1734 ±  674pg/ml) compared to PP-MS (78 ±  15pg/ml), 
CON (79 ±  27pg/ml) and OND (79 ±  42pg/m l). These findings were confirmed 
by another study th a t reported an increase in CXCL10 level in the CSF in MS 
patients compared to normal individuals [Mahad et al., 2002b]. The same pat­
tern  was observed with CXCL10 expression in the serum with lower expression of 
CXCL10 in CON, OND and PP-MS (between 59 ±  29pg/m l and 78 ±  15pg/ml) 
than  active RR-MS, stable RR-MS, SP-MS and OIND (between 221 ±  52 and 
635 ±  175pg/ml). Similar findings were observed by Narikawa et al. (2004) 
using CSF of 13 relapsing neuromyelitis optica (RNMO), 17 MS and 15 con­
trol. CSF CXCL10 levels in RMNO (2147.9 ±  560.5pg/ml) and in MS (2308.1 ±  
857.4pg/ml) were significantly higher than  control (755.5 ±  366.2pg/ml). How­
ever, the CXCL10 level in the serum did not shown any difference between the 
three patient groups.
The fact th a t CXCL10 increases in CSF and possibly in the serum of all the 
subtypes of MS, but not PP-M S compared to controls, suggests th a t CXCL10 is 
involved in inflammation but not demyelination. Additionally, CXCL10 levels in
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the CSF correlated with the CSF leukocyte count, suggesting in vivo chemoat- 
trac tan t activity of CXCL10 on these cells [Sorensen et al., 1999].
1.4.9.5 Function of CXCL10 in the CNS in MS
The role of CXCL10 has been extensively studied using EAE animal models. 
CXCL10, measured by ELISA, was increased before the clinical symptoms of the 
disease in SJL mice with EAE. The production of CXCL10 was also m aintained 
at high levels during the peak of the disease [Fife et al., 2001]. Injection of 
an antibody against CXCL10 in the adoptive transfer model of EAE showed an 
amelioration of the disease and a reduction in the accumulation of pathogenic 
T cells [Fife et al., 2001, Liu et al., 2001]. This evidence highlights the role of 
CXCL10 in the recruitment of pathogenic cells a t the lesion site into the CNS.
1.4.9.6 Chemokine receptors in MS
Expression of CCR1, CCR2 , CCR3 and CCR5 on CNS post-m ortem  tissue 
from MS patients have been detected on foamy macrophages and activated mi­
croglia in chronic active lesions, which correlated with the level of expression of
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their ligands [Balashov et al., 1999, Simpson et al., 1998, 2000a].
O ther evidence for chemokine receptor involvement is MS was obtained in a study 
by Trebst et al. (2003). CCR8  expression was found in MS white m atter and local­
ized on phagocytic macrophages and activated microglia which showed correlation 
with the degree of demyelination [Trebst et al., 2003].
The im portance of chemokine receptor expression on PBM Cs has been ob­
tained using blood and CSF from MS patients and healthy controls. CCR2 and 
CCR5 expression on CD4+ cells was shown to be significantly higher in MS pa­
tients at relapse compared to control, whereas CCR3 and CCR4 expression on 
CD4+ T cells was significantly lower [Misu et al., 2001]. Chemokine receptors are 
also m odulated on CD8 + T cells. CCR5 expression was shown to be significantly 
up-regulated in MS patients compared to control, whereas CCR4 was shown to
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be down-regulated [Misu et al., 2001].
CXCR3 expression was also observed on CSF cells as well as lymphocytes in 
the perivascular cuffs in inflammation lesions. It was found th a t peripheral T 
lymphocytes have up-regulated CXCR3 expression in MS patients compared to 
controls [Nakajima et al., 2004]. Another study has implicated CXCR3 in the 
pathogenesis of MS [Mahad et al., 2003]. CXCR3 expression was shown to be 
up-regulated on peripheral blood CD4+ T  cells in MS patients blood compared 
to controls which correlate with relapses.
All these in vivo findings on the expression of chemokine receptors suggest th a t 
they play an im portant role in the pathogenesis of MS. O ther evidence for the 
involvement of chemokine receptors in MS are further discussed in the chapters 3 
and 4.
1.4.10 C hem okines and chem okine receptors in EA E
1.4.10.1 Chemokines in EAE
Many studies have described an increase in chemokine expression in the CNS 
of animals with EAE. In acute EAE, CCL4, CCL5, CCL3, CXCL10 were up- 
regulated at the initiation of the active stage of the disease [Godiska et al., 
1995]. During disease relapse, the same chemokines and CXCL1 was up-regulated 
[Glabinski et al., 1997]. The im portance of these chemokines in the pathogenesis 
of the disease was supported by other studies. For instance, the use of anti-CCL3 
neutralizing antibodies ameliorates clinical signs in acute EAE [Kennedy et al., 
1998]. The im portance of chemokines has been also highlighted using specific an­
tagonists. Use of Met-RANTES, a peptide th a t blocks both CCR1 and CCR5, 
has been shown to ameliorate the course of EAE disease [Matsui et al., 2002]. The 
time course of expression of chemokines follows the clinical and histological stages 
of the disease. For instance CXCL10 mRNA expression level has been linked to 
the extent of histological inflammation [Ransohoff et al., 1993]. Indeed, CCL2 
and CXCL10 expression was never detected in the absence of leukocyte infiltrates
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[Glabinski et al., 1995]. In a recent study using CXCL13-deficient mice, it was 
shown th a t mice develop a less severe form of the disease indicating th a t CXCL13 
plays an im portant role in the development of EAE [Bagaeva et' al., 2006].
1.4.10.2 Chemokine receptors in EAE
Because the recruitment of inflammatory cells occurs via establishment of 
chemotactic gradients of chemokines, together with chemokine receptor expression 
on the responding cell surface, receptor expression has been extensively studied. 
A number of recent studies using knock-out mice for different chemokine receptors 
have been reported. The use of mice deficient for CCR1 and CCR2, revealed th a t 
they play an im portant role in the development of acute EAE [Fife et al., 2000, 
Rottm an et al., 2000]. In CCR1 deficient mice, there is a 50% decrease in the 
clinical disease severity. This could be explained by a study th a t looked a t the 
expression pattern  of CCR1 mRNA in chronic-relapsing EAE [Glabinski et al., 
2 0 0 2 ], They showed th a t the mRNA pattern  of CCR1 increased and correlated 
with the number of T h l T  cells in the spinal cord at relapse.
Studies using CCR2-/- mice have shown th a t these mice were resistant to EAE 
and had no CNS histopathology [Izikson et al., 2000, Fife et al., 2000]. CCR2-/- 
mice had reduced mononuclear cell migration both  into and within the CNS. Sim­
ilarly, CCL2 deficient mice showed a failure in peripheral macrophage recruitm ent 
[Huang et al., 2001]. In EAE CCR2-/- mice, induced by injection of encephali- 
togenic MOG35-55 emulsified in incomplete Freunds adjuvant, showed a delayed 
onset and attenuated disease, with a greatly reduced clinical severity of relapse 
[Gaupp et al., 2003].
These findings support a significant functional role for CCR2 in the pathogenesis 
of the disease.
Inactivation of the CXCR3 gene in EAE mice, would be expected to am eliorate 
the disease due to decreased T  cell recruitm ent to the CNS. Surprisingly, CXCR3
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gene inactivation in MOG-induced EAE, resulted in an increase in the severity 
score of the disease by almost 50% compared to the W T, at day 12 post induction 
[Liu et al., 2006b]. Similarly, injection of antibody directed against CXCR3 in 
P L P i39—i5i adoptive transfer EAE a t days 9, 13 and 16 post-induction induced an 
increase in the EAE score up to 3.5 a t the day 30 compared to the control anti­
body which had an EAE score of 1 [Liu et al., 2006b]. There was no alteration in 
the migration of T  lymphocytes into the CNS, which confirmed a previous study 
where CXCR3 has been shown not to be required for transendothelial m igration 
[Callahan et al., 2004]. No difference was observed in the relative CNS population 
of CD4+ , CD8 + T  cells and TCRa(3 and TCRq# cells between CXCR3-/- and W T 
mice at the peak and the recovery of EAE [Liu et al., 2006b]. It was shown th a t 
isolated lymphocytes from the lymph node had an increase in proliferation and 
decrease in IFN 7  production when the CXCR3 gene was inactivated, which was 
confirmed in vivo. They also showed th a t the BBB was disrupted and there was 
an increase in angiogenesis, shown by an increase in expression of Von W illebrand 
factor, in CXCR3-/- mice [Liu et al., 2006b].
These findings suggest th a t CXCR3 exerts its effect on EAE at the effector phase 
by increasing the synthesis of IFN 7  by T  cells rather than  by controlling the mi­
gration and retention of immunological cells a t the inflammation site.
1.4.11 C hem okines and astrocytes
As previously discussed, astrocytes have been shown to be actively involved 
in MS pathogenesis by producing a wide range of chemokines including CCL2 
and CXCL10. I t was shown th a t astrocytes also secrete CCL5, CCL7, CCL8 , 
CXCL12 which result in the recruitm ent of activated T cells, monocytes and B 
cells as discussed in table 1.1 [Kim et al., 2004, Krumbholz et al., 2006, Trebst 
and Ransohoff, 2001]. Thus, astrocytes contribute to the orchestration of the 
inflammatory response in the CNS by producing chemokines to recruit immune 
cells.
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1.5 Aim s of this thesis
The overall aim of this thesis is to  elucidate the involvement of astrocytes in 
control of chemokine expression in the CNS. Indeed, astrocytes are the most abun­
dant cells within the brain and are located at the vicinity of the BBB, they are in 
a perfect location to regulate the level of chemokines and hence cell recruitment. 
This aim will be addressed by the following objectives:
1. Determine whether there is a differential expression of chemokines, CCL2 
and CXCL10, by astrocytes under pro-inflammatory conditions.
2 . Determine whether astrocytes can sequester CCL2  in the CNS, either under 
basal and pro-inflammatory conditions.
3. Determine the expression of CXCR3 under basal and pro-inflammatory 
conditions and the effects of CXCL10 on astrocytes.
4. Determine the expression of chemokine decoy receptor, D6 , by astrocytes 
in vitro and in vivo and its involvement in the regulation of CC chemokine levels 
under pro-inflammatory conditions.
60
CHAPTER 2
Expression of CCL2 and CXCL10 
by primary human adult
astrocytes
2.1 Introduction
2.1.1 CCL2 and CXCL10 expression in M S
Reports on CCL2 and CXCL10 expression in the CNS white m atter in MS 
pathogenesis have found th a t both CCL2 and CXCL10 are strongly expressed at 
the lesion site compared to control [McManus et al., 1998, Simpson et ah, 2000a]. 
However, it was also shown th a t CCL2 expression was decreased in the CSF of 
MS patients at the time of relapse whereas CXCL1 0  expression was increased 
[Scarpini et al., 2002, Narikawa et al., 2004]. Reports on serum levels of CCL2 
are contradictory. Scarpini et al. (2002) showed a decrease of CCL2 in MS 
compared to control [Scarpini et al., 2002] whereas Kivisakk et al. (1998) showed 
no difference between the expression of CCL2 in serum of MS patients and norm al 
controls [Kivisakk et al., 1998].
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2.1.2 Pro-inflam m atory cytokines in CNS inflam m ation
Cytokines are soluble proteins th a t are involved in many pathological processes 
in the CNS such as oligodendrocyte death, axonal degeneration and neuronal dys­
function [Bjartmar et al., 2003, Owens, 2002, Lucchinetti et al., 1998]. M odulation 
of cytokine expression levels in MS indicate a key role for cytokines in the patho­
genesis of MS. Mycko et al. (2004) analysed gene expression in chronic active and 
chronic inactive lesions in MS by cDNA microarray analysis. IL6  and TN F showed 
significant increases of 15.2 and 8.1 fold between chronic active and chronic inac­
tive lesion [Mycko et al., 2004]. Similar findings were seen for IL-17 which was 
increased in MS brain compared to control [Lock et al., 2 0 0 2 ]. A nother study 
showed th a t PBM C secretion of IL6  and TNF was significantly increased in MS 
patients compared to control but no difference was observed with IL-10 and IFN 7  
[Ozenci et al., 2000].
During MS pathogenesis, astrocytes become reactive and increase expression of 
cytokines and growth factors [Meeuwsen et al., 2003]. Three cytokines, expressed 
a t CNS inflammatory sites [Link, 1998, Pan et al., 1997, Rothwell and Luheshi, 
2000], are commonly used in in vitro studies: IL-1/3, TN F and IFN 7 .
2 .1 .2.1 Interleukinl-/? (ILl-fi): effect on CNS resident cells
IL1-/3 is a 17KDa protein expressed by numerous cells within the CNS includ­
ing astrocytes, neurons and oligodendrocytes as well as microglia and invading 
macrophages, during inflammation [Vitkovic et al., 2000, Davies et al., 1999, Blasi 
et al., 1999]. IL1 -(3 exerts its biological effect through the binding to  a 6 8 KDa 
cell surface receptor which requires an accessory protein for induction of signalling 
events [Rothwell and Luheshi, 2000].
IL1-/3 has been shown to induce oligodendrocyte cell death when co-cultured 
with astrocytes and microglia but not in pure cultures of oligodendrocytes. The 
mechanism responsible for the cell death seems to  be related to the impairment 
of glutam ate uptake by astrocytes [Takahashi et al., 2003]. G lutam ate has been
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shown to  be taken up by five transporters, including GLT-1  and GLAST, princi­
pally expressed by astrocytes, which are down regulated by IL-1/3 [Hu et al., 2000, 
MacAulay et al., 2002, Rothstein et al., 1996]. Thus, IL-1/? can regulate the level 
of glutam ate which results in an increase in extracellular glutam ate level inducing 
excitotoxic neurodegeneration.
Further evidence for a detrimental role for IL1-/3 in MS was obtained by a 
genetic study which discovered th a t MS patients who were carriers of the IL1RN2 
allele and non-carriers of the IL1B2 allele had a higher rate of progression than  
the patients w ith other allelic combinations [Schrijver et al., 2003].
However, the role of IL1-/? is not only detrim ental bu t has also been reported to 
mediate neuroprotection. In vitro studies have shown th a t incubation of neurons 
with NMDA resulted in cell death which was partly  inhibited by co-incubation 
with IL1 -(5 (at 25 and 50ng/ml). The IL1/? neuroprotective effect was inhibited 
when IL1RA (IL1 receptor antagonist) was added thus confirming the in vitro 
neuroprotective effect of IL1/? on neurons [Carlson et al., 1999]. The mechanism 
underlying the neuroprotection has been partly  elucidated in studies using IL1 
KO mice, in which IL1-/5 might promote oligodendrocyte repair via induction of 
insulin growth factor I (IGF-I) by astrocytes and macrophages/microglia [Mason 
et al., 2 0 0 1 ].
2 .1.2.2 Tumor necrosis factor (TNF): effect on CNS resident cells
TN F is a 17 KDa protein th a t is expressed by many immune cells includ­
ing T  and B lymphocytes, NK cells, eosinophils and monocytic cells. In the 
CNS, activated microglia are the main producers of TNF, although astrocytes 
also produce TN F bu t to a much lesser extent [Sawada et al., 1989, Kuno et al., 
2006]. TN F exerts its biological effect through binding to two different receptors, 
TNFR1 (p55) and TNFR2 (p75). Following CNS injury, TN F expression is dra­
matically increased and leads to the activation of mononuclear phagocytic cells,
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endothelial cells and gliosis and eventually to initiation of apoptosis of oligoden­
drocytes. Takeushi et al. (2006) showed th a t TNF induced activation of microglia 
cells resulting in the release of glutam ate leading to neuronal excitotoxicity and 
death. TN F has been shown to enhance expression of Fas, T N F R 1 and MHC 
class I molecules resulting in oligodendrocyte apoptosis by direct cytotoxic effect 
[Buntinx et al., 2004].
TN F has been shown to induce demyelination and neuronal degeneration either 
directly or indirectly via the production of toxic mediators such as NO and reac­
tive oxygen species (ROS) [Tanaka et al., 1994].
However, there is also evidence to suggest beneficial effect of TN F on remyeli- 
nation. For example, TN F deficient animals display a significant delay in remyeli- 
nation associated with a reduction in the pool of proliferating oligodendrocytes 
and a reduction in the number of m ature oligodendrocytes [Arnett et al., 2001]. 
TN F not only acts on oligodendrocytes but also on astrocytes and especially in 
induction of the secretion of growth factors such as NGF (nerve growth factor).
2 .1.2.3 Interferoiry (IFN7 ): effect on CNS resident cells
IFN7  is a pleotropic cytokine th a t plays an im portant role in the regulation 
of the immune response. It has been shown to activate mononuclear cells, dif­
ferentiate T  cells into T h l phenotype, increase cell expression of MHC class I 
and II molecules and induce apoptosis of T  cells and other cell types [Imitola 
et al., 2005]. The exact role of IFN7  in MS pathogenesis is not clear. I t has been 
shown to have a detrim ental effect on oligodendrocyte function and survival. In 
presence the of IFN 7 , oligodendrocytes have been shown to up-regulate the ex­
pression of surface receptors th a t mediate cell-cytotoxicty such as MHC class I or 
the death receptor Fas [Agresti et al., 1998, Pouly et al., 2000]. O ther evidence 
has been obtained by over-expressing IFN 7  in the CNS which results in oligoden­
drocyte apoptosis and inhibition of myelination [Balabanov et al., 2006, Horwitz 
et al., 1997, Lin et al., 2006]. Therefore IFN 7  play an active role in demyelination.
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Paradoxically, a low level of IFN7  provides protection to  m ature oligodendro­
cytes against demyelination in M B P/IFN 7  transgenic mice [Gao et al., 2000]. It 
was shown th a t these mice presented with higher levels of expression of IGF-1 
which protects oligodendrocytes in vitro [Ye and D ’Ercole, 1999]. Similarly, IFN7  
KO mice were more susceptible to EAE and showed a more severe invasion of CNS 
by immune cells [Ferber et al., 1996]. This surprising finding might be explained 
by the anti-proliferative effect and the pro-apoptotic effect of IFN 7  on T cells 
therefore preventing the accumulation of activated T  cells in the CNS [Chu et al., 
2000].
IFN 7  has been shown to be involved in the immune response by increasing the 
expression of MHC class II molecules on astrocytes, which allows them  to act as 
APCs as discussed in section 1.2.6 .6  [Dong and Benveniste, 2001]. A recent study 
reported th a t, following IFN7  treatm ent of murine astrocytes, the upregulation 
of genes involved in the immune response, including chemokines, cytokines and 
most predom inantly MHC class I and II antigen presentation pathway genes. In 
addition to  MHC class II molecules, IFN 7  treatm ent induced upregulation of B7.1, 
B7.2 and HLA-DM expression by murine astrocytes indicating th a t astrocytes are 
able to  present antigen and activate naive T  cells [Carpentier et al., 2005, Halonen 
et al., 2006].
2.1.3 A im  o f the study
To elucidate why there is differential expression of CCL2 and CXCL10 in the 
CSF and the possible contribution of astrocytes to  this process, the rate of syn­
thesis and secretion of these two chemokines under pro-inflammatory conditions 
was investigated. Indeed, chemokine expression by astrocytes is affected by the 
cytokine milieu within the CNS during active inflammation, as evidenced by stud­
ies on post-m ortem  tissues.
This aim will be addressed by the following objectives:
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1 . To determine whether human adult astrocytes express CCL2 and CXCL10 
mRNA and protein.
2. To assess whether pro-inflammatory cytokines are able to modulate the 
expression of CCL2  and CXCL10 mRNA and protein.
3. To determine any difference between the levels of expression of CCL2 and 
CXCL10 in between control and cytokine stim ulated astrocytes.
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2.2 M aterials and m ethods
2.2.1 Isolation o f astrocytes from CNS tissue
Prim ary adult human astrocytes were isolated from CNS normal appearing 
white m atter tissue obtained from the UK MS Society Tissue Bank (UKMSTB; 
donor labelled SMS262) following Open University, Kings College Hospital (KCH) 
and UKMSTB ethics guidelines. Seven other prim ary hum an adult astrocytes 
were used in this thesis and were isolated from CNS normal appearing white m at­
ter tissue (SMS-12), MS lesions (donor labelled MS16 and MS21) from the UK MS 
Society Tissue Bank or from temporal lobectomy resections at KCH (B327/01, 
B668/01, B1029, B79/01 and Epl5). These astrocyte preparations were provided 
by Dr. Ignacio Romero from the Open University.
Astrocytes were isolated as described by Flynn et al. (2003). Approximatively 
1 g of brain tissue per preparation was used. Meninges and visible blood vessels 
were removed with forceps to.avoid contamination with fibroblasts. Samples were 
minced with scalpel and the tissue fragments were transferred to  10 ml of Hank’s 
balanced salts solution containing 10 mM HEPES, 50 U /m l penicillin and 50 
/ig/m l streptomycin, and 2.5 ^g /m l fungizone (Invitrogen, UK) and centrifuged 
for 5 min a t 600 g in a Sorvall legend RT (Thermo Scientific, UK). The pellet 
was resuspended by trituration  in 15 ml of 1 m g/m l collagenase dispase solution 
containing 10 mg/1 DNase I and 0.147 mg/1 N-p-tosyl-L-lysine chloromethyl ke­
tone (TLCK), an irreversible inhibitor of trypsin, and incubated for 1 h a t 37°C 
with shaking every 10 min. After digestion, the astrocytes were separated from 
microvessel fragments and other m aterial by density-gradient centrifugation for 
30 min at 1000 g with 20 ml of 25% bovine serum albumin (BSA). 75-cm2 flasks 
were coated with poly-L-ornithine diluted in PBS (1.5 g/1; Sigma, UK) for 1 hour 
a t (RT). The floating myelin layer was removed and plated onto coated 75-cm2 
flasks in astrocyte media composed of 1:1 nutrient m ixture F-10 and MEM alpha 
medium, supplemented with 1 0 % heat-inactivated foetal calf serum, 1 % human 
serum ,50 U /m l penicillin and 50 /ig/m l streptomycin (Invitrogen, UK) in a humid
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atmosphere a t 37°C in 95% air/5%  C0 2 - After 48 h, the medium was changed 
to remove unattached cells and myelin debris. Cells resembling astrocytes grew 
to confluence within 2-3 weeks. lxlO 6 astrocytes were resuspended in 1 ml freez­
ing media (1ml DMSO (Sigma Aldrich, UK), 1ml FCS and 9ml media) and kept 
overnight a t -80°C before being stored in liquid nitrogen.
Astrocytes were used up to passage 8  to have optimal viability and avoid 
senescence of astrocytes [Flynn et al., 2003].
2.2.2 C haracterization o f different prim ary hum an adult 
astrocytes by im m unocytochem istry using anti-G FAP  
antibody
To assess the purity of the astrocyte preparations, immunostaining with an­
tibody directed against GFAP was performed. Astrocytom a cell line (U373-MG) 
was used as a positive control.
2.2.2.1 Principle of immunocytochemistry
The technique of immunofluorescence was first described by Coons et al. in 
1941 using on tissue sections [Coons, 1941]. It is now commonly used to  identify 
the expression and distribution of proteins in cells or tissues by specific anti­
gen/antibody interaction. The immunofluorescence technique is based on the 
binding of antibodies, often IgG class, to  a specific antigen.
Two types of antibodies can be used: polyclonal or monoclonal antibody. 
Polyclonal antibodies can be produced in number of animal species, particularly 
rabbit, horse, goat, and chicken by injecting an immunogen (peptide) which re­
sults in antibody production specific to the immunogen. Monoclonal antibodies 
are mostly produced in mice. Polyclonal antibodies have higher affinity and wide 
reactivity bu t lower specificity when compared with monoclonal antibodies.
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Detection of bound antibody is revealed either by direct or indirect labelling 
(secondary antibody) with fluorescent probes, enzymes or radioactive elements 
(figure 2.1). In this chapter, indirect immunostaining using fluorescent probes has 
been used. In chapter 3, direct labelling of antibody is used for flow cytometry 
detection of antigen. Indirect immunofluorescence is more sensitive due to the 
amplification of the signal with the secondary antibody [Myers, 1989].
2.2.2.2 Astrocyte characterization by immunocytochemistry for GFAP
Seven astrocyte preparations were tested for GFAP staining: B327/01, Epl5, 
MS16, MS21, B668/01, B79/01, B1029. Glioblastoma-astrocytoma cell line (U373- 
MG), from a human Caucasian (ECACC 89081403), was used as a positive control. 
The cells were grown in 75 cm2 in astrocyte media at 37°C in 95% air/5%  C02. 
After several days in culture, astrocytes were washed once with PBS (Gibco, UK) 
and 3 ml of trypsin-EDTA (Gibco, UK) was added to  the cells for 5 min to de­
tach them  from the flask. Cells were resuspended in astrocyte media and 0.4ml of 
lx l0 5/m l cell suspension were plated in each well of an 8 well chamber slide (Nalge 
Nunc International, UK) and incubated overnight a t 37°C in 95% air/5%  CO2 . 
Cells were washed twice in PBS and 0.4ml of 4% paraformaldehyde in PBS, pH
7.2 (Appendix) was added to cells for 15 minutes a t RT. Cells were then washed 
3 times (5 min each) with PBS. 100 //I of polyclonal rabbit anti-GFAP antibody 
(Abeam, UK) a t a dilution of 1:1000 in PBS with 0.5% Triton X100 (for per- 
meabilization of the cell membrane) was added to cells and incubated overnight 
a t 4°C. Cells were washed 3 times with PBS and then 100 fA of goat anti-rabbit 
IgG-Alexa 488 (Molecular Probes, UK) was added a t 1:500 in PBS. Cells were 
incubated for 1.5h in the dark in a humid chamber. Antibody was washed away 
as described above, the chambers were gently removed and the slides were washed 
3 times in PBS. The seal from the chamber was gently removed and one drop of 
mounting medium with DAPI (Vector Laboratories Inc., UK) was added to  mount 
the coverslip. Slides were incubated for lh  a t in the dark to allow the DAPI to  
stain the nuclei. Coverslips were sealed with nail varnish to  avoid drying out. La­
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belling of cells was observed with an Axiovert 200 M (Zeiss) confocal microscope 
w ith an LSM 510 laser module (see below).
2.2.3 V isualisation  of GFAP staining by astrocytes using  
confocal m icroscopy
2.2.3.1 Principle of Confocal laser scanning microscopy (CLSM)
CLSM is a technique th a t is able to produce high resolution optical images. A 
laser emits a light source, which passes through a pinhole aperture, reflected by 
a dichromatic mirror and light is collected in an objective to  be scanned across 
the sample on the focal plan. The sample is also scanned in depth by fixed in­
crements (Z-stack) th a t can be reconstructed into three dimensions. The light is 
then refracted and collected again in the lens. There is therefore a m ixture of 
refracted and em itted light. The dichromatic mirror directs the reflected fluores­
cence through a detector pinhole aperture. This pinhole allows light from the focal 
plane to reach the detector but rejects the out-of-focus photons th a t contribute to 
background in the image. The light is collected in the photon multiplier tube to  
be converted into an electronic signal, which is then digitalized by an analogue- 
digitalized converter and a digital image processor th a t create an image. This 
image can be further processed by the computer [Lucitti and Dickinson, 2006, 
Paddock, 2000].
An Axiovert 200M microscope (Zeiss) with an LSM 510 laser module (Zeiss) 
was used to  assess cell staining in this thesis. The LSM 510 program was used 
and the laser (488 nm) was switched on and warmed up for 30 min prior to use. 
The current and the output of the laser were respectively 6.3A and 50%.
2.2.4 D etection  o f m ycoplasm a in cell cultures by P C R
It is vital to ensure th a t cells maintained in continuous culture are not infected 
with mycoplasma. Mycoplasma is a bacteria contam ination th a t perturbs the nor­
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mal metabolism of cells and interferes with biological processes and could mask 
the normal response of astrocytes to cytokine stim ulation [Rottem et al. 1993]. 
Detection of mycoplasma was assessed using PCR amplication following the man­
ufacturer’s instruction (Geneflow Ltd, UK). Briefly, supernatant from astrocyte 
cultures was spun for 5 min at 250g in a Mini Spin Plus centrifuge (Eppendorf, 
UK) to  remove cellular debris. This supernatant was further centrifuged for 10 
min at 12,000g. The supernatant was discarded and 50//1 of buffer solution pro­
vided in the kit was added to the pellet and heated a t 95°C for 3 min. PCR was 
undertaken using the following conditions: hold 94°C 30 s; 35 cycles of 94°C 30s, 
60°C 1 2 0 s, 72°C 60s and 1 cycle 94°C 30s; 60°C 120 s and 72°C 5 min. PC R  prod­
ucts were loaded on a 50 ml 2% agarose gel with 5 /d ethidium  bromide (Sigma, 
UK). A positive control, giving a band at 270bp, was run alongside the samples 
and gels were visualized using a UVP Bioimaging system (Bio-Rad, UK).
2.2.5 Effect of pro-inflam m atory cytokines on th e expres­
sion of CCL2 and CXCL10 by different astrocyte  
preparations
2 .2 .5.1 Stimulation of astrocytes with pro-inflammatory cytokines
Astrocytes (SMS-12) were seeded into 24 well plates at a density of 1x10s 
cells/m l/well in astrocyte media and then allowed to adhere for 24 hours. Media 
was removed and cells were rinsed with PBS. The cytokines diluted in the same 
medium w ithout serum were applied to the cells. The cells were stim ulated in 
triplicate wells w ith the cytokines IL-1 (3, TN F or IFN 7  a t 0, 1, 10 and lOOng/ml 
(Peprotech, UK) and incubated for 2 to 48 hours in a humid atmosphere a t 37°C 
in 95% air/5%  CO2 . Supernatants were removed and spun for 5 min a t 300g to 
pellet the cellular debris and collected for CCL2  and CXCL10 quantification by 
ELISA (performed by Dr. Omer Suliman) and stored a t -20°C. Stim ulations were 
performed in triplicate. The cells were harvested with Tri reagent (Sigma, UK) 
for RNA extraction and real time PCR as described in section 2 .2.6 .2 .
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Fig. 2.1: P r in c ip le  o f im m u n o s ta in in g : d ire c t a n d  in d ire c t la b e llin g .
Immunofluorescence is based on the properties of an antibody to specifically bind 
to a protein (antigen) enabling the detection and localization of a protein on cells 
or tissue. There are two type of immunofluorescence. Direct immunofluorescence 
is performed with the antibody directly labelled with a probe (fluorescent, enzyme 
or radioactive) (a). Indirect immunofluorescence requires two steps (b): the first 
step is the interaction of the antigen with an antibody and the second step is the 
detection of the interaction using a secondary antibody directed against the im­
munoglobulin species of the primary antibody coupled with a probe. For example 
if the primary antibody is a mouse antibody, the secondary antibody is rabbit or 
goat anti mouse.
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Fig. 2.2: P rin c ip le  of confocal laser scanning  confocal m icroscope
(C LSM ).
Schematic diagram of the optical pathway and principal components in a laser 
scanning confocal microscope. The laser passes through the light source pinhole 
aperture to be collected by a lens. The light is scanned on the sample and re­
flected to the dichromatic mirror. The light is then collected by a detector pinhole 
aperture but not the non-focussed light. The photons are then converted into a 
digital signal by the computer tha t generates an image of the sample. Taken from 
www. olympusconfocal. com /  theory/LS C M lntro .pdf
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2.2 .5.2 Comparison of response of three different astrocyte prepara­
tions, following pro-inflammatory stimulation
Comparison of the response of three different normal human adult primary 
astrocyte cell preparations (SMS-12, B327/01 and E pl5) was performed following 
stim ulation with IL-1/?, TN F and IFN7  (lOng/ml) for 24 hours, as described 
above. RNA was extracted to perform qRT-PCR.
2.2.6 R eal tim e P C R  to  quantitate m R N A  isolated  from
astrocytes stim ulated w ith  pro-inflam m atory cytokines
2 .2 .6.1 Principle of qRT-PCR
The technique of real time PCR (qRT-PCR) is based on the RT-PCR reaction 
[Heid et al., 1996, Wilhelm and Pingoud, 2003]. As with RT-PCR, qRT-PCR 
consists of two steps. The first step translates mRNA into cDNA, followed by 
a classical PC R  reaction. In the classical PC R  reaction, 2  primers (forward and 
reverse) m atch and anneal to sequences th a t are on each side of the sequence to 
be amplified. The polymerase enzyme can therefore amplify the desired DNA 
sequence. The product is double-stranded DNA characterized by a length corre­
sponding to the length of DNA between the two primers, determined when the 
primers are designed. At the end of the amplification, a graph is produced th a t 
shows the amount, of DNA amplified for each cycle.
In this thesis, SybrGreen DNA binding dye is used to  detect the amplifica­
tion products because of its simplicity. I t produces a fluorescent signal only when 
bound to  double stranded DNA upon light stimulation. In contrast w ith other 
probes, SybrGreen is not specific and cannot differentiate amplified gene target 
and non specific PC R  products formed like primer-dimer in the reaction (W ittwer 
et al., 1997). Therefore, it is im portant to run a melt curve following qRT-PCR 
by increasing the tem perature by 1°C and recording the fluorescence. By viewing 
a melt curve, you ensure th a t the desired amplicon was detected.
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Amplification and detection during qRT-PCR are directly visualized and cor­
respond to  the quantity of fluorescence in each cycle of the PC R  reaction. Quan­
tification is based on the increase in fluorescence directly linked to the increasing 
amount of double-stranded DNA [Heid et al., 1996]. Thus the am ount of fluores­
cence is correlated to the amount of mRNA of the target gene th a t is present.
qRT-PCR is composed of 3 steps:
•  Denaturation: 95° C.
•  Annealing: dependent on the characteristics of the primers and especially 
the quantity of bases cytosine (C) and guanine (G) in the prim er sequence.
•  Elongation: 62°C.
Before using qRT-PCR on different samples, the selection of the most ap­
propriate housekeeping gene must be performed to use as an internal control for 
normalisation.
Housekeeping genes
A housekeeping gene (HK) is a class of gene th a t has a basal cellular function in or­
ganisms and is constitutively expressed in all cells. In molecular biology, the com­
parison of the rate of synthesis of a protein is fundam ental for the understanding 
of cellular mechanisms. Before carrying out such experiments, an internal control, 
which should not vary amongst the various cells or under different experimental 
conditions, must be selected: this is the HK gene [Thellin et al., 1999]. However, 
since the expression rate  of HK genes may be m odulated under different experi­
m ental conditions, tests must be performed to select the best set of housekeeping 
genes for use in the experimental conditions under study. In this study, five HK 
genes commonly used were assessed; glyceraldehyde-3-phosphate dehydrogenase
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(GAPDH), /?-actin, hypoxanthine phosphoribosyl transferase 1 (HPRT1), Ubiqui- 
tin  C (UBC) and ribosomal protein L 13A (RPL13A) [Vandesompele et a l ,  2002].
Primer design using primer3 software
There are some requirements for the design of efficient primers [Innis MA, 1990]:
•  the length should be between 17 and 28 bp
• the composition should be 50-60% of (G +C)
•  3’ prim er end should be G and/or C
•  Melting tem perature (Tm) should be between 55 and 80°C
The primers, used in this thesis, were designed using Primer3 software [Rozen 
and Skaletsky, 2000] which considers many factors including the melting tem per­
ature, the length, the GC composition and the primer-dimer formation between 
two copies of the same primer.
Quantification of PCR products: comparative Ct method
In the amplification curve, the fluorescence is very low and corresponds to the 
baseline. As soon as fluorescence increases and is above the baseline, which is 
evidence of the accumulation of PCR products, a fixed fluorescence threshold can 
be established above the baseline. The C t (Cycle threshold) value is defined as 
the fractional cycle at which the fluorescence crosses the fixed threshold [Bustin,
2000, 2 0 0 2 ]. The early cycles of qRT-PCR are characterized by an exponential
increase in DNA product. W hen the components of the reaction become limiting, 
the amplification is strongly decreased corresponding to  the plateau. Since slight 
variations in the reaction components can induce large differences in the amount 
of PC R  product a t the end of the reaction, the C t value is used for quantitation 
of RNA in the sample. Indeed, during the exponential phase of the reaction, none 
of the components are in a limiting state so th a t the C t value is reproducible and
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accurate. It gives therefore a more reliable measure of starting copy number than 
the end point of the PC R  product [Bustin, 2002].
This m ethod compares the C t value of a reference (HK) and the test sample. 
The Ct value m ethod is also known as the 2e-(A A C t) m ethod where A ACt 
corresponds to  A C tconfro/ - A C t stimulation [Livak and Schmittgen, 2001]. Here 
A C t corresponds to  the C tsampie-CtHK• This m ethod does not account for primer 
efficiency. Thus if the primer efficiencies between the sample and the HK are 
very different, the determ ination of the ratio of expression between the HK gene 
and the target gene will not be accurate. Calculation of the prim er efficiency is 
therefore vital for the quantification of the PC R  product and will allow use of the 
formula to calculate the fold increase or decrease. To obtain the primer efficiency, 
the slope (a) is calculated from the graph Ct value= ax[log of dilution]+b. Then 
the efficiency is calculated by the formula; Efficiency= 10—
Ideally the efficiency of the primers should be 100%, meaning th a t tem plates 
double after each cycle during the exponential phase. B ut some factors can affect 
the efficiency of the primer, e.g. the length of primer, secondary structure and the 
use of non optimal reagent concentration [Bustin, 2004]. Such factors can there­
fore decrease the efficiency of the primer below 90%. A good primer efficiency is 
between 90 and 110%.
Quantification of PCR products: Pfaffl method
If the efficiency of the primers are different, the Pfaffl method, which considers the 
primer efficiency of the target and HK gene, has to be used [Pfaffl, 2001] following 
the formula:
Efficiency= (Efar5ef)c'icon^ oZ- c ^ arn^ e/(E if^ ) c'ic07ltroZ- Cfsampie
D eterm ination of the primer efficiency is therefore im portant for the quantifi­
cation of the PC R  product, which will determine the formula to use to calculate
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the fold increase or decrease of the target gene.
2 .2 .6.2 mRNA extraction
RNA was extracted from stim ulated prim ary human adult astrocytes using 
Tri reagent (Sigma, UK) according to the m anufacturer’s instructions. Briefly, 
2 wells of cells from 24 well plates a t a density of lxlO 5 cells/well (2xl05) were 
resuspended in 1ml of Tri reagent, transferred into an eppendorf tube and 0.2ml of 
chloroform (Sigma,UK) added to samples, mixed and incubated for 10 min at RT. 
Samples were centrifuged in a Mini Spin Plus centrifuge (Eppendorf, UK) for 15 
min a t 12  000 g a t 4°C and the aqueous phase was collected for RNA precipitation 
with 1.5 ml of isopropanol (Sigma, UK). Samples were centrifuged a t 12,000 g for 
10 min a t 4°C. Pellets were washed with 1ml of ethanol (75%) and resuspended 
in autoclaved water, usually 20/d to 30/d, depending on the size of the pellet. 
The integrity of RNA (double bands corresponding to  the two different subunit 
of RNA) was confirmed by running 1/d of mRNA with 5/d of RNA loading buffer 
(Appendix) on 1% agarose gel electrophoresis.
2.2.6 .3 cDNA synthesis
The mRNA was transcribed into cDNA using the iScript cDNA synthesis kit 
(Biorad,UK). Two to four /d of mRNA, depending on the am ount of mRNA 
visualized on the 1% agarose gel, was mixed with 4/d of 5X iScript Reaction mix, 
1/d iScript reverse transcriptase and nuclease free water to a final volume of 2 0 /d. 
Samples were incubated for 5 min a t 25°C, 30 min a t 42°C and 5 min a t 85°C 
using a QBD2 heating block (Grant Instruments, UK). Samples were stored at 
-2 0 °C until required.
2.2.6.4 Real time PCR optimisation: selection of the most stable 
housekeeping gene using GeNorm software
GeNorm software is an excel based software which was used to select the most 
stable housekeeping gene between UBC, GAPDH, HPRT, RLP13A and /?-actin.
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The GeNorm program, which has been cited in over 600 papers, is based on the 
A A C t value method. I t determines the gene expression stability measure (M) 
and the average pairwise variation (V) of the tested gene under IL1-/3, TN F and 
IFN 7  (lOOng/ml) treatm ent, by calculating the ratio:
Ratio =  2  (C tsam pie-ctcontroi)  ^ where control corresponds to the unstim ulated as­
trocytes.
Stepwise exclusion of the gene with the highest M value allows ranking of the 
tested genes according to  their stability leading to the selection of the most stable 
HK gene [Vandesompele et al., 2002].
2.2 .6 .5 Real time PCR amplification
CCL2 primers were provided by Dr. Alison Cross who designed them  using 
Prim er Express software (Applied Biosystems). CXCL10 primers were obtained 
from published sequences [Grassi et al., 2003]. The sequences of primers used in 
this study are summarized in table 2.1. The fold increase in the target gene was 
determined using the formula 2e-(A A Ct) (for CCL2  and CXCL10).
Each cDNA from the cell stimulations experiments (section 2.2.5.1) (n=3) was 
amplified twice. The real time PCR reactions were conducted with Absolute Sybr­
Green (Abgene,UK). 2.5/d of cDNA was combined with 0.5/dVI of each primer, 3 
or 4mM M gC^ (for CCL2 and CXCL10 respectively) and IX  absolute SybrGreen. 
The real time PC R  conditions were as follows: hold 95°C 15 min; 40 cycles of 95°C 
15s, 60°C 15s, 72°C 30s; 1 cycle 95°C 30s; 1 cycle 50°C 30s and the melt ram p 
from 50°C to 95°C at l ° C /1 0 s to determine the product specificity. All samples 
were run on the iCycler (Biorad).
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2.2.7 M easurem ent o f CCL2 and CXCL10 secretion by as­
trocytes following pro-inflam m atory stim ulation  us­
ing Enzym e-Linked Im m unoSorbent A ssay (ELISA)
Supernatants from cell stimulation experiments (section 2.2.5.1) were spun 
down for 5 min a t 300g to pellet the cellular debris. Supernatants were transferred 
into clean eppendorf tubes and stored a t -70°C. ELISAs were performed by Dr. 
Omer Suliman. Briefly, 100 /d of capture antibody CCL2 and CXCL10 (R&D 
Systems, UK) were loaded into wells at 4 fig / ml and incubated overnight at 4?C. 
Wells were washed three times with 400/d of PBS and then 300/d PBS containing 
1% BSA, 5% sucrose, 0.05% NaN3 was added to the wells and incubated for 1 
hour a t RT to prevent non specific binding. Wells were washed three times with 
PBS. S tandard curve were performed in duplicate with recombinant hum an CCL2 
or CXCL10 (Peprotech, UK) using the following concentrations: 2000, 1000, 500, 
250, 62.5 and 37.25 pg/m l. 100 /d  of standard dilutions or 100/d of supernatants 
were loaded into wells and incubated for two hours at RT. Following washing as 
described above, biotinylated primary antibody was applied to wells (50ng/ml 
for CCL2 and lOOng/ml for CXCL10, R&D Systems, UK) and incubated for 2 
hours at RT. Wells were washed three times with PBS and 1 0 0 /d  of streptavidin 
HRP (R&D Systems, UK) at a dilution of 1/200 was added and incubated for 
20 min at RT. Wells were washed as previously and 100/d of substrate (3,3’,5 ,5- 
tetram ethylbenzidine (TMB) Liquid Substrate System, Sigma UK) was added per 
well and incubated for 30 min at RT in the dark. 100/d of stop solution (sulphuric 
acid, 1M) was added per well. Absorbance was read using a plate reader (Wallac 
Victor2) a t 450 nm. Secreted CCL2  and CXCL10 was determined by using the 
equation from the standard curve, y= ax  +  b where a is the slope of the standard 
curve. Chemokine secretion under pro-inflammatory stim ulations was performed 
in triplicate and expressed as fold increase compared to  the baseline (unstim ulated 
cells).
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2.2.8 S tatistica l analysis
Real time PC R  and ELISA data  are shown as mean ±  SEM. For experiments 
on mRNA level expression and protein expression, level of significance for compar­
ison between samples was determined using the ANOVA param etric test, which 
allows comparison between three or more groups. D unnett’s test was used to de­
term ine if there was any difference in the mean value of the stim ulated astrocytes 
compared to  the reference (unstimulated astrocytes). In all cases, P<0.05 was 
considered significant.
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Primers Sequences Tm  (°C)
GAPDH forward ACCCAGAAGACTGTGGATGG 59.4
GAPDH reverse CACATTGGGGGTAGGAACAC 59.4
/?-Actin forward TGTTACCAACTGGGACGACA 57.3
/3-Actin reverse GGGGTGTTGAAGGTCTCAAA 57.3
RPL13A forward CCTGAAGAAGAGGAAAGAGA 62.4
RPL13A reverse TTGAGGACCTCTGTGTATTTGTCA.A 59.7
HPRT forward TGACACTGGCAAAACAATGCA 55.9
HPRT reverse GGTCCTTTTCACCAGCAAGCT 55.9
UBC-forward A TTTG G GTCCCG GTTCTT 53.7
UBC-reverse TGCCTTGACATTCTCGATGGT 57.9
CCL2-forward CTGTGCCTGCTGCTCATAGC 61.4
CCL2-reverse GCACTGAGATCTTCCTATTGGTGAA 61.3
CXCL 10-forward TGAGCCTACAGCAGAGGAA 57.6
CXCLlO-reverse TACTCCTTGAATGCCACTTAGA 56.5
Tab. 2.1: P r im e r  seq u en ces  u sed  in  th is  s tu d y .
Commonly used housekeeping genes were tested in this study to  determine which 
was the most stable gene. GAPDH, /?-actin, RPL13A, HPRT and UBC were 
tested using GeNorm software. The primers for the two target genes, CCL2 and 
CXCL10 were either designed by Dr. Alison Cross using primer express software 
(Applied Biosystems) or obtained from published sequences.
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2.3 R esults
2.3.1 C haracterization of primary hum an adult astrocytes  
using im m unocytochem istry
Seven different human prim ary astrocyte preparations (SMS-12, B37/01, 668/01, 
B1029, B79/01, MS16, MS21) and an astrocytom a cell line (U373-MG) were tested 
by immunocytochemistry using an antibody against GFAP, a specific marker of 
astrocytes. All the prim ary adult astrocytes were positive for GFAP (figure 2.3 
c-i). However, a non-fibrillary staining pattern  was observed as seen for B327/01, 
E pl5 , MS 2 1  and MS16 (figure 2.3c,d, e and f respectively). This was not due to 
technical issues as U373-MG, an astroglioma cell line, showed the characteristic 
fibrillary staining for GFAP. Despite positive staining for GFAP, several astrocyte 
preparations showed an uncharacteristic phenotype e.g. B668/01 (figure 2.3g), 
B79/01 (figure 2.3h) and B1029 (figure 2.3i) with a small rounded cell morphol­
ogy, not characteristic of astrocytes, whereas other astrocytes showed the charac­
teristic star-shaped cell phenotype. No difference in the phenotype was observed 
between normal astrocytes and astrocytes from MS lesions.
SMS-1 2 , B327/01, Epl5 , MS21 and MS16 preparations were tested for con­
tam ination with mycoplasma using a PC R  mycoplasma test kit. Mycoplasma 
is an intracellular bacteria tha t perturbs the normal metabolism of cells and in­
terferes with biological processes (Rottem et al 1993). This PC R  based kit for 
detection of mycoplasma amplified a conserved and mycoplasma-specific 16 S ri- 
bosomal RNA gene region (positive control). The absence of a band at 270 bp 
in astrocyte supernatants dem onstrated th a t the astrocyte preparations were not 
contam inated by mycoplasma (figure 2.4).
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Fig. 2.3: C h arac te risa tio n  of p rim ary  hum an  ad u lt a s tro c y te s  using  im- 
m unosta in ing  for th e  a s tro cy tic  m ark er, G FAP.
Cells were stained with rabbit anti-GFAP antibody and mouse anti-rabbit anti­
body labelled with alexa lluor 488. Staining was visualized by confocal microscopy, 
(a) the negative control corresponds to the omission of the prim ary antibody, (b) 
Astrocytoma, U373-MG, was used as a positive control. Seven astrocyte prepa­
rations were tested for GFAP staining (c)B327/01, (d)Epl5, (e)MS16, (f)MS21, 
(g)B668/01, (h)B79/01 and (i)B 1029). No difference in the phenotype was ob­
served between astrocytes from MS lesion and from NAWM.
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Fig. 2.4: D e te c tio n  fo r m y c o p la sm a  c o n ta m in a tio n  in  a s tro c y te  su p e r­
n a ta n ts  u s in g  P C R  am p lifica tio n .
Mycoplasma contam ination of cells was tested by PC R  on the supernatant of 
cultured astrocytes, using primers specific for conserved-mycoplasma ribosomal 
RNA subunit. Supernatant of five astrocyte preparations, which had a normal 
astrocytic phenotype were tested (B327/01, SMS-12, E pl5 , MS16 and MS21). 
The positive control, which corresponds to  the mycoplasma-specific 16S rRNA 
gene region, was used and gave a band at 270bp, following amplification by PCR. 
lOObp ladder was used to  determine the size of the PC R  products. Absence of 
bands a t 270bp in astrocyte preparations indicates they were free of mycoplasma.
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2.3.2 R eal tim e PCR: optim isation
2.3.2.1 Selection of the housekeeping gene (HK gene)
In this pilot project, five HK genes commonly used with GeNorm software 
were tested to determine the most stable housekeeping gene [Vandesompele et al., 
2002].
•  /?-actin
•  GAPDH
• UBC
• RPL13A
• HPRT
To assess the selection of the best HK gene, astrocytes were stim ulated with 
IL1-/?, TN F and IFN 7  (lOOng/ml), mRNA was extracted and transcribed into 
cDNA. Sample were run on qRT-PCR and ratios were calculated following the 
formula: Ratio =  2^ctsample~ctcontro1  ^ where control corresponds to  the unstim u­
lated astrocytes and sample corresponds to the stim ulated astrocytes (table 2 .2 ). 
The ratios for the different set of primers were analysed with geNorm program. 
Table 2.2 shows the result of the calculation of the M value by GeNorm software. 
The highest M value was obtained with GAPDH gene, whereas the lowest M value 
was obtained w ith the HPRT gene. This means th a t GAPDH was the least stable 
HK gene between the five HK genes tested. Because the M value of GAPDH was 
above the cut off value of 1.5 (not stable enough) and /?-actin, RPL13A, UBC 
and HPRT were lower than  1.5, the primer efficiency of these four HK genes was 
determined. By stepwise exclusion of the gene with the highest M value, UBC 
and RPL13A were the most stable genes.
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HK gene 
Treatm ent
Actin RLP13A HPRT UBC GAPDH
0 1 1 1 1 1
IFN-100 2.549121 2.549121 4 3.605002 0.7579
TNF-100 3.24901 2.549121 5.098242509 3.363589 48.503
IL-1/5-100 1.681793 2.297397 3.732131966 3.482202 5.6569
M value 0.926 0 .8 8 6 0.870 0.884 2.447
Tab. 2.2: R a t io  a n d  M  v a lu e  d e te rm in a tio n  o f th e  d iffe re n t h o u sek eep in g  
g en e  a n a ly se d  u s in g  G e N o rm  so ftw are .
Real tim e PC R  was performed in duplicate on cDNA of unstim ulated and 
stim ulated astrocytes (SMS-12). Ratios were determined following the formula 
2 {C tsam pie-ctcon tro i)' r a t i 0  was used w ith . GeNorm software to determine the
most stable housekeeping gene by calculating the gene expression stability value 
or M value (Vandesompele et al., 2002). Genes th a t have an M value below the 
cut-off value (1.5) are considered stable and can be used as reference gene for the 
real-time PCR.
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Fig. 2.5: A nalysis of th e  m elt-cu rve  to  d e te rm in e  th e  specificity  of P C R  
p ro d u c t.
Melt curve analysis is used to determine whether the amplification is specific. 
The Y-axis is the change of fluorescence (dF) /  change of tem perature (dT) which 
is plotted against X-axis (tem perature) The negative control has an increase in 
fluorescence in region 2 (lower tem perature) corresponding to the primer dimer 
formation and in region 1, which corresponds to the melting tem perature of spe­
cific products. RPL13A was not selected for further experiments due to the non 
specific amplification seen in the negative control (dark blue curve). O ther HK 
genes did not show amplification in the region 1 (light blue (UBC), blue (/?-actin), 
brown (HPRT) and green (GAPDH) curves) under the same conditions.
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2 .3.2.2 Determination of primer efficiency
As previously stated, determination of the primer efficiency is essential for 
quantitative determ ination of the fold increase in the product. To assess the 
primer efficiency of the housekeeping gene, different dilutions of cDNA were pre­
pared: neat, 1/5, 1/50, 1/500 and 1/5000, in duplicate. Figure 2.6 is an example 
of an amplification curve with the UBC set of primers, with diluted cDNA. Theo­
retically, a 1 0  fold dilution should give a shift in the appearance of the fluorescence 
of 3.3 cycles. The primer efficiency was calculated using the C t value of the di­
luted cDNA using the formula:
Efficiency= (1 0 “ ^ /sZ°Pe))-l where the slope is obtained from the graph Ct 
value= slope[log of cDNA dilution]+b (figure 2.7).
Efficiencies of the four HK genes are summarized in table 2.3. RPL13A and 
the UBC primers were the two best candidates for further experiments. But the 
melt-curve analysis for RPL13A showed an amplification of fluorescence at the 
specific melting tem perature of specific products for the negative control (blue 
curve, figure 2.5, region 1). The melt curve analysis also showed the formation of 
primer-dimer for the negative control at the lower tem perature (figure 2.5, region 
2). Therefore, RPL13A was not selected for the further experiments. UBC was 
the best candidate for the internal control, with an efficiency of 1 0 2 % and no 
specific amplification for the negative control . For the two target genes CCL2 
and CXCL10, efficiency was determined with five different dilutions (neat, 1/5, 
1/25, 1/50, 1/500 and 1/2500). The efficiencies summarized in table 2.3 were close 
to 100% (2 e-(A A C t) method). The dilution used for the qRT-PCR reaction for 
CCL2  and CXCL10 was 1/25 and neat respectively. Different cDNA dilutions 
were used for the two chemokines in order to  obtain the optimal signal for real­
time PC R  analysis. The same dilution was used for the HK gene depending on 
the target gene amplified.
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Actin RLP13A UBC HPRT CCL2 CXCL10
Slope -2.78 -3.383 -3.2684 -2.448 -3.51 -3.01
1/Slope -0.3679 -0.2956 -0.3096 -0.4084 -0.28 -0.32
Efficiency
(%)
133 97.5 102 156 93 109
Tab. 2.3: P rim e r efficiency of th e  housekeeping  and  ta rg e t genes.
The primer efficiency was determined following the formula: Efficiency^
(10_(1/s/°Pe))-i where the slope is obtained from the graph Ct value= slope[log 
of cDNA dilution]+b. The best candidate for the internal control was UBC with 
an efficiency of 102%. Experiments were done in duplicate.
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Fig. 2.6: U B C  p rim er efficiency in q R T -P C R : serial cD N A  d ilu tio n s .
The efficiency of the set of primers for the UBC gene was determined using dif­
ferent dilutions of cDNA (neat, 1/5, 1/50, 1/500 and 1/5000). Theoretically, a 10 
fold dilution should give a shift in the appearance of the fluorescence of 3.3 cycles. 
The shift obtained between 1/5 and 1/50 dilution was 3.5.
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UBC efficiency
y = -3.2684x + 19.845
20
-2.5 -1.5 
Log dilution
-0.5
Fig. 2.7: C a lc u la tio n  o f U B C  p r im e r  effic iency  u s in g  th e  C t v a lu e  fro m  
q R T -P C R  re a c tio n  w ith  se ria l d ilu tio n s .
This graph dem onstrates the Ct value obtained from the diluted cDNA using the 
specific set of primers, in this case UBC, against the log of dilution of the cDNA. 
The slope of the curve is used further to  determine the primer efficiency of the 
gene of interest.
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2.3.3 M easurem ent of CCL2 and CXCL10 m R N A  expres­
sion by stim ulated  prim ary hum an astrocytes using  
real tim e P C R
At baseline, in unstim ulated cells, CCL2 mRNA was more highly expressed 
than  CXCL10 mRNA (figure 2.8).
2.3.3.1 Determination of CCL2 mRNA expression following cytokine 
stimulation
CCL2 mRNA expression was upregulated following 24 and 48 h stim ulation 
in prim ary hum an adult astrocytes (SMS-12) w ith all three pro-inflammatory 
cytokines (IL1-/5, TN F and IFN 7 ) (figure 2.9a-b). IL1-/? induced the greatest 
increase in CCL2 mRNA expression a t 1 ng/m l for 24 h (29.6 =b 5.4 fold increase, 
P<0.01) (figure 2.9a). TNF induced a significant increase in CCL2 mRNA ex­
pression, which peaked at 48 h following stim ulation with lOOng/ml (26.2 ±  7 fold 
increase, P<0.01) (figure 2.9b). IFN 7  had a maximal effect at lOOng/ml for 24 h 
(7.9 ±  0.5 fold increase, P<0.01) but to a lesser extent compared to IL1-/? and 
TNF.
These results were confirmed by stim ulating prim ary astrocytes isolated from 
three different preparations (SMS-12, B327/01 and E pl5) for 24 h with IL1-/?, 
TN F and IFN 7  a t lOng/ml (n = 6 ). All three astrocyte preparations had a signifi­
cant increase in CCL2 mRNA expression following IL1-/3 and TN F treatm ent but 
not with IFN 7  using ANOVA followed by D unnett’s test, (figure 2.10).
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Fig. 2.8: CCL2 and  CX CL10 m R N A  expression  in u n s tim u la te d  a s tro ­
cytes.
The Ct value for CCL2 and CXCL10 mRNA expression is 26 and 33 respectively. 
Since the efficiency for CCL2 and CXCL10 were close to 100%, then CCL2 was 
more highly expressed than CXCL10 at the baseline.
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2 .3.3.2 Determination of CXCL10 mRNA following cytokine stimula­
tion
CXCL10 mRNA increased in expression following 24 and 48 h stim ulation with 
the three pro-inflammatory cytokines IL-1/5, TN F and IFN 7 . IFN 7  induced a dose 
dependant increase, with a maximum effect observed at lOOng/ml reaching a 479.0 
dh 139.6 fold increase (P<0.05) and 2903.0 ±  848.5 fold increase (P<0.05), follow­
ing 24 and 48 h stim ulation respectively. TNF (lOng/ml) and IL-1-/3 (lOOng/ml) 
showed an slight increase in expression of CXCL10 with a maximum effect reach­
ing 4.4 ±  2.9 fold increase and 4.1 ±  0.4 fold increase a t 24 and 48 h respectively.
Comparison of the mRNA from three astrocyte preparations showed th a t in 
two preparations out of three, IFN7  was the most potent inducer of CXCL10 
at 201.9 ±  32.1 fold and 613.7 ±  324.4 fold increase for SMS-12 and E pl5  using 
ANOVA followed by D unnett’s test. However, in the th ird  preparation (B327/01), 
TN F and IFN 7  were the most potent inducer of CXCL10 with 483.4 ±  120.2 fold 
increase and 284.5 ±  59.8 fold increase. IL1 (3 did not induced any significant effect 
on CXCL10 synthesis in all three cell preparations assessed.
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Fig. 2.9: E ffec t o f  p ro - in f la m m a to ry  c y to k in e s  o n  C C L 2  m R N A  e x p re s ­
sion  b y  p r im a ry  h u m a n  a d u l t  a s tro c y te s  u s in g  q R T -P C R .
Cells (SMS-12) were stim ulated with IL1 -j3 (white), TN F (grey) and IFN 7  (dark 
grey) a t 0 to  lOOng/ml for 24h (a) and 48h (b) (n=3) performed in duplicate. 
UBC was used as internal control. ANOVA followed by D unnett’s test was ap­
plied. *p<0.05, **p<0.01
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Fig. 2.10: E ffec t o f  p ro - in f la m m a to ry  c y to k in es  o n  C C L 2 m R N A  e x p re s ­
sion  b y  th r e e  d iffe re n t a s tro c y te s  p re p a ra t io n s  u s in g  q R T -P C R .
CCL2 mRNA expression by astrocytes from three different donors (SMS-12, 
B327/01 and E pl5) were measured by qRT-PCR using SybrGreen (n=3) per­
formed in duplicate. ANOVA followed by D unnett’s was used to assess the signif­
icance. * p<0.05, ** p<0.01
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Fig. 2.11: E ffec t o f  p ro - in f la m m a to ry  c y to k in e s  o n  C X C L 10  m R N A  ex­
p re ss io n  b y  p r im a ry  h u m a n  a d u l t  a s tro c y te s  u s in g  q R T -P C R .
CXCL10 mRNA expression by prim ary human adult astrocytes was assessed fol­
lowing pro-inflammatory stimulation, using real tim e PC R  with SybrGreen. Cells 
(SMS-12) were stim ulated with IL1-/? (white), TN F (grey) and IFN 7  (dark grey) 
a t 0 to lOOng/ml for 24h (a) and 48h (b) (n=3) performed in duplicate. UBC was 
used as internal control. ANOVA followed by D unnett’s test was assessed and *, 
** and *** indicates p<0.05, p<0.01, p<0.001.
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Fig. 2.12: E ffec t o f  p ro - in f la m m a to ry  cy to k in es  o n  C X C L 10  m R N A  ex­
p re ss io n  b y  th r e e  d iffe re n t a s tro c y te  p re p a ra t io n s  u s in g  q R T -P C R .
CXCL10 mRNA expression by astrocytes prepared from three different donors 
(SMS-1 2 , B327/01 and E pl5) was assessed following 24 h cytokine stim ulation by 
real time PC R  using SybrGreen (n=3) performed in duplicate. ANOVA followed 
by D unnett’s was assessed. *p<0.05, **p<0.01, ***p<0.001
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2.3 .4  ELISA m easurem ent of CCL2 secretion  by astro­
cytes following stim ulation w ith  pro-inflam m atory  
cytokines
Secretion of CCL2 was assessed under IL1-/?, TNF, IFN 7  and serum free media 
using ELISA.
2 .3.4.1 Unstimulated cells
Unstim ulated cells were found to produce and secrete CCL2 constitutively 
a t 24 h (352.9 dh 8.56pg/ml) and 48 h (1820 ±  2 0 1 .8 pg/m l). As expected, the 
expression of CCL2 at baseline increased following 48 hours stim ulation due to 
accumulation of secreted CCL2  in the supernatant. To determine the relative 
secretion of CCL2 following cytokine stim ulation compared to  the unstim ulated 
control, the baseline level of CCL2 was normalized to 1.
2.3.4.2 IL-/3 stimulation
Following 24 h stimulation, the most potent effect on CCL2 secretion was ob­
served with IL1-/? a t 1, 10 and lOOng/ml (4.2 ±  0.5 fold increase, 4.0 dh 0.4 fold 
increase, 3.2 ±  0.2 fold increase respectively, p<0.01)(figure 2.13a).
Following 48 h stimulation, the most potent effect was observed a t ln g /m l (5.6 ±  
0.1, p<0.01) compared to 10 and 100 ng/m l with respectively 5.2 ±  0.1 fold in­
crease and 4.3 ±  0.4 fold increase, p < 0 .01) (figure 2.13b). However, no significant 
difference was observed between the three cytokine concentrations a t 24 and 48 h 
using ANOVA followed by Bonferroni test.
2.3.4.3 TNF stimulation
Following 24 h stimulation, TNF significantly increased CCL2 secretion, with 
the maximum effect observed at lng /m l (4±  0.9, p<0.01) compared to  10 ng/m l
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(3.8 ±  0.9, p<0.01) and lOOng/ml (3.1±0.4, p<0.05) (figure 2.13a).
Following 48 h stim ulation (figure 2.13b), the level of CCL2 did not show signifi­
cant difference compared to  non stimulated astrocytes w ith 4 .2±  0.9 fold increase 
(lng /m l, p<0.01), 5.2±0.4 (lOng/ml, p<0.01) and 4.0 ±  0.5 (lOOng/ml, p<0.01). 
No significant difference in CCL2 secretion was observed between the three con­
centrations of TN F (D unnett te s t) .
2.3.4.4 IFN7 stimulation
IFN 7  had a modest effect on CCL2 secretion a t 24 h compared to th a t in­
duced by IL-1/3 bu t a similar effect compared to TN F stim ulation (figure 2.13a).. 
The maximum effect on CCL2 secretion was observed a t 10 and 100 ng/m l (3.7 
fold increase ±0.8, 3.5 fold increase ±0.1, p<0.01) compared to  ln g /m l (2.6±0.1, 
p>0.05). Following 48 h stimulation the only significant increase in CCL2 secre­
tion was observed a t lOOng/ml (3.3±0.1, p<0.01) (figure 2.13b).
2.3.5 ELISA m easurem ent o f CXCL10 secretion  by astro­
cytes following stim ulation w ith  pro-inflam m atory  
cytokines
Unstimulated astrocytes (SMS-1 2 ) secreted CXCL10 constitutively at 24 h 
(82.22 ±  4.235pg/ml) and 48 h (993 ±  22.86pg/ml) (data not shown). Similarly 
to the changes observed a t the mRNA level, CXCL10 secretion was increased only 
by IFN 7  stim ulation in a dose dependent manner (figure 2.14a). However only 
IFN 7  a t 10 and lOOng/ml reached statistical significance with respectively 1.8 ±  
0.1 fold increase, n = 6 , p <  0.001) and 2.4 fold increase ±  0.2 (p<0.001). IL1/5 
and TN F did not have any effect on the secretion of CXCL10 compared to the 
baseline from 0 upto lOOng/ml cytokine treatm ent.
The same pattern  of expression for the secretion of CXCL10 was observed fol­
lowing 48 h cytokine treatm ent (figure 2.14b). Only IFN 7  a t lOOng/ml induced a
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significant increase in CXCL10 secretion (1.9 fold increase ±0.4, p<0.01).
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Fig. 2.13: E ffec t o f  p ro - in f la m m a to ry  c y to k in e  s tim u la t io n  o n  C C L 2 se­
c re t io n  b y  a s tro c y te s  m e a su re d  b y  E L IS A .
CCL2 expression was assessed on astrocytes (SMS-12) following pro-inflammatory 
stimulation. SMS-12 were stimulated with IL1-/? (white), TN F (grey) and IFN7  
(dark grey) a t 0 to  lOOng/ml for 24h (a) and 48h (b) (n=3) performed in dupli­
cate. CCL2 secretion was measured by ELISA. CCL2 expression in the super­
natan t of stim ulated astrocytes was expressed as a fold increase compared to the 
baseline (unstim ulated cells). ANOVA followed by D unnett’s test was assessed.
***p<0 .0 0 1
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Fig. 2.14: E ffec t o f  p ro - in f la m m a to ry  c y to k in e  s tim u la t io n  o n  C X C L 10  
se c re tio n  b y  a s tro c y te s  m e a su re d  b y  E L IS A .
CXCL10 expression was assessed on astrocytes (SMS-12) following pro- 
inflammatory stimulation. SMS-12 were stim ulated with IL1-/? (white), TN F 
(grey) and IFN 7  (dark grey) a t 0 to lOOng/ml for 24h (a) and 48h (b) (n=3) 
performed in duplicate. CXCL10 expression in the supernatant of stim ulated as­
trocytes was expressed as a fold increase compared to the baseline (unstim ulated 
cells). ANOVA followed by D unnett’s test was assessed. ***p<0.001
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2.4 D iscussion
Chemokines are low relative molecular mass proteins from 8  to  10 KDa and 
have a variety of functions including: cell migration, differentiation of T-cells 
[Luther and Cyster, 2001], leukocyte activation, angiogenesis and antimicrobial 
function [Adams and Lloyd, 1997]. The evidence implicating a role for chemokines 
in MS pathology are mainly shown by descriptive and observational analysis of 
post-m ortem  tissue and studies on CSF and serum from MS patients [Kieseier 
et ah, 2 0 0 2 , Scarpini et al., 2 0 0 2 ].
Histological examination of autopsy MS brain tissue has dem onstrated CXCL9, 
CXCL10, CCL2, CCL3, CCL5, CCL7 and CCL8  im munoreactivity localised to 
reactive astrocytes in demyelinating lesions and in the surrounding parenchyma 
[Banisor et al., 2005, Sospedra and M artin, 2005]. There are many reports of 
CCL2 and CXCL10 expression in CNS white m atter in MS pathogenesis. It has 
been shown th a t CCL2  and CXCL10 are strongly expressed at the lesion site by 
astrocytes compared to control [McManus et al., 1998, Simpson et al., 2000a]. 
However, it has been reported th a t CCL2 expression is decreased in the CSF of MS 
patients a t times of relapse, whereas CXCL10 expression is increased [Narikawa 
et al., 2004, Scarpini et al., 2 0 0 2 ]. Contradictory findings are reported for the 
serum level of CCL2. Scarpini et al. (2002) showed a decrease in CCL2 in MS 
compared to  control [Scarpini et al., 2 0 0 2 ] whereas Kivisakk et al. (1998) showed 
no difference between the expression of CCL2 in serum of MS and normal indi­
viduals.
Because astrocytes, the most abundant cell type in the CNS, are located a t the 
BBB and have been reported to express chemokines in the CNS using immunohis- 
tochemistry on post-m ortem  tissue, the rate of synthesis and secretion of CCL2 
and CXCL10 by prim ary human adult astrocytes, following pro-inflammatory 
stim ulation was examined to  assess whether there are differences in the rate of 
synthesis and /o r secretion of CCL2  and CXCL10, which could explain this differ-
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ence in chemokine levels, reported within the CSF. It has to be mentioned th a t 
other cells can produce CCL2 such as microglia, endothelial cells and neurons 
[Coughlan et al., 2000, Hua and Lee, 2000, Harkness et al., 2003]. Therefore, 
other CNS resident cells might also be involved in the regulation of CCL2  in the 
CNS.
2.4.1 C onstitu tive expression of CCL2 and CXCL10 m R N A  
by prim ary human adult astrocytes using qR T -PC R
In this study, astrocytes (SMS-12) expressed CCL2 and CXCL10 mRNA con- 
stitutively. However, CCL2 mRNA was much more highly expressed a t baseline 
and under pro-inflammatory conditions than  CXCL10. The difference in gene ex­
pression cannot be explained by lower primer efficiencies for CXCL10 compared 
to CCL2, since the primer efficiencies, which were determined during real time 
PC R  optimisation, were both close to 100%. Previous studies on prim ary human 
foetal astrocytes and prim ary human adult astrocytes showed th a t CCL2 mRNA 
was highly expressed whereas CXCL10 mRNA was not detected by ribonuclease 
protection assay [Hua and Lee, 2000, Oh et al., 1999]. The absence of expression of 
CXCL10 mRNA by astrocytes reported by Hua et al. (2000) and Oh et al. (1999) 
studies could be explained by the fact th a t they used a ribonuclease protection 
assay which is less sensitive than  real time PCR.
2.4.2 CCL2 m R N A  expression by astrocytes following pro- 
inflam m atory cytokine treatm ent using qR T -PC R
Following 24 and 48 h stimulation with the three pro-inflammatory cytokines 
tested, CCL2 mRNA was upregulated. All of the three cytokines induced an 
increase in expression of CCL2 mRNA, however IL1/? and TN F were the most 
potent inducers of CCL2 mRNA. These results are in agreement w ith previous 
studies on human foetal and simian astrocytes [Croitoru-Lamoury et al., 2003, 
Oh et al., 1999]. Croitoru Lamoury et al. (2003) showed th a t IL1-/? and TN F
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induced a 3 to 3.5 fold increase in CCL2 mRNA compared to IFN 7 , which did not 
affect the expression of CCL2 mRNA following 72 h stimulation. Oh et al. (1999) 
showed th a t IL1 -f3 and TNF induced an 8  fold increase compared to  IFN7 , which 
induced a 5 fold increase in CCL2 mRNA. Although IL1/3 and TN F were the most 
potent inducers for CCL2 mRNA expression in astrocytes in the work reported 
here, differences in CCL2 mRNA expression were found, compared to  published 
literature, which could be explained by the different methodologies used. Indeed, 
Croitoru-Lamoury et al. (2003) and Oh et al. (1999) stim ulated astrocytes for 
72 h and 10 h respectively and assessed mRNA by semi quantitative RT-PCR 
and ribonuclease protection assay whereas, in the current study, astrocytes were 
stim ulated for 24 and 48 h and CCL2 mRNA expression was assessed by real time 
PCR.
The response obtained with the astrocyte preparation, SMS-12, was reproduced 
in two other preparations of prim ary adult human astrocytes from normal appear­
ing white m atter. CCL2 mRNA expression did not show any significant difference 
between the three astrocyte preparations following corresponding cytokine stim­
ulations, using ANOVA followed by D unnett’s test. This comparison of three 
astrocyte preparations confirms the potent effect of IL1/? and TN F bu t not IFN 7  
on CCL2 mRNA synthesis and th a t it was not specific to one astrocyte prepara­
tion. Analysis of the expression of CCL2  mRNA by astrocytes from MS lesion 
(MS 16) did not show any difference with normal astrocytes (data not shown).
2.4.3 CXCL10 m R N A  expression by astrocytes following  
pro-inflam m atory cytokine treatm ent using qR T -PC R
For CXCL10, although the three cytokines induced an increase in mRNA 
synthesis, IFN 7  was the most potent inducer of CXCL10 synthesis, in a dose 
dependent manner. These results are in agreement w ith a previous study [Hua 
and Lee, 2000] using foetal human astrocytes stim ulated for 5 h with IL1/?, TN F 
and IFN7  a t lOng/ml. Both IL1/3 and TNF induced CXCL10 mRNA expression 
bu t to a lower extent compared to IFN7 .
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Two out of three astrocyte preparations showed the same pattern  of expression 
(SMS-12 and E pl5), whereas B327/01 astrocyte preparation showed th a t both 
IFN 7  and TN F induced a strong increase on CXCL10 mRNA synthesis. Since the 
same cDNA was used for the mRNA comparison between astrocyte preparations 
for both  CCL2 and CXCL10, then the difference might be dependent on the 
astrocyte preparations. Despite this difference for B327/01, IFN 7  was the most 
potent inducer for CXCL10 mRNA.
2.4.4 CCL2 and CXCL10 secretion by unstim ulated  astro­
cytes using ELISA
Similar to mRNA expression, CCL2 protein was more highly expressed a t base­
line than  CXCL10 with almost 4 and 2  times more CCL2  than  CXCL10 following 
24 and 48 h respectively. The differential expression between CCL2 and CXCL10 
decreased following 48 h incubation possibly due to an increase in constitutive 
expression of CXCL10. Therefore, the ability of astrocyte to  express CXCL10 
at the baseline increases with time. Croitoru-Lamoury et al. (2003) showed 
th a t CXCL10 was not constitutively expressed by astrocytes whereas CCL2  was 
(20ng/ml, following 24 h incubation in serum free media). Although the quali­
tative response of astrocytes to stimulation by cytokines is similar for CCL2 and 
CXCL10, their level of expression is not the same. In our study, the constitutive 
expression of CCL2 and CXCL10 (following 24 h incubation) was 352.9 ±8.56 
pg/m l and 82.22 ±  4.235 pg/m l respectively. It was not possible to compare the 
level of expression of CCL2 in foetal and human astrocytes in this thesis, however 
from the current study adult astrocytes expressed almost 60 times less CCL2 than  
human foetal astrocytes, based on published levels reported for foetal astrocytes 
[Croitoru-Lamoury et al., 2003]. Although the same ELISA kit was used, different 
experimental conditions could explained this differences. Developmental stage of 
astrocytes might also be one explanation for the difference in CCL2 levels. Since 
chemokines are involved in embryogenesis by regulating the migration of progen­
itor cells into the post natal brain [Tran et al., 2007, Lazarini et al., 2003], it is
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then not surprising to observed differences in the level of expression of chemokines 
between foetal and adult astrocytes.
2.4.5 CCL2 secretion by astrocytes following pro-inflam m atory  
cytokine treatm ent using ELISA
Following 24 h and 48 h stimulation IL1/? and TN F were the most potent in­
ducers of CCL2 (5.2 fold increase, 9464 ±  180 pg/m l) whereas IFN 7  had a limited 
effect on CCL2 secretion especially following 48 h stimulation. These results are in 
agreement w ith a previous study Croitoru-Lamoury et al (2003) where they found 
th a t CCL2 was mainly secreted following IL-1/? and TN F stim ulation (around 
150 and 180 ng/m l respectively, Table 2.4) compared to IFN 7  (around 60ng/ml) 
and unstim ulated cells (around 50ng/ml). In this study they found a difference in 
the am ount of released chemokines between simian adult and foetal human astro­
cytes. Human foetal astrocytes clearly secreted more chemokine than  the simian 
adult astrocytes (between 2  and 5 fold higher). Although no comparison between 
human adult and other astrocytes have been assessed in our study, the difference 
in the basal level of expression of the secreted chemokine between human adult 
(352.9 pg/m l) and foetal astrocytes (around 25ng/ml) might reflect the different 
developmental stage of the astrocytes as discussed above.
2.4.6 O ther CCL2 producing cells in th e  CNS
Astrocytes are not the only cells in the CNS to  produce CCL2 (Table 2.5). 
Endothelial cells have also been shown to secrete CCL2 following IL1-/?, TN F and 
IFN 7 . It was shown th a t CCL2 secretion, following TN F stim ulation a t 10 ng/m l, 
was maximal effect in brain endothelium cells (5.2 ±  0.22 ng/m l) [Harkness et al.,
2003]. This finding was confirmed by another study which analysed the expres­
sion of CCL2 on cytokine-activated human microvascular endothelial cells. They 
reported th a t TN F was the most potent inducer (14.8 dh 0.4 ng/m l) compared to 
IFN - 7  (7.3 diO.l ng/m l) [Brown et al., 1994]. Although no direct comparison in
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CCL2 secretion between astrocytes and ECs was assessed, it seems th a t ECs had 
a higher capacity to secrete CCL2. Therefore, they are another active player in 
the recruitm ent of immune cells into the CNS.
CCL2 expression by macrophages is contradictory. Microglia have been found to 
express CCL2 mRNA in vitro and CCL2 protein in vivo [Calvo et al., 1996, Hua 
and Lee, 2000]. However, CCL2 secretion was not detected in the supernatant 
of microglia cells following stim ulation with pro-inflammatory cytokines [Hayashi 
et al., 1995]. Neurons have also been shown to express CCL2 in vivo [Meng et al.,
1999]. However, it was shown th a t CCL2 secretion was lower compared to levels 
secreted by hum an foetal astrocytes [Coughlan et al., 2000].
2.4.7 CXCL10 secretion by astrocytes following pro-inflam m atory  
cytokine treatm ent using ELISA
Changes observed for CXCL10 secretion mirrored changes observed for CXCL10 
mRNA. Indeed, CXCL10 was mainly increased by IFN 7  w ith the maximum effect 
a t lOOng/ml a t both  24 and 48 h (276.3 pg/m l and 1972 pg/m l) respectively.
These findings are in agreement with Croitoru-Lamoury et al. (2003) where they 
showed th a t CXCL10 was mainly increased with IFN 7  a t 50ng/m l following 24 
and 72 h stim ulation on prim ary human fetal astrocytes (almost 50 and 100 ng/m l 
respectively, Table 2.4)). However, the changes observed for the mRNA are much 
more im portant compared to the changes observed for the protein. This might 
be explained by regulatory mechanisms th a t control the mRNA level expression 
before being translated into protein such as nonsense-mediated mRNA decay or 
RNA surveillance mechanism [Shyu et al., 2008].
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2.4.8 O ther CXCL10 producing cells in th e CNS
CXCL10 production is not solely due to  astrocytes (Table 2.5). It was shown 
th a t microglia are also involved in the synthesis of CXCL10 [Hua and Lee, 2000]. 
In vitro stim ulation of microglia cells resulted in the increase in secretion of 
CXCL10 (around 2500 pg/m l) compared to the control (1000 pg/m l). This in­
crease in CXCL10 secretion was abrogated by co-incubating microglia w ith TNF 
and antibody directed against TNF [Seguin et al., 2003]. Endothelial cells have 
also been shown to secrete CXCL10 under IFN 7  stim ulation to  reach 1 0 2  ±  18 
ng/m l [Marx et al., 2000]. Another study dem onstrated the ability for aortic ECs 
' to secrete CXCL10 [Raju et al., 2003]. CXCL10 was increased from 13.4 ±  10.8 
pg/m l to  299.5 ±  13.4 pg/m l following incubation of ECs with PBMCs, which was 
inhibited by an antibody directed against IFN 7  (33.8±17.8 pg/m l). Although the 
other CNS resident cells produce CXCL10, levels of CXCL10 expression is dif­
ficult to  compare with the current study because of the different experimental 
conditions.
2.4.9 D o astrocytes contribute to  th e differential expres­
sion o f CCL2 and CXCL10 in th e  CSF of MS pa­
tien ts at tim e of relapse?
In the brain, CSF, produced by the plexus choroid, has many functions such as 
in mechanical support, bu t also acting as a drainage pathway for the brain, where 
products from metabolism or inflammatory mediators are diluted and eliminated. 
Thus the CSF composition reflects the state of the CNS at a specific time when 
sample is taken [Segal, 1993, Brown et al., 2004].
The reason why CCL2 is decreased in the CSF a t the time of relapse in MS 
patients is unclear. One explanation for the differential expression of CCL2 and 
CXCL10 in the CSF at the time of relapse might be the reflection of the cytokine 
milieu in the brain a t the time of relapse. Indeed higher concentration of IFN - 7  
compared to IL1/? or TN F would result in stronger CXCL10 expression compared
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to  CCL2 although no published evidences are available in human. It was shown 
in EAE study th a t there was a differential expression of TN F and IFN - 7  in EAE 
mice [Tanuma et al., 1999]. TN F was shown to be associated with the first a t­
tack in chronic relapsing EAE whereas IFN - 7  was closely related to  the latter 
attacks. This could explain the differential expression of chemokines during the 
pathogenesis of the disease. The question addressed in this chapter was the possi­
ble contribution to this finding by a differential expression of CCL2 and CXCL10 
by prim ary hum an adult astrocytes in the CNS under control and inflammatory 
conditions. Our study showed th a t the synthesis of these two chemokines were 
increased under pro-inflammatory conditions but also th a t CCL2 was more highly 
expressed than  CXCL10 both  at the mRNA and protein level. Thus, the decrease 
in levels of CCL2  in the CSF, during relapse in MS patients cannot be explained 
by a differential expression of CCL2 and CXCL10, either by an im pairm ent in the 
synthesis or secretion of CCL2 by astrocytes, during relapse in MS patients. 
W ith the caveat th a t in vivo astrocytes may behave differently, several hypothe­
ses could explain the decrease in the CSF of CCL2 , based on the in vitro findings 
reported here:
•  sequestration of CCL2 by CNS resident cells. CCL2  has been shown to 
bind to various CNS resident cells including endothelial cells and astrocytes 
[Andjelkovic et al., 1999a, Stamatovic et al., 2003]
•  comsumption of CCL2 in the CNS by invading immune cells. A recent 
study in vitro showed th a t CCL2 was removed from the extracellular fluid 
by CCR2-positive migrating cells as they cross the BBB, which was proposed 
to  explain the decrease in CCL2 level in the CSF in MS patients [Mahad 
et al., 2006].
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C ell ty p e C C L 2 C X C L 1 0 R efe re n ce
Human adult 
astrocytes
IL1/?, TNF IFN 7
TNF, IFN 7
Current study 
(qRT-PCR)
Oh et al. (1999) 
(RPA)
Fetal hum an as­
trocytes
IL1 /?, TNF IFN 7 Hua et al. 
(2000) (RPA) 
Croitoru- 
Lamoury et 
al. (2003) (RT- 
PCR)
Tab. 2.4: S u m m a ry  ta b le  fo r cy to k in e  effects o n  C C L 2 a n d  C X C L 10 
m R N A  e x p re s s io n  b y  a s tro c y te s .
In this table, the main inducers for CCL2 and CXCL10 are given. IL1/? was 
the most potent inducer for CCL2 whereas IFN 7  was main inducer for CXCL10. 
Different methodologies were used in the different study. Real time PC R  (qRT- 
PCR), semi quantitative reverse transcription PC R  (RT PCR) and ribonuclease 
protection assay (RPA) were used respectively in the current study, Croitoru- 
Lamoury et al. (2003); Oh et al. (1999) and Hua et al. (2000).
I l l
C ell ty p e C C L 2
(n g /m l)
C X C L 10
(n g /m l)
R e fe re n c e
Human adult 
astrocytes
9.5 (IL1/3, TNF) 1.9 (IFN7 ) Current study
Human foetal 
astrocytes
150 (IL1/J) 
180 (TNF)
50-100 (IFN7 ) Croitoru- 
Lamoury et 
al. (2003)
Brain endothe­
lial cells
5.2-14.8 (TNF) 0.3-102 (IFN7 ) Brown et al. 
(1994)
Harkness et al. 
(2003)
M arx et al. 
(2 0 0 0 )
microglia ND 2.5 (TNF) Seguin et al. 
(2003)
Tab. 2.5: S u m m a ry  ta b le  fo r th e  co m p ariso n  o f  ex p re ss io n  o f  C C L 2 a n d  
C X C L 10  b y  C N S  re s id e n t cells u n d e r  c y to k in e  s tim u la tio n s .
D ata from the current and published studies showed th a t CCL2 is mainly induced 
by IL1/? and TN F whereas CXCL10 was mainly induced by TN F and IFN 7 . D ata 
shown in the talbe correspond to the maximal secretion of CCL2 and CXCL10 
following cytokine stimulation. Although the comparison of chemokine secretion 
was not performed in the current study, human adult astrocytes seems to  produce 
less chemokine than  human foetal astrocytes.
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CHAPTER 3
M easurem ent of CCL2 binding to  
primary human adult astrocytes
in vitro
3.1 Introduction
CCL2 exerts its biological effect through binding to  CCR2 , a G protein cou­
pled receptor (GPCR). CCR2  has two isoforms: CCR2-A and CCR2 -B, which 
differ in the C term inal cytoplasmic domain of the receptor [Sozzani et al., 1997].
3.1.1 CCL2 effects on astrocytes
Astrocytes have been shown to sense and respond to  gradients of CCL2 in an 
in vitro chemotactic assay [Andjelkovic et al., 2 0 0 2 ]. I t was proposed th a t this 
chemotactic effect could either promote the recruitm ent of astrocytes at lesion 
sites w ithin the brain or affect the position of astrocytes a t the BBB [Dorf et al.,
2000]. It was also shown in vitro th a t astrocyte treatm ent with CCL2 leads to 
secretion of bFGF, which would facilitate neuronal cell differentiation and promote
113
survival of neurons in vitro [Kalehua et al., 2004]. Thus astrocyte gene expression 
is altered in response to CCL2, indicating th a t they express receptors for CCL2.
3.1.2 CCR2 expression by astrocytes in th e CNS in MS
A recent immunohistochemical study on CNS tissue from secondary progres­
sive MS patients (SPMS) has reported th a t CCR2  expression was strong at the 
rim of the lesion with ongoing demyelination but not in the centre. Double stain­
ing with anti-GFAP and CCL2 or CCR2 antibodies dem onstrated th a t reactive 
astrocytes stain  strongly for both  CCL2 and express CCR2 [Tanuma et al., 2006]. 
However the expression of CCR2 by astrocytes is controversial. Simpson et al 
(2000) have shown th a t CCR2 reactivity was associated with foamy macrophages 
and activated microglia in chronic active lesions. Another study reports a low 
immunoreactivity for CCR2  in the CNS, mainly associated with T  cells and rare 
activated monocytes [Mahad et al., 2006].
3.1.3 CCR2 expression by astrocytes in vitro
Expression of CCR2 on astrocytes has been assessed in vitro. However con­
tradicting da ta  was obtained. Expression of CCR2 was reported in foetal human 
astrocytes using immunocytochemistry [Andjelkovic et al., 2 0 0 2 , Rezaie et al., 
2002]. These findings are in contradiction with Heesen et al. (1996) and Flynn 
et al. (2003) studies, which failed to detect CCR2 using post-natal murine mouse 
and hum an adult astrocytes by RT-PCR and flow cytom etry respectively. Fur­
ther work has to be performed to confirm the expression of CCR2 by astrocytes 
in vitro.
3.1.4 CCR2 signalling and functional effect o f CCL2
Chemokines have been shown to interact with their cognate receptor to induce 
various functional effects including chemotaxis, cell adhesion molecule expression,
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such as integrins, through activation of downstream signalling pathways [Wain 
et al., 2002, Ashida et al., 2001, D atta  et al., 2006]. CCR2 has been shown 
to increase integrin expression in monocytes as well as increase their migration 
following MAPK activation following CCL2 stim ulation [Ashida et al., 2001]. It 
was dem onstrated th a t CCL2 induces Erk and PKB signalling pathways following 
binding to  CCR2 [Ashida et al., 2001].
3.1.4.1 Calcium flux following CCL2 treatment
As discussed in section 1.4.7.1 , binding of chemokines to their receptors induces 
activation of PLC resulting in an increase in intracellular calcium. There is much 
evidence on the effect of CCL2 on levels of intracellular calcium. It was shown in 
a study by Salentin et al. (2003) th a t CCL2 treatm ent of monocytes transfected 
with CCR2, induced a strong increase in intracellular calcium. Astrocytes have 
also been shown to increase intracellular calcium following CCL2 treatm ent, al­
though the expression of CCR2 in astrocytes is controversial [Andjelkovic et al., 
2002].
The level of expression of GPCRs at the cell surface is an im portant factor in 
induction of increased in the intracellular calcium. Indeed, I t was shown in a den­
dritic cell line (D1 cells) treated for 2-3 h with LPS (10/ig/ml) th a t the decrease 
in CCR 1 expression mirrored the changes observed for the level of intracellular 
calcium when stim ulated with CCL3 [Foti et al., 1999]. Therefore calcium flux 
is an accurate indicator to monitor the downstream effect of chemokines on cells 
when bound to  their receptors.
3.1.4.2 Erk signalling
Erk is a well characterised signalling kinase, and is activated by phosphoryla­
tion on threonine and tyrosine residues by M A PK /Erk kinase 1/2 (M EK1/2) as 
discussed in section 1 .4.7.2 [Chang and Karin, 2001].
CCL2, 7, 8  and 13 have been shown to rapidly and transiently activate the
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MAPK in peripheral blood mononuclear cells and in HEK-293 cells expressing 
CCR2. U0126, an inhibitor of MAPK-kinase activation, not only prevented Erk 
1 / 2  activation but also significantly inhibited CC chemokine-mediated chemotaxis 
[Wain et al., 2002]. In another study, it was shown th a t family members of the 
MAPKs have different effects on the monocytic cell line (THP-1 cells) when acti­
vated by CCL2 [Ashida et al., 2001]. They showed th a t CCL2 induced an increase 
in integrin expression by THP1 cells, which was inhibited by a MEK inhibitor but 
not by the p38-MAPKs inhibitors. CCL2 also induced chemotaxis of THP1 cells 
but it was mediated by p38 MAPK, not Erk.
3.1.4.3 PK B/Akt signalling
The PK B /A kt subfamily consists of three members, P K B a /A k tl, PKB/?/Akt2 
and PK B 7 /A k t3  which are activated by phosphorylation of two residues; T hr308 
and Ser473 [Alessi et al., 1996, Walker et al., 1998] as discussed in section I.4.7.2.
Much evidence has confirmed the involvement of P K B /A kt signalling in the 
process of chemotaxis. Wain et al. (2001) showed th a t inhibition of the PI3 
Kinase by W ortm annin (0.1/iM) and LY294002 (100/iM) partly  inhibited THP- 
1 cell chemotaxis. Similarly, D atta  et al. (2006) have shown th a t incubation 
of CD4+ T  cells w ith cyclosporin A, a common immunosuppressant, selectively 
inhibits P K B /A kt bu t not the Erk 1 and 2 pathway, resulting in a decrease in 
transendothelial m igration in vitro, following CXCL12 stimulation.
PK B /A kt have also been shown to be involved in CCL2 synthesis by vascular 
endothelial cells. W hen cells were incubated with W ortmannin, an inhibition of 
TNF-dependent CCL2 secretion was seen in a dose dependent manner. Human 
umbilical vein endothelial cells (HUVECs) transfected with a dominant negative 
PK B /A kt resulted in the suppression of activation of the prom oter of CCL2 under 
TN F stim ulation [Murao et al., 2000].
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3.1.5 A im  o f th e study
In chapter 2, it was found th a t primary human adult astrocytes express CCL2 
at much higher levels than  CXCL10. Thus decreased CCL2 expression by astro­
cytes does not appear to  explain the decreased expression of CCL2 reported in 
the CSF in people with MS. CCL2  may bind in an autocrine manner to astrocytes 
leading to  sequestration preventing it from reaching the CSF com partment.
This aim will be addressed by the following objectives:
1. Investigate the synthesis and expression of CCR2 under pro-inflammatory 
conditions using qRT-PCR and flow cytometry.
2. Determine the effect of pro-inflammatory cytokine treatm ent on binding 
of CCL2 to astrocytes using biotinylated CCL2 assessed by flow cytom etry and 
immunocytochemistry.
3. Determine the functional effect of CCL2 binding to astrocytes by measuring 
calcium flux and phosphorylation of E rk l and 2 and Akt, following CCL2 stim u­
lation.
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3.2 M aterials and m ethods
3.2.1 D eterm ination  of CCR2 m R N A  expression by hu­
m an adult astrocytes following pro-inflam m atory stim ­
ulation
3.2 .1.1 Sequences of forward and reverse primers for CCR2 gene
The same procedure was followed as described in section 2.2.6. The primer 
sequences used for the amplification of the CCR2 cDNA were designed using 
Primer3 software as described in section 2.2.6.1
• forward primer: 5’-TTG G CGGAATCTTCTTCATC-3’ (Tm, 55.3°C)
• reverse primer: 5’-CGTGGACAGAAGCAAACACA-3’ (Tm, 57.3°C)
3.2.1.2 Sequencing of PCR products to check the specificity of CCR2 
primers amplicons
PC R  products were cleaned using Sigmaspin post reaction purification columns 
(Sigma, UK) prior to sequencing, according to the m anufacturer’s instructions. 
Briefly columns were spun a t 300 g for 2 min in the mini spin plus centrifuge 
(Eppendorf, UK). 30 fA of PC R  product was loaded on the top of the column 
and centrifuged for 5 min at 300g. Columns were washed once using washing 
buffer and centrifuged again for 2 min at 300g. Samples were collected in a new 
eppendorf tube by applying elution buffer and centrifugation for 2 min a t 300g. 
Samples were sequenced at the Core Genetics Service, Sheffield University.
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3.2.1.3 Real time PCR on cDNA from stimulated astrocytes
Real tim e PC R  was performed in duplicate on cDNA from astrocytes (SMS- 
12) stim ulated three times for 24 and 48 h with IL1-/5, TN F and IFN 7  from 0 
to lOOng/ml as previously described in section 2.2.6.5. Comparison of three dif­
ferent human adult prim ary astrocyte preparations (SMS-12, B327/01 and Epl5) 
for CCR2 mRNA expression was performed by stim ulation with IL-1/3, TNF and 
IFN 7  (lOng/ml) for 24 hours.
3.2.2 D eterm ination  of CCR2 expression by prim ary hu­
m an adult astrocytes, using flow cytom etry
3.2 .2.1 Principle of flow cytometry
Flow cytom etry is a technique used for counting and examining cell suspen­
sions in a stream  of fluid. It allows simultaneous m ultiparam etric analysis of the 
physical and /o r chemical characteristics of a single cell through the excitation 
of a bound fluorescent marker. The flow cytometer is composed of three main 
systems: fluidics, optics, and electronics [Givan, 2001]. The fluidics system trans­
ports the samples to the laser beam to be analysed and quantifies the intensity of 
fluorophore upon laser excitation. The optics system consists of lasers to illumi­
nate the cells and optical filters to direct the signal to the appropriate detectors. 
There are three optical filters (figure 3.1) which are summarized in the table (3.1). 
The electronics system converts the detected light signals into electronic signals 
th a t can be processed by the computer. One cell excited by the laser beam will 
produce da ta  composed of a t least three values: the size of the cells (FSC), the 
complexity of the cells (SSC) and the intensity of the fluorophore depending on 
the laser used (FL1-3) (figure 3.1). The light from the laser beam is detracted and 
reflected a t 90° and is collected by a lens and then directed to  the detector by the 
beam splitter. The FSC measures the size of the particles or cells by measuring 
mostly diffracted light from the laser beam. The light is collected off the axis of
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the laser beam  in the forward direction by the FSC photodiode (figure 3.1). The 
combination of the two param eters allows the analysis and differentiation of dif­
ferent cell types. For instance, the analysis of peripheral blood mononuclear cells 
(PBMC) isolated from whole blood using histopaque™  (Sigma Aldrich), kindly 
provided by H. Denney (BMRC, Sheffield Hallam University) w ith these two pa­
ram eters (FSC and SSC) allows differentiation of the lymphocyte and monocyte 
populations (figure 3.2a). W hen a cell line is subjected to  flow cytometry, the 
analysis of the FSC and SSC param eters should give a single, uniform population 
in the two dimension dot plot (figure 3.2b).
W hen examining the expression of a specific protein in cells, antibodies specific 
for th a t protein labelled with a fluorophore are used. The different fluorophores 
compatible with the FACsalibur are summarized in table 3.1. Only fluorescein 
isothiocyanate (FITC) and phycoerythrin (PE) were used in this study.
The da ta  generated by a flow cytometer is presented in two windows.The first 
window is a two-dimension dot plot with FSC (X-axis) plotted against the SSC 
(Y-axis) to determine the physical characteristics of the cells in the cell suspen­
sion. The second window is a single dimension histogram with the fluorescence 
intensity of the samples (X-axis) plotted against the number of events (Y-axis). 
This window allows the level of expression of the protein of interest to be anal­
ysed when compared to the negative control. The negative control is assessed by 
incubating cells with an isotype control, which belongs to  the same class of im­
munoglobulin as the antibody used to detect the protein of interest. The isotype 
control is labelled with the same fluorophore used for the antibody of interest 
(figure 3.3). The negative control is fundamental to  determine the background 
fluorescence in the sample.
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Channel Band Pass Filter Fluorophore
FL1 530/30 FITC, Alexa-488, 
GFP
FL2 585/42 PE
FL3 670LP PerCP, PE- 
Cy5, PE-Cy5.5, 
PerCP-Cy5.5, 
PE-Alexa647, 
PE-Alexa680, PE- 
Alexa700, PE-Cy7, 
PE-Alexa750
Tab. 3.1: F lu o ro p h o re s  c o m p a tib le  w ith  th e  B D  F A C sca lib u r.
FACscalibur is a two laser and four colour instrum ent th a t is able to use a wide 
variety of fluorophores. Fluorophores are detected in different channels (FL1, 
FL2 and FL3) depending on the fluorophore. Each fluorophore has an excitation 
wavelength (laser) and an emission wavelength th a t will go through the band 
pass filter. GFP: green fluorescent protein, PerCP: Peridinin-chlorophyll-protein 
Complex, PE-Cy: phycoerythrin cyanine.
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9 0 / i e  Beam sputter
DM 560$ F'
•1 640L;:‘
670LR/ n a i f  Mirror Fluorescence 
Collection lens
488/10
Fig. 3.1: O ptical system  in a flow cy to m eter.
W hen the sample is illuminated by the laser, the fluorophore emits fluorescence 
which is collected by a fluorescent collection lens. Depending on the wavelength of 
the signal em itted by the fluorophore, the signal will be collected in different chan­
nels (FL1: 530/30, FL2:585/42, FL3: 670LP). Information on the size and com­
plexity of the cells is also collected in the FSC and SSC channel. This allows the 
differentiation of different cell populations within the sample. Image obtained from 
w ww .m ed.umich.edu/flowcytometry/InitialTraining/lessons/lesson4/images/calo 
ptics.gif.
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Fig. 3.2: Two dim ension  do t p lo ts  of P B M C s an d  a s tro c y te  cells in  
suspension .
The 2 dimension dot plot determines the physical characteristic of a sample by 
analyzing the complexity of the cell (FSC) and the size of the cells (SSC). In this 
figure, PBMCs isolated from whole blood using H istopaque™  (Sigma Aldrich, 
UK) were kindly provided by H. Denney (BMRC, Sheffield Hallam University) 
and were analyzed with the FCS and SSC param eters (a). The lymphocyte and 
monocyte subpopulations can be visualized. The second two dimension dot plot 
(b) corresponds to astrocyte cells with a single uniform cell population. The 
population of interest can be gated. This means th a t during the analysis, only 
the cells with these characteristics (FSC and SSC) will be analysed.
1 2 3
No staining Low staining Strong staining
CellCell Cell
Specific directly 
labelled antibody for 
the protein of interest
■*->c<D>LD
Fluorescence intensity
Fig. 3.3: Single d im ension  h is to g ram  d e te rm in es  th e  level of expression  
of th e  p ro te in  of in te re s t.
The X-axis represents the intensity of the staining and the Y-axis represents the 
number of events. Three cases are presented here. Case 1, with the peak on the 
left of the X-axis, corresponds to the negative control with no antibody attached 
to protein of interest. Cases 2 and 3 correspond to positive cells with increasing 
amount of antibody bound, which are coupled to a fiuorophore.
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3.2.2.2 Detection of cell surface expression of CCR2 on unstimulated 
astrocytes by flow cytometry
Cells were trypsinised and incubated for 1 h at 37°C in astrocyte media for re­
covery. 0.25xl06 cells/25 //I PB S /tube were stained with antibody directed against 
CCR2 protein. Cells were incubated for 1.5 h w ith 10/d of PE-labelled IgG2b 
mouse-anti hum an CCR2 (R&D Systems, UK) on ice in the dark, to limit the 
internalisation of the receptor. Cells were stained, in parallel, w ith the corre­
sponding isotype control, PE-labelled mouse IgG2b antibody, to  assess the signal 
in the negative control. Monocytic cell line, THP-1 cells, known to express CCR2 
were used as a positive control for CCR2 staining (Phillips et al. 2005). Cells 
were washed w ith 1ml of PBS and centrifuged for 5 min at 300g a t 4°C. PBS was 
removed and cells were incubated for 1 h with 30/d of PE-conjugated goat anti 
mouse IgG whole molecule at a dilution of 1/40 in PBS (Sigma, UK) to  amplify 
the signal. Cells were washed with PBS and run on flow cytometer where 10 000 
events were counted. CCR2 expression was quantitated using FACScalibur (BD 
Bioscicences, UK) and CellQuestTM software (BD Biosciences, UK) (n=3).
3.2.2.3 Detection of CCR2 on permeabilised unstimulated astrocytes 
by flow cytometry
0.5xl06cells/25/d PB S/tube were used and stained intracellularly. Cells were 
fixed in 1ml of 4% paraformaldehyde (Appendix) for 15 min a t RT. Cells were 
centrifuged for 5 min a t 300g in a mini spin centrifuge (Eppendorf, UK) and PFA 
was removed. 1ml of PBS-0.5%Triton X100 was added to the cells for 5 min at 
RT. Cells were centrifuged, supernatant was removed and cells were resuspended 
in 25/d of PBS. CCR2 staining was assessed as described for cell surface staining 
above.
Different procedures for fixation and permeabilization of astrocytes were as­
sessed to determine the optimal staining conditions. The first condition was fixa­
tion with 4% PFA and permeabilisation with 0.5% saponin (Sigma Aldrich, UK)
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followed by staining as described above. In the second condition, cells were treated 
following the protocol for the intracellular cytokine staining starter kit (BD Bio­
sciences, UK). 0.25xl06 cells were incubated in 100/zl of BD Cytofix/C ytoperm ™  
buffer, which contains 4% paraformaldehyde and saponin, for 20 min a t RT. Cells 
were washed with 1ml of BD Perm /W ash ™  buffer and resuspended in 30/d of BD 
Perm /W ash™  buffer. This buffer contains both  FBS and saponin. The staining 
procedure was then carried out as described above. An antigenic protection site 
step was also included in the staining procedure using glycine (0.1M) for 15 min 
a t RT to assess wether there was any difference in the staining for CCR2.
3.2.2.4 Measurement of CCR2 expression at the astrocyte cell surface 
following pro-inflammatory stimulation.
0.25xl06 cells/2ml/well were plated in 6  well-plates and allowed to  adhere 
for 24 h in astrocyte cell culture media (described in section 2.2.5). Cells were 
stim ulated with IL-1/3, TN F or IFN 7  (lOng/ml) in serum-free media for 24 to 48 
h. The cell surface staining procedure was described in section 3.2.2.2 following 
trypsinisation (n=3).
3.2.2.5 Acquisition of CCR2 PE-labelled (FL-2) astrocytes using flow 
cytometry.
Before running the samples, optimisation of the settings was performed on 
FSC, SSC and FL-2. Non labelled cells were run through the flow cytometer to 
optimize the settings for the FSC and SSC to have a uniform cell population in 
the middle of the two dimension dot plot. If the population was a t the bottom  of 
the two dimensional dot plot, the intensity of the laser for SSC was increased. If 
it was a t the top of the two dimension dot plot, the intensity of the laser for SSC 
was decreased. The same principle was applied for setting the FSC.
Astrocytes stained with the isotype control (negative control) were run to opti­
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mize the settings for FL-2. The peak for the negative control was located on the 
left side of the one dimension histogram by displacing the peak to the left or right 
of the X-axis by increasing or decreasing the intensity of the laser. W hen the peak 
for the negative control was correctly located, samples were analysed.
For the da ta  acquisition of the stained samples, 10,000 events (or cells) were 
counted.
3.2.2.6 Analysis of CCR2 PE-labelled (FL-2) astrocytes using BD™  
CellQuest Pro software.
For the analysis, the B D ™  CellQuest Pro software (BD Biosciences, UK) was 
used. A two dimension dot plot was opened with the desired file to  analyze the 
10,000 events counted during the acquisition. The 10,000 events include live cells, 
dead cells and cellular debris. To avoid background signal due to  cellular debris 
or dead cells, which give false positive staining, only the live cells were analysed 
by drawing a region or gate th a t includes only the live cell population (figure 
3.2b). At this stage, only the cells present in the gate will be further analysed. To 
determine the intensity of fluorescence of the gated cells, a single dimension his­
togram  was opened with the desired file for analysis. The gate drawn previously 
was selected as well as the channel for analysis (FL-2 in this case). The mean 
of fluorescence intensity (MFI) of the analyzed sample was obtained by using the 
’’sta ts” function of the B D ™  CellQuest Pro software. The same procedure was 
followed for all samples stained.
3.2.2.7 CCR2 expression by primary human adult astrocytes by im- 
muno cy to chemistry
The same m ethod was followed as described in section 2 .2 .2 .2  for the charac­
terisation of astrocytes by GFAP staining. Cells were incubated with monoclonal 
antibody directed against human CCR2 (R&D Systems, UK) at 1:100 dilution in
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PBS-1%BSA for 1 h a t RT. Three different secondary antibodies were assessed to 
determine the optim al signal. Cells were either incubated with PE-conjuguated 
goat anti-mouse IgG (1:40, Sigma Aldrich, UK) or FITC-conjuguated goat anti­
mouse IgG(l:100, Chemicon, UK) or Rhodamine-conjugated goat anti-mouse IgG 
(1:100, Chemicon, UK) diluted in PBS-1%BSA for 1 h a t RT in the dark.
3.2.3 M easurem ent of CCL2 binding to  astrocytes using  
biotinylated  CCL2 by flow cytom etry
3.2.3.1 Optimisation of CCL2 binding to astrocytes: dose response
Astrocytes (B327/01) in 6  well-plates were washed w ith PBS, harvested with 
trypsin-EDTA and incubated for 1 h in a humid atmosphere a t 37°C in 95% 
air/5%  CO2 in serum-free media to allow the cell membrane to recover after 
trypsinization. Cells were centrifuged at 300 g, supernatant was removed, and 
cells were resuspended and incubated with various concentrations of biotinylated 
CCL2 (0, 1, 100, 500, 800, 2000ng/ml, R&D Systems, UK) for 1 h in a humid 
atmosphere a t 37°C in 95% air/5%  CO2 . Biotinylated soybean trypsin inhibitor, 
supplied by the manufacturer, was used as negative control to  quantitate the 
non-specific binding (R&D Systems, UK). 10//1 of avidin-FITC was added to  the 
cell suspension (2 .2 /ig/m l) and incubated for a further 30 min a t 4°C in the dark. 
Binding was quantitated  using FACScalibur flow cytom etry (BD Biosciences, UK) 
and CellQuestTM software (BD Biosciences, UK) following the same procedure as 
described in section 3.2.2.5. Binding was expressed as MFI. The channel used for 
this experiment was FL-1, corresponding to detection of FITC. Three independent 
experiments were performed.
3.2.3.2 Optimisation of binding of biotinylated-CCL2 to astrocytes: 
time course experiment
The same protocol was followed as above with 0.25 /ig /m l of biotinylated- 
CCL2 th a t corresponded to previously determined half maximal effective binding
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of biotinylated-CCL2. Cells were incubated for 0, 30, 60, 180 and 360 min with 
biotinylated-CCL2 (n=2). Then staining was performed as described above.
3.2.3.3 Specificity of CCL2 binding to astrocytes: competition assay
The specificity of CCL2 binding was assessed by incubation of astrocytes with 
a constant concentration of biotinylated-CCL2 in the presence of increasing con­
centrations of unlabelled CCL2 (Prepotech, UK). Unlabelled CCL2 (zero, 25 and 
100 times more unlabelled CCL2 than  biotinylated-CCL2 ) was pre-incubated for 
30 min with the cell suspension prior to  addition of biotinylated CCL2. The 
binding procedure was performed as previously described in section 3.2.3.2 (n=3) 
using biotinylated CCL2  a t 0.25/ig/ml, incubated for 1 h a t 37°C in 95% air/5%  
CO2 and avidin FITC (2 .2 /ig/m l) for a further 30 min incubation a t 4°C in the 
dark prior to  analysis by flow cytometry.
3.2.3.4 Detection of CCL2 binding to primary human astrocytes under 
pro-inflammatory conditions
Astrocytes (B327/01) were plated into 6  well-plates (0.25xl06 cells/2 ml/well) 
and allowed to  adhere for 24 h in astrocyte cell culture media. Cells were stim u­
lated with IL-1/?, TN F or IFN7  (lOng/ml) in serum free media for 24 and 48 h, 
which was the optimal concentration determined for CCL2 secretion as described 
in section 2.3.4. The binding procedure was carried as described in section 3.2.3.3.
3.2.4 D etection  of CCL2 binding to  astrocytes using con- 
focal m icroscopy
CCL2 binding was also assessed on adherent cells using confocal microscopy, 
lm l of 5xl04/m l cells in complete media was plated onto sterile glass coverslips 
in 24 well plates (3.8cm2) and allowed to adhere for 24 h. Cells were washed with
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PBS prior to  addition of 40/d of biotinylated CCL2 (3/ig/ml), to completely cover 
the cells, for 1 h a t RT. As above, biotinylated soybean trypsin inhibitor was used 
as a negative control at the same concentration. Excess biotinylated CCL2 was 
removed by tapping on filter-paper and 40 /d of avidin-FITC (1 0 /tg/m l) was added 
to the cells and incubated for 30 min at 4°C in the dark. Cells were dipped three 
times in PBS, fixed with paraformaldehyde (4%) for 15 min and rinsed 3 times with 
PBS for 5 min. Coverslips were mounted using Vectashield mounting media with 
DAPI (Amersham, UK) and binding was visualized a t an excitation wavelength 
of 488 nm and emission wavelength of 520 nm using an Axiovert 200M confocal 
microscopy with LSM 510 laser module (Zeiss), equipped with a krypton/argon 
laser. Images were captured using the DSM software provided with the Axiovert 
200M confocal microscope as described in section 2.2.3.1.
3.2.5 M easurem ent of calcium  flux following stim ulation  
of astrocytes w ith  CCL2
3.2.5.1 Principle of calcium flux measurement
G-protein coupled receptors use Ca2+ as a second messenger to  activate intra­
cellular signalling events, th a t will activate various downstream pathways such as 
Akt, resulting in gene activation [Kiselyov et al., 2003]. To assess the increase in 
intracellular calcium, fluorescent calcium indicators have been developed. Fluo- 
3 was first introduced in 1989 to observe the movement of intracellular calcium 
[Minta et al., 1989]. The most im portant properties of this dye is th a t it has an 
absorbance a t 505nm, following excitation and fluorescence emission a t 530nm 
when complexed with Ca2+.
Fluo-4 is an analog of fluo-3 but generates a stronger signal following the 
binding to  intracellular Ca2+. Fluo-4 has a maximum absorption at 494nm and 
maximum emission a t 516nm. The dye is coupled with a nonpolar acetoxymethyl 
ester(AM) which results in an uncharged molecule th a t can penetrate the cell
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membrane. Once inside the cell, non specific esterase cleaves the AM ester re­
sulting in a charged form of the dye th a t leaks out of cells, far more slowly than 
the original compound. To reduce the leakage of the de-esterified dye from the 
cells, sulfinpyrazone, an anion transport inhibitor, is added to  the washing buffer 
(figure 3.4) [Kao, 1994, Di Virgilio et al., 1990].
To detect fluorescence, the Fluostar Optim a plate reader (BMG labtech Ltd., UK) 
was used. The FLU Ostar OPTIM A is a versatile microplate reader th a t allows 
the injection of a solution in the well to analyse and simultaneously record the 
level of fluorescence in a well, which corresponds to the calcium increase [Lin et al., 
1999].
3.2.5.2 Procedure for calcium imaging following CCL2 treatment of 
astrocytes
3xl04 astrocytes (B327/01)/200/d/well were plated in a black polystyrene 96 
well-plate (Corning Costar, UK) and allowed to adhere for 24 h. Cells were washed 
three times in Krebs HEPES buffer pH7.4 (Appendix) and incubated for 30min 
in the dark a t RT with Fluo-4AM at 5/zM (Molecular Probes, UK) in Krebs 
HEPES buffer with 0.25mM sulfinpyrazone (Sigma, UK) and 1% F I 2  pluronic to 
optimize the dispersion of the dye (Sigma, UK). Cells were washed twice with 
Krebs HEPES buffer and 0.1%BSA to remove the dye not taken up by cells. An 
additional wash was carried out for 30 min to allow complete de-esterification of 
intracellular AM esters. Before stimulation of cells, the buffer was changed to 
Krebs-HEPES. The plate was placed in the FLUOstar OPTIM A (BMG labtech, 
UK) a t 37°C. Two tubes containing 2 ml of either hum an recombinant CCL2 
(Peprotech, UK) (Ong/ml which is later replaced by lOOng/ml) or ionomycin at 
25/iM (Sigma Aldrich, UK) in Krebs-HEPES with Ca2+ (1.2mM) were kept in 
the FLU Ostar OPTIM A plate reader a t 37°C.
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Fig. 3.4: P r in c ip le  o f ca lc iu m  im ag in g  in  cells fo llow ing  a c tiv a tio n  o f a  
re c e p to r .
The intracellular calcium movement is monitored with a dye (Fluo-4) th a t is com- 
plexed to a non polar acetoxymethyl ester (AM) rendering the complex uncharged 
allowing the penetration into the cells (1). Inside the cell the AM ester is cleaved 
by non-specific esterase (2) resulting in a charged dye tha t leaks out far more 
slowly than the dye-ester (3). Fluo-4 has the property of a maximal absorption 
at 494nm and a maximal emission at 516nm when complexed with Ca2+ (4). In­
cubation with sulfinpyrazone, an anion transport inhibitor, prevents the leakage 
of Fluo-4 out of the cells.
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Ionomycin, a commonly used selective Ca2+ ionophore, was used as a positive 
control a t 5 /tM[Brylla et al., 2005, Turner et al., 2007]. CCL2 was injected at 
20 and ionomycin was injected a t 150s. M easurement of the calcium signal was 
taken every second for 5 min, using an excitation filter of 485 ±  12nm and an 
emission filter of 520nm. The amplitude of the response following CCL2 addition 
was expressed as a percentage of the maximum response (ionomycin) (n=3).
3.2.6 M easurem ent of Erk and A kt signalling using SDS 
PA G E and w estern b lotting by detectin g  phospho- 
rylated  forms
3.2.6.1 Cell stimulation with CCL2 and fetal calf serum (FCS)
lm l of astrocyte-suspension (B327/01 and E pl5) was plated into 6  well-plates 
(0.25xl06 cells/ml/well) and allowed to adhere for 24 h. Media was removed and 
cells were cultured for 24h in SFM and then stim ulated for 15 min w ith CCL2 at 0 
to lOOng/ml (Peprotech, UK) FCS (10%) was used as a positive control [Henkler 
et al., 1998, Posern et al., 1998].
3.2.6.2 Sample preparation for the measurement of Erk and Akt phos­
phorylation following CCL2 treatment by western blotting
Cells were washed once in ice cold PBS supplemented with ImM orthovanadate 
ImM  (Sigma, UK) a phosphatase inhibitor. 50/d of Laemmli buffer (Appendix) 
was added to the cells, which were quickly harvested using a cell scraper (Greiner 
Laboratories Limited, UK) and transfered into an Eppendorf tube. Samples were 
heated a t 95°C for 10 min and sonicated for 5s a t 40% am plitude (VibraCell 
processor 750W, Sonics) to disrupt the DNA. Samples were kept a t -20°C until 
used.
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3.2.6 .3 Measurement of Erk and Akt phosphorylation following CCL2 
treatment by western blotting
Since measurement of protein was not possible, due to the sample buffer, which 
would interfere in the assay, equivalent volumes were loaded for each conditions. 
Samples were run on a 10% acrylamide/0.13% bis-acrylamide gel (National Diag­
nostics, UK) and transferred onto a nitrocellulose membrane, HybondTM  C E xtra 
(Amersham, UK) overnight at 4°C at 0.15 A using the blotting apparatus, Power 
Pac 300 (Biorad, UK). Before probing the membrane with antibodies for Erk and 
'Akt, membranes were blocked for 1 h at RT in TBS-5% powdered milk. Phospho- 
rylated forms of Erk and Akt were visualized using rabbit polyclonal antibodies 
specific for Erk 1 and 2 [pTpY185/ 187] and Akt [pS473] (Biosource, UK) a t 1:1000 
in PBS-5% powdered milk for 2h at RT. Membranes were washed five times (10 
min each) w ith PBS-0.05%Tween 20 a t RT. Secondary HRP-conjugated goat anti 
rabbit IgG in PBS-0.05%Tween 20 (Sigma, UK) a t 1:20 000 was used for lh  a t RT 
(Table 3.2) and membranes were then washed as before with PBS-0.05%Tween 
20. An extra washing step was done with PBS for 10 min a t RT.
Imm unoreactivity was detected by chemiluminescence using the ECL Reagent 
K it Plus, western blotting detection system (Amersham, Buckinghamshire, UK), 
according to  the m anufacturer’s instructions. Briefly, 2 ml of ECL Plus substrate 
solution containing Tris buffer (solution A) and 50//1 of stock acridan solution 
in dioxane and ethanol (solution B) were incubated on the membrane for 5 min 
a t RT. Chemiluminescent signal was visualised using a UVP Bioimaging system 
(Bio-Rad, Hertfordshire, UK). Q uantitative analysis was carried out by compar­
ing the integrated optical density (IOD) using densitometric software of the UVP 
Bioimaging system.
To normalize the level of expression of phosphorylated forms of Erk and Akt, 
to tal Erk and Akt expression was assessed. First, each blot had to be stripped 
and re-probed with different primary antibodies. Blots were washed three times
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for 5 min each in TBS, which acted as a neutralizing buffer. This was followed 
by incubating for 30 min a t 50°C in stripping buffer (lOOmM H-mercapto-ethanol 
(Sigma Aldrich, UK), 2%w/v SDS, 62.5mM Tris/HCL pH 6 .8 ). Blots were washed 
three times for 5 min each in TBS before starting the staining procedure with the 
second set of antibodies.
Total Erk was visualized using mouse monoclonal antibody specific for Erk 1 and 
2 a t a 1:500 dilution (Upstate, UK) and HRP-conjugated goat anti-mouse IgG 
antibody (1:10 000). Total Akt was visualized by probing the membrane with 
rabbit polyclonal antibody specific for Akt a t a 1:1000 dilution (Cell Signalling, 
UK) and HRP-conjugated goat anti-rabbit IgG antibody (1:10 000). Visualisation 
of the blots was performed as described above. The antibodies used to  determine 
the phosphorylation level of both Erk and Akt are summarised in table 3.2.
To compare the phosphorylation of Erk and Akt under pro-inflammatory con­
ditions (section 3.2.6.1), IOD values of Erk 1 and 2  [pTpY185/ 187] and Akt [pS473] 
were normalized to the IOD values of Erk to tal and Akt to ta l respectively consid­
ering these as a value of 1. Experiments were performed twice for both  SMS-12 
and E pl5 . Experiments were performed once with B327/01 due to limited cell 
availability.
3.2 .7  Statistica l analysis
D ata are shown as mean ±  SEM. For experiments on CCR2 level expression, 
CCR2 expression, CCL2 binding and phosphorylation of Erk and Akt, level of 
significance for comparisons between samples was determined using the ANOVA 
param etric test w ith D unnett’s test. In all cases, P<0.05 was considered signifi­
cant.
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Prim ary antibody Secondary antibody 
HRP-conjugated
Suppliers
p T p Y 185/187 rabbit polyclonal anti­
bodies specific for Erk 
1 and 2 [pTpY185/ 187] 
(1 :1 0 0 0 )
goat anti rabbit IgG 
(1 :2 0 ,0 0 0 )
Biosource
(UK)
Total Erk mouse monoclonal anti­
body specific for Erk 1 
and 2 (1:500)
goat anti mouse IgG an­
tibody (1 :1 0 ,0 0 0 )
U pstate (UK)
pS473 rabbit polyclonal anti­
bodies specific for Akt 
[pS473] (1:1000)
same as secondary anti­
body for pTpY 185//187
Biosource
(UK)
Total Akt rabbit polyclonal anti­
body specific for Akt 
(1 :1 0 0 0 )
same as secondary anti­
body for pTpY 185/ 187
Cell sig­
nalling (UK)
Tab. 3.2: A n tib o d ie s  u sed  to  assess p h o sp h o ry la t io n  o f A k t a n d  E rk  by  
w e s te rn  b lo tt in g .
Antibody dilutions are given in parentheses.
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3.3 R esults
3.3.1 M easurem ent of CCR2 m R N A  expression by astro­
cytes following cytokine stim ulation  using qR T -PC R
CCR2 mRNA was detected in unstim ulated prim ary human adult astrocytes 
using real-time RT-PCR (figure 3.5). Following 24 and 48 h stim ulation with 
TN F (lOOng/ml), CCR2 mRNA expression was significantly increased, compared 
to  unstim ulated cells (P<0.05) (figure 3.5 a-b). IL-1 (5 and IFN 7  slightly increased 
CCR2 mRNA expression by astrocytes a t 100 ng/m l, although this increase did 
not reach statistical significance. Stimulation of prim ary human adult astrocytes 
from three donors (SMS-12, B327/01 and EP15) with IL-1/3, TN F and IFN 7  at 
lOng/ml for 24 h showed no significant differences in their response to cytokines 
using non param etric ANOVA with D unnett’s test (figure 3.6).
3.3.2 CCR2 expression by astrocytes using flow cytom etry
By contrast, CCR2 expression by astrocytes from two different donors (B327/01 
and E pl5) either a t the cell surface, or in Triton X-100-permeabilised cells was 
not detected using flow cytometry either constitutively (figure 3.7) or following 24 
and 48 h stim ulation with TNF at 100 ng/m l (data not shown). TN F stim ulation 
was used as it was the only cytokine to  induce a significant increase in CCR2 
mRNA. The lack of detection of CCR2 on astrocytes was not due to problems 
related to antibody specificity, as CCR2 expression was readily detected on the 
monocytic cell line, THP-1 (figure 3.7c).
Various protocols were assessed to improve the detection sensitivity for CCR2 by 
astrocytes. Protection of the antigenic site (glycine 0.1M) as well as different fix­
ation procedures (PBS-Triton X100, 0.5% saponin and Fix and Perm buffer from 
BD Bioscience (UK)) did not enhance the detection of CCR2.
137
a  24h
50
©atg  40H 
o
-  30H 2  o
0
1 10" Oq:
I
I I I I — I 1 I I 1 I 11 I 1 T I0 1 10 100 0 1 10 100 0 1 10 100
IL1-P TNF IFN-y
Cytokine stimulation (ng/ml)
b 48h
50n
0 1 10 100 0 1 10 100 0 1 10 100
IL1-P TNF IFN-y
Cytokine stimulation (ng/ml)
Fig. 3.5: D e te c tio n  o f  C C R 2  m R N A  e x p re ss io n  b y  a s tro c y te s  fo llow ing  
p ro - in f la m m a to ry  c y to k in e  s tim u la tio n  u s in g  q R T -P C R .
Cells (SMS-12) were stim ulated with IL1-/5 (white), TN F (grey) and IFN 7  (dark 
grey) at 0 to  lOOng/ml for 24h (a) and 48h (b). Real tim e PC R  was performed 
in triplicate on each sample (three stimulations). ANOVA followed by D unnett’s 
test was performed. *p< 0.05 is considered as significantly different.
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Fig. 3.6: C o m p a riso n  o f  C C R 2  m R N A  ex p re ss io n  b e tw e e n  th r e e  a s tro ­
c y te  p re p a ra t io n s
CCR2 mRNA expression by prim ary human adult astrocytes following pro- 
inflammatory stim ulation using qRT-PCR with SybrGreen. SMS-12, B327/01 
and E p l5  were stim ulated with IL1-/? (white), TN F (grey) and IFN 7  (dark grey) 
a t 0 and lOng/m l for 24h (n = 6 ). ANOVA followed by D unnett’s test was per­
formed and dem onstrated no significant differences in CCR2 mRNA expression 
following pro-inflammatory stimulation for the three astrocyte preparations.
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Fig. 3.7: H is to g ra m  re p re s e n ta t io n  o f cell C C R 2  ex p re ss io n  u s in g  flow 
c y to m e try .
CCI12 expression 011 the cell surface (a) and intracellular staining (b) on astrocytes 
(13327/01) was assessed. CCR2 staining at the cell surface on the monocytic cell 
line THP-1 cells was performed as a positive control using the same procedure 
as for the astrocytes (c). Green line corresponds to the negative control (cells 
incubated with corresponding PE-labelled isotype control antibody).
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Similarly, CCR2 was not detected by immunocytochemistry under basal con­
ditions, using three different secondary antibodies (data not shown).
3.3.3 B ind ing of b iotinylated CCL2 to  th e cell surface 
of hum an adult astrocytes d etected  by avidin-FITC  
and flow cytom etry
In the absence of stimulation, biotinylated CCL2 binding to  the astrocyte cell 
surface membrane (B327/01) was observed using biotinylated CCL2 with avidin- 
FITC  and nuclei counterstained with DAPI (figure 3.8b). Biotinylated soybean 
trypsin inhibitor was used as negative control, which showed no staining (figure 
3.8a). CCL2 binding was assessed on B327/01 (figure 3.8 c-d) and SMS-12 (figure 
3.8 e-f). Strong localized staining for CCL2 was observed a t the edge of the cells.
Binding was also assessed by flow cytometry (figure 3.9). Determ ination of 
50% of the maximal binding, and the optimal incubation time for the biotiny- 
ated CCL2 was assessed with dose response (n=3) and time course experiments 
(n=2) (figure 3.10a-b). The optimal conditions for biotinylated CCL2 binding 
using 0.25xl06 cells was 0.25/zg/ml biotinylated CCL2 (figure 3.10a) for lh  (figure 
3.10b). The specificity of the binding was assessed by incubating biotinylated 
CCL2 with increasing concentrations of unlabelled CCL2 (figure 3.11). Unla­
belled CCL2 reduced the binding of biotinylated CCL2 on astrocytes in a dose- 
dependent m anner by 30.78% (n=3, p<0.05) and 53.61% (n=3, P<0.01) when 
using concentrations of unlabelled CCL2 at 25 and 100 times higher, respectively. 
High concentrations of cold CCL2 were required to prevent the binding of biotiny­
lated CCL2 to astrocytes. A 50% reduction in binding of labelled CCL2 would 
be expected when incubating twice as much cold CCL2 than  biotinylated CCL2, 
if bo th  labelled and unlabelled CCL2 bind equally. Therefore biotinylated CCL2 
has a  higher affinity for binding to astrocytes than  the unlabelled CCL2. This 
might be explained by non specific binding to  astrocytes due to  the biotin label.
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However the use of biotinylated soybean trypsin inhibitor as a negative control, 
which showed no binding, confirmed the absence of non specific binding through 
the biotin label. S tructural alteration of the biotinylated CCL2  may lead to this 
higher affinity to the binding site on astrocytes than  native CCL2. However, some 
specificity for biotinylated CCL2 binding to astrocytes was observed in our study. 
Similar finding was observed in a study by Andjelkovic et al (1999) where they 
showed in com petition experiments with human fetal astrocyte cell cultures th a t 
cold CCL2  (5 times more than  biotinylated CCL2) induced a reduction of 20% in 
biotinylated CCL2 binding.
Following pro-inflammatory stimulation with IL-1/?, TN F and IFN 7  a t lOng/ml 
for 24 h, no significant difference in CCL2 binding to  astrocytes (B327/01) was 
observed (figure 3.12). However, following 48 h stim ulation, IL-1/5 (76.15 ±  28.85 
MFI), TN F (81.56 ±  29.30 MFI) and IFN 7  (72.20 ±  24.47 M FI), a non signifi­
cant increase in CCL2 binding to astrocytes was observed compared to the baseline 
(45.10 ±  16.17 MFI) (figure 3.12). Although the absolute am ount of biotinylated- 
CCL2 bound decreased following 48 h stimulation compared to 24 h stimulation, 
it did not reach statistical significance (ANOVA followed by D unnett’s test).
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Fig. 3.8: B io tin y la te d  C C L 2 b in d in g  to  p r im a ry  h u m a n  a d u l t  a s tro c y te s  
d e te c te d  by  a v id in -F IT C .
(a) Biotinylated soybean trypsin inhibitor with avidin-FITC was used as negative 
control on the astrocytes (B327/01). Visualization of binding with biotinylated 
CCL2 (3/yg/ml) on B327/01 astrocyte preparation (b, c and d) and SMS-12 as­
trocyte preparation (e-f).
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Fig. 3.9: C C L 2 b in d in g  to  p r im a ry  h u m a n  a d u lt  a s tro c y te s  (B 3 2 7 /0 1 )  
u s in g  flow c y to m e try .
Representative flow cytometric histogram to dem onstrate the binding of biotiny­
lated CCL2 (0.25/xg/ml) to B327/01 astrocytes, followed by detection with avidin- 
FITC, in PBS (blue histogram). Biotinylated soybean trypsin inhibitor was used 
as a negative contol (filled histogram). This is representative of results obtained 
in three independent experiments.
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Fig. 3.10: O p tim is a tio n  o f C C L 2  b in d in g  d e te rm in e d  b y  flow  c y to m e try : 
do se  re s p o n se  a n d  tim e  cou rse .
(a) Dose response experiments were done to determine the concentration of bi­
otinylated CCL2 th a t produced 50% of maximal binding. Astrocytes (B327/01) 
were incubated w ith increasing concentrations of biotinylated CCL2 for lh  a t 37°C 
(0 up to  2000ng/ml, n=3). (b) The optimal incubation tim e was determined by 
performing tim e course experiments (0 to 360min) using the concentration for bi­
otinylated CCL2 th a t represents 50% of the maximal binding (n=2). The optimal 
conditions were 0.25/zg/ml of biotinylated CCL2 , incubated with astrocytes for lh  
a t 37° C. The background value with biotinylated trypsin inhibitor was substracted 
for each condition.
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Fig. 3.11: D e te rm in a t io n  o f  th e  sp ec ific ity  o f b io t in y la te d  C C L 2  b in d in g : 
c o m p e tit io n  e x p e rim e n ts .
The specificity of CCL2 binding to  astrocytes (B327/01) was assessed by per­
forming com petition experiments with pre-incubated unlabelled CCL2 (25 fold 
(squares) and 100 fold (horizontal lines)) CCL2 prior to  the binding procedure 
(n=3). The background value with biotinylated trypsin inhibitor was subtracted 
for each condition and results were expressed as the percentage reduction in CCL2 
binding to astrocytes. ANOVA followed by D unnett’s test was performed. *p< 
0.05, **p< 0.01 was considered as significantly different.
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Fig. 3.12: B io tin y la te d  C C L 2  b in d in g  to  a s tro c y te s  u n d e r  p ro -
in f la m m a to ry  c o n d itio n s  b y  flow c y to m e try .
Cells (B327/01) were stim ulated with IL1-/3, TN F and IFN 7  a t lOng/ml for 24h 
(blank) and 48h (grey) in triplicate and binding experiments were performed in 
duplicate on each sample. ANOVA followed by D unnett’s test was performed to  
determine the significant difference between binding on unstim ulated and stim u­
lated cells. Differences in binding following 24 and 48 h stim ulation was assessed 
by ANOVA followed by D unnett’s test and no significant difference was observed.
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3.3.4 M easurem ent of calcium  flux in astrocytes following  
CCL2 treatm ent
3.3.4.1 Optimisation of experimental conditions
Before stim ulating the cells with recombinant hum an CCL2 , optimisation of 
the technique was undertaken. As the system is extremely sensitive, turbidity 
resulting from injection of buffer could indicate an artefactual increase in Ca2+ 
[Miyazaki et al., 2007]. Testing the volume of solution to  inject was the first 
optimisation step. Injection of 80/d of FCS (10%) on to  the cells (in 80/d of 
Krebs-HEPES buffer) induced a strong increase in fluorescence due to  an increase 
in intracellular Ca2+ (95% of the maximum response) (figure 3.13a). W hen inject­
ing Krebs-HEPES buffer under the same conditions, a strong increase was also 
observed (80% of the maximum response). However, the signal obtained with 
FCS (figure 3.13a) was stronger than  for Krebs-HEPES alone (figure 3.13b).
To reduce the background, a reduction in the injected volume of buffer was 
tested. One fifth of the initial volume was added to the cells (12.5/d). Figure 3.14a 
shows the absence of response following injection of buffer, and a strong response 
following ionomycin injection (from 5,865 units of fluorescence to  18,591 units of 
fluorescence). However, the signal for ionomycin decreased with tim e from 12,526 
units of fluorescence (5 min) to 5,330 units of fluorescence (15 min), w ith 0 min 
corresponding to the cells just after the last wash (figure 3.14b). This provides 
evidence th a t Fluo-4 was expelled by the cells. Sulfinpyrazone, an anion inhibitor, 
was added to the cells to  avoid any dye leakage. Stim ulation of cells (B327/01) 
w ith FCS (10%, 2 0 s) and ionomycin (25/zM, 150 s) was done a t 0 min (blue), 5 
min (yellow) and 10 min (light blue) after the last wash. The am plitude of the 
fluorescence was 11194, 11473 and 10 088 respectively which showed a reduction 
in Fluo-4 leakage (figure 3.15).
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Fig. 3.13: O p tim isa tio n  of th e  volum e of so lu tion  in jec ted  for d e tec tio n  
of calcium  flux in  a s tro cy te s  (1).
Cells were loaded with 5/iM Fluo-4AM. Calcium imaging was assessed on B327/01 
astrocytes following stim ulation with FCS (1, 20s) and ionomycin (2 , 150s) (a). 
Negative control was assessed by injecting Krebs-HEPES buffer after 20s (1) and 
ionomycin after 150s (2) (b). In this experiment, half of the final volume (80/d) 
of FCS or Krebs-HEPES was injected.
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Fig. 3.14: O p tim isa tio n  o f th e  v o lu m e  o f so lu tio n  in je c te d  fo r d e te c t io n  
o f ca lc iu m  flux  in  a s tro c y te s  (2 ).
Cells were loaded with 5/zM Fluo-4AM. Calcium imaging was assessed on B327/01 
astrocytes following stim ulation with Krebs-HEPES (1, 20s) and ionomycin (2 , 
150s) (a). In this experiment. One fifth of the initial volume (12.5/d) was injected. 
Injection of Krebs-HEPES (20s.) and ionomycin (150s) was assessed at 5 min 
(a) and 15 min (b) after the last 30 min wash. Amplitude of the response for 
ionomycin decreased with time.
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Fig. 3.15: In c u b a t io n  w ith  su lfin p y raz o n e  to  p re v e n t dye  leakage.
Cells (B327/01) were loaded with 5/iM Fluo-4AM with sulfinpyrazone to assess 
prevention of dye leakage. Cells were stim ulated after the last wash (30 min wash) 
with FCS (1. 20s) and ionomycin (2, 150s) at 0 min (blue), 5 min (yellow) and 10 
min (light blue). The pink line represents the baseline fluorescence.
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3.3.4.2 Effect of CCL2 treatment on intracellular calcium flux in as­
trocytes
Stim ulation of astrocytes with CCL2 (0 and lOOng/ml) was assessed to deter­
mine whether CCL2 binding had any functional effect on astrocytes. No difference 
in the calcium flux was observed following CCL2 stim ulation (100 ng/m l) and the 
untreated control. Indeed, Ca2+ response from non stim ulated astrocytes (n=3) 
represents 22.23 ±  4.9% of the maximal response (ionomycin) whereas Ca2+ re­
sponse from astrocytes treated  with CCL2  (100 ng/m l) represents 23.8 ±  1% 
(n=3) of the maximal response.
3.3.5 Effect o f CCL2 treatm ent on Erk and A kt signalling  
pathw ays in astrocytes
To confirm the previous results, showing the absence of Ca2+ flux, effects of 
CCL2 binding to  astrocytes (B327/01 and E pl5) on downstream signalling events 
was assessed by measurement of Erk and Akt phosphorylation. Astrocytes were 
stim ulated with CCL2 from 0 to  100 ng/m l. No difference was observed in the level 
of phosphorylation of Erk in E pl5  (n=2), SMS-12 (n=2) and in B327/01 astrocyte 
(n = l)  (figure 4.5). No difference in the band intensity was observed between CCL2 
stim ulation and unstim ulated cells in the three astrocyte preparations assessed. 
Q uantitative analysis, carried out by comparing the integrated optical density 
of each treatm ent (IOD) using densitometric software of the UVP Bioimaging 
system (n = 2 ), showed th a t there was no difference in the phosphorylation between 
CCL2 stim ulated and unstim ulated cells. The absence of phosphorylation of Erk 
following CCL2 stim ulation was not due to a technical problem as FCS, used as 
a positive control, induced a significant increase in expression of phosphorylated 
forms of Erk (p<0.01, n=2).
Similarly to  Erk, CCL2 stimulation on E p l5  (n=2) and B327/01 (n = l)  did not 
induce any increase in phosphorylated forms of Akt compared to  unstim ulated 
cells. Again, FCS significantly increased the phosphorylation of Akt (P<0.05,
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11= 2 ) (figure 4.6).
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Fig. 3.16: E ffec t o f C C L 2 t r e a tm e n t  on  E rk  1 a n d  2 p h o s p h o ry la t io n  in  
p r im a ry  h u m a n  a d u l t  a s tro c y te s  u s in g  SD S P A G E  a n d  w e s te rn  b lo t­
tin g .
Astrocytes ( SMS-1 2 , B327/01 and E pl5) were serum starved for 24 h and stim ­
ulated with CCL2  a t 0 -1 0 0 ng/m l or FCS, as a positive control. Erk 1 and 2 
(pTpY185/ 187) as well as the to tal amount of Erk were assessed by western blot­
ting (a). Q uantitative analysis was carried out by comparing the integrated op­
tical density of each stim ulation (IOD) using densitometric software of the UVP 
Bioimaging system (Epl5, n=2) . To compare phosphorylation following pro- 
inflammatory stim ulation, IOD values of Erk 1 and 2 (pTpY 185/ 187) were normal­
ized to the IOD values of Erk to tal (b). ANOVA followed by D unnett’s test was 
performed and p < 0 .0 1  was considered as significantly different.
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Fig. 3.17: E ffec t o f  C C L 2  t r e a tm e n t  on  A k t p h o s p h o ry la t io n  in  p r im a ry  
h u m a n  a d u l t  a s tro c y te s  u s in g  SD S P A G E  a n d  w e s te rn  b lo ttin g .
Astrocytes (B327/01 and Epl5) were serum starved for 24 h and stim ulated with 
CCL2  a t 0 -1 0 0 ng/m l or FCS as a positive control. Akt (pS473) as well as the to tal 
am ount of Akt were assessed by western blotting (a). Q uantitative analysis was 
carried out by comparing the integrated optical density of each stim ulation (IOD) 
using densitometric software of the UVP Bioimaging system (B327/01, n = 2 ) (b). 
ANOVA followed by D unnett’s test was performed and p<0.05 was considered as 
significantly different.
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3.4 D iscussion
Much evidence for a role for CCL2 in MS pathogenesis has been obtained in 
the EAE mouse model in which either CCL2 or CCR2 genes were knocked-out 
[Kennedy et ah, 1998, Huang et ah, 2001, Gaupp et al., 2003]. A significant re­
duction in macrophage recruitment into the CNS was observed in these animals 
[Huang et al., 2001]. In other reports, use of anti-CCL2 antibodies prevented the 
firm adhesion of leukocytes to the endothelium, bu t not the rolling in CNS in­
flammation in the EAE model induced with MOG35-55  and myelin basic protein 
(MBP) [dos Santos et al., 2005, Youssef et al., 1999], thus leading to a reduction 
in the severity of the disease.
However, a role for CCL2 in MS pathogenesis is less well defined. For example, 
the significance of the observation th a t CCL2 levels decrease in the CSF of MS 
patients during relapse [Mahad et al., 2002a, Narikawa et al., 2004, Scarpini et al., 
2002] remains to be determined. CCL2 levels in the serum have also been assessed 
but showed no consistency between different studies as discussed in section 1.4.9.2 
[Kivisakk et al., 1998, Scarpini et al., 2002].
In the previous chapter, the rate of synthesis and secretion of CCL2 by astro­
cytes was assessed and no decrease in the synthesis and secretion of CCL2 was 
observed following pro-inflammatory treatm ent. Therefore the decrease in the 
CSF level of CCL2 might be a result of sequestration of CCL2 in the CNS by 
astrocytes a t times of relapse in MS patients.
3.4.1 CCR2 m R N A  expression by astrocytes using qRT- 
P C R
Firstly, the synthesis and expression of CCR2  was assessed to determine whether 
CCR2, expressed by astrocytes, could sequestrate CCL2 locally. Human adult
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astrocytes express CCR2 mRNA constitutively dem onstrated by qRT-PCR, con­
firming previous studies using human foetal and adult simian astrocytes [And- 
jelkovic et al. 2002, Croitoru-Lamoury et al. 2003]. However, there are previ­
ously contradicting reports of IL1 -j3 and TNF effects on CCR2 mRNA expression. 
Croitoru-Lamoury et al. (2003) found by RT-PCR th a t IL1 j3 and TN F signifi­
cantly induced a 3 fold increase in CCR2 mRNA using simian adult astrocytes 
whereas Andjelkovic et al. (2002) found the loss of CCR2 mRNA expression fol­
lowing 48 and 72h stimulation with IL1/? and TN F using hum an foetal astrocytes 
compared to 24 h stimulation. In this study using qRT-PCR, CCR2 mRNA was 
constitutively expressed and showed a significant increase following TN F stimu­
lation w ith lOOng/ml for 24 and 48 hours. Although 111-/? and IFN - 7  increased 
CCR2 mRNA expression with lOOng/ml for both  24 and 48 h, it was not signifi­
cant.
3.4.2 CCR2 protein expression by astrocytes using flow 
cytom etry
Surprisingly, human adult astrocytes did not express CCR2 protein even fol­
lowing TN F stim ulation a t lOOng/ml. This particular stim ulation (TNF at lOOng/ml) 
was chosen as it was the only stimulation th a t significantly increased CCR2 mRNA 
expression by prim ary human adult astrocytes. The absence of detection of CCR2 
on prim ary hum an adult astrocytes was not as a result of a technical problem as 
strong staining was observed on the monocytic cell line (THP-1 cells), using the 
same procedure. Similar findings were obtained with another chemokine recep­
tor (CXCR3), where CXCR3 mRNA was detected but not protein in intestinal 
myofibroblasts possibly due to  a receptor expression below the detection limit 
[Kouroumalis et al., 2005].
Several in vitro studies reported th a t cultured hum an foetal astrocytes express 
CCR2 [Andjelkovic et al., 2002, Rezaie et al., 2002] whereas others studies re­
ported th a t human adult astrocytes or mouse astrocytes do not express CCR2
156
[Flynn et al., 2003, Heesen et al., 1996]. In this regard, it has to be mentioned 
th a t the astrocytes used in the different in vitro studies come from either different 
species or different developmental stages. Human foetal astrocytes aged 21 to  23 
weeks and 13 to  29 weeks were used respectively by Andjelkovic et al. (2 0 0 2 ) and 
Rezaie et al. (2001) which were both positive for CCR2 expression. Postnatal 
day 0 animals [Heesen et al. 1996] and human adult astrocytes (the present study 
and the Flynn study) have shown an absence of expression of CCR2. The func­
tion of astrocytes in response to inflammation thus might vary depending on the 
developmental stage of the cells and species origin.
The absence of detectable CCR2 protein may be due to  several factors. First, 
qRT-PCR is the most sensitive technique currently available for the quantifica­
tion of RNA samples [Klein et al., 2000] and has a high sensitivity (±5 copies). 
Thus, the transcriptional activity of CCR2, and hence mRNA levels, might be so 
low th a t there is little protein expressed. However, this is unlikely to  happen as 
the C t values for CCR2 were similar to what found for another chemokine receptor 
(CXCR3) which was readily detected by flow cytom etry and immunocytochem­
istry as shown in chapter 4. Secondly, CCR2 mRNA may be rapidly degraded 
or possibly repressed although studies th a t support this possibility are lacking. 
Finally, there may be a rapid turn-over of the CCR2 receptor targeting it to  
degradation by the proteasome rather than recycling. However, this hypothesis is 
unlikely as astrocytes were negative for intracellular CCR2 expression (figure 3.7).
3.4.3 M easurem ent of signalling pathw ays induced by CCL2 
in astrocytes
To confirm the hypothesis th a t astrocytes did not express CCR2 or CCR2 was 
present but not detectable, measurement of the calcium flux as well as phospho­
rylation of the main signal transduction pathways Erk and Akt, responsible for 
differentiation/proliferation and chemotaxis were assessed following CCL2 trea t­
ment [Ashida et al., 2001, Thelen, 2001, Wain et al., 2002]. Despite high calcium
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flux detected w ith ionomycin, no calcium flux was detected following CCL2 stim ­
ulation. FITC-Phalloidin staining, which stains the actin stress fibres due to 
chemokine stim ulation, did not shown any difference between unstim ulated and 
stim ulated astrocytes with CCL2 from 0 to lOOng/ml for 15 min to  60 min. (data 
not shown). The phosphorylation of Erk and Akt pathways was unchanged fol­
lowing 15 min stim ulation with 0 to  100 ng/m l of CCL2 compared to the control. 
Again, the absence of an increase in phosphorylation was not as result of technical 
problems as astrocytes responded to FCS treatm ent, a commonly used positive 
control for the phosphorylation of both Akt and Erk [Posern et al., 1998, Henkler 
et al., 1998].
The absence of CCR2 expression by prim ary human adult astrocytes raises the 
question as to  w hether they are able to bind CCL2 in the absence of its cognate 
receptor. As discussed in sections 1 .4.4.1 and 1.4.6, CCL2  has been shown to bind 
to various proteoglycans and the D6  decoy receptor [Kuschert et al., 1999, John­
son et al., 2005, Fra et al., 2003, Weber et al., 2004]. Therefore CCL2 binding to 
prim ary hum an adult astrocytes was assessed in one astrocyte preparation. Us­
ing biotinylated CCL2, astrocytes constitutively bound exogenous CCL2  on the 
cell surface and this was largely unaffected by pro-inflammatory cytokine trea t­
ment of the cells (24h stimulation). Since different astrocyte preparations may 
behave differently depending on the donor, binding of biotinylated CCL2 under 
pro-inflammatory conditions needs to  be performed on other astrocyte prepara­
tions to confirm the statem ent th a t CCL2 binding to astrocytes was unaffected by 
pro-inflammatory conditions. Following 48h stim ulation with pro-inflammatory 
cytokines, CCL2 binding to astrocytes increased compared to  the baseline level at 
48 h, although it was not significant. These results agree in part w ith a previous 
study [Andjelkovic et al., 1999a] where it was shown th a t lhl-(3  and TN F induced 
an increase in CCL2 binding following 48h stim ulation using fetal human astro­
cytes. The am ount of CCL2 binding to astrocytes slightly decreased from 24 to  
48h but it was not significant. CCL2 binding to prim ary adult human astrocytes
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is therefore, in this study, CCR2-independent. Thus, an alternative hypothesis is 
th a t CCL2 binding to astrocytes involves either chemokine decoy receptors [Fra 
et ah, 2003] and /o r proteoglycan [Johnson et al., 2005] expressed on the cell mem­
brane, rather than  CCR2.
Human adult astrocytes differ in respect to CCR2  expression compared to hu­
man foetal astrocytes. Fetal astrocytes sense and respond to gradients of CCL2 
[Andjelkovic et al., 2 0 0 2 ] th a t might determine the position of astrocytes a t the 
BBB during CNS development [Dorf et al., 2000], whereas, as reported here, hu­
man adult astrocytes are not responsive to CCL2 in term s of calcium signalling. 
The secretion of CCL2  by prim ary human adult astrocytes will mainly affect other 
CNS resident cells including neurons, microglia and endothelial cells bu t also in­
filtrating monocytes, which express CCR2, through paracrine effects [Banisadr 
et al., 2005, M ahad et al., 2006, Stamatovic et al., 2003, Tanum a et al., 2006]. 
Banisadr et al. (2005) showed by immunohistochemistry th a t neurons constitu- 
tively express CCR2. In  vitro, CCL2 activation of neurons from the cortex, the 
hippocampus, the hypothalamus and the mesencephalon resulted in an increase 
in calcium flux which dem onstrated a possible neuron-glia interaction. CCL2 was 
shown to act on brain endothelial cells by disorganizing tight junctions resulting 
in an increase in the permeability of the BBB [Stamatovic et al., 2003]. This was 
confirmed by the absence of effect on endothelial cells from CCR2 - /-  mice.
In the Tanum a et al. (2005) study, it was shown th a t in vivo microglia/macrophages 
expressed CCR2 but not CCL2. This suggests th a t CCL2, produced by astrocytes, 
will act in a paracrine way. This hypothesis was confirmed by a recent study, which 
showed th a t intrathecal injection of CCL2 induced microglial activation in W T 
mice bu t not in CCR2-deficient mice [Zhang et al., 2007]. All these findings con­
firm the potential paracrine effect of astrocyte derived CCL2  on CNS resident cells.
Therefore, in this in vitro study, human adult astrocytes have a complex role 
in promoting inflammation by recruiting inflammatory cells into the CNS through
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the establishment of a CCL2 chemotactic gradient (figure 3.18). The constitutive 
binding of CCL2 in the absence of CCR2 expression by astrocytes dem onstrates 
th a t CCL2 binding is CCR2-independent in prim ary adult human astrocytes. The 
absence of activation of the common signal transduction pathways for chemokine 
receptors dem onstrates a novel function for human adult astrocytes during inflam­
m ation in MS. Astrocytes may promote inflammation by establishing a chemo­
tactic gradient via presentation of CCL2 to infiltrating cells and may also act as a 
’’sink” to regulate the level of CCL2 at the inflammation site possibly explaining 
the decrease in CCL2  in the CSF in people with MS, which correlates to tim e of re­
lapse. Recently, M ahad et al. (2006) have suggested th a t the invading cells would 
consume CCL2 when entering the CNS. However, this would not fully explain 
the decrease in CCL2  in the CSF in MS patients at times of relapse, since other 
cell types are also able to bind CCL2. Endothelial cells and neurons have been 
shown to bind CCL2  [Banidsar et al. 2005, Stamatovic et al. 2003]. This current 
study gives some insight into the understanding of the mechanism resulting in the 
decrease of CCL2 in the CSF and the possible involvement of astrocytes.
Finally, this current study on human adult astrocytes and other studies on hu­
man foetal astrocytes [Andjelkovic et al., 2 0 0 2 , Rezaie et al., 2002] would suggest 
differences in gene regulation during development, hence caution is required when 
translating the da ta  from in vitro studies using cells a t different developmental 
stage to  the understanding of the pathogenesis of MS.
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Fig. 3.18: H y p o th e t ic a l m e c h a n ism  for C C L 2  b in d in g  to  p r im a ry  h u m a n  
a d u lt  a s tro c y te s  in  v itro .
Prim ary human adult astrocytes respond to pro-inflammatory stim ulation (IL1 -(3. 
TNF and IFN7 ) by increasing secretion of CCL2 (1) th a t binds to astrocytes in a 
CCR2-independent way. The binding could be via proteoglycans (2) to establish 
a chemotactic gradient for immune cells expressing the corresponding receptor 
(CCR2) (3). Astrocytes might then have a role in promoting inflammation. Al­
ternatively, CCL2 bound to the proteoglycan may be degraded by extracellular 
proteases [McQuibban et al., 2002]. CCL2 could also bind to decoy receptors. The 
absence of activation of the common signal transduction pathways for chemokine 
receptors suggests th a t CCL2 might bind to a decoy receptor, which would reg­
ulate inflammation through the internalization of CCL2 and degradation via the 
endosome, while the decoy receptor is recycled to the cell surface membrane (4).
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CHAPTER 4
CXCR3 expression by primary 
human adult astrocytes
4.1 Introduction
4.1.1 CXCR3: overview
CXCL10 exerts its biological function through the interaction with the 7 trans­
membrane receptor, CXCR3. As previously discussed in section 1.4.3, CXCR3 
can bind several chemokines belonging to  the CXC chemokine family (CXCL9, 
CXCL10 and CXCL1 1 ). CXCR3 mRNA was first cloned from a cDNA library 
from CD4+ T  cells [Loetscher et al., 1996]. The cDNA for CXCR3 has an open 
reading frame of 1041bp and encodes for a protein of 40KDa. A new mRNA 
spliced variant was discovered called CXCR3-B, which has an extended extracel­
lular N-terminal domain of 52 amino acids [Lasagni et al., 2003], The rest of 
the receptor is similar. W hen ligated, the two isoforms lead to distinct effects in 
human microvascular endothelial cell line-1  :
CXCR3-A: pro-proliferative effects, chemotactic and apoptotic 
CXCR3-B: anti proliferative, no chemotactic effect and apoptotic effects
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A new isoform of the receptor produced as a result of post transcriptional exon 
skipping was discovered. This variant, called CXCR3-alt, has a drastically altered 
C-terminal domain resulting in a four or five transm em brane domain structure 
[Ehlert et al., 2004]. I t was shown th a t CXCR3 mediates chemotaxis and calcium 
mobilization via the C term inal part of the receptor [Colvin et al., 2004, Dagan- 
Berger et al., 2006]. Therefore it was surprising to  find th a t, despite this major 
alteration of the structure of CXCR3-alt, flow cytom etry experiments and migra­
tion assays showed th a t it is expressed a t the cell surface and mediates CXCL11 
activity [Ehlert et al., 2004].
4.1.2 C X CR 3 expression in the CNS w hite m atter in MS 
patients
Post-m ortem  tissue analysis by immunohisto chemistry has dem onstrated the 
accumulation of CXCR3+ T  cells in more than  99% of perivascular leukocytes 
in active MS lesions [Balashov et al., 1999, Sorensen et al., 1999].' Quantitative 
correlation of the CXCR3+ cell number and demyelinating stage of MS disease 
has been assessed on post-mortem tissue by Sorensen et al. (2002). They found a 
significant increase in CXCR3+ T  cells between early and late stages of MS lesions 
(early active demyelination, late active demyelination and inactive demyelinated 
areas). Staining for CXCR3 was occasionally found in control brain tissue samples 
on T  cells [Sorensen et al 2002].
Expression of CXCR3 has also been observed in active and chronic MS lesions 
on foamy macrophages and astrocytes within the plaques [Simpson et al., 2000b, 
Sorensen et al., 2002], Furthermore, in a study by Tanum a (2006) on CNS tissue 
from SP-MS, by dual immunostaining for CXCR3 with GFAP as well as CXCR3 
with HLA-DP, DQ and DR, both astrocytes and microglia expressed CXCR3. 
Expression of CXCR3 was strong at the rim of the active and inactive MS plaque 
w ith ongoing demyelination, compared to the centre of the plaque where the 
immunoreactivity of this receptor was low. In control brain, no reactivity was 
detected.
163
4.1.3 E ffect o f CX CR 3 agonists on Erk and A kt signalling
There are many reports on CXCR3 signalling activation pathways especially 
P I3K /A kt and MAPK [Bonacchi et al., 2001, Smit et al., 2003, K ukhtina et al., 
2005].
K ukhtina et al. (2005) investigated intracellular pathways involved in chemokine- 
stim ulated migration of in vitro activated human peripheral blood CD4+ T- 
lymphocytes. They showed th a t the use of specific inhibitors of PI3K, E rk l and 
2, resulted in a decrease in migration of activated lymphocytes by 35% and 40% 
respectively.
Phosphorylation of Akt and P44/P42 MAPK was shown to be increased in IL2 
activated prim ary human T  cells when stim ulated with agonists of CXCR3 [Smit 
et al., 2003]. These findings were confirmed by incubating activated-T cells with 
W ortm annin and MEK inhibitor (U0126 and PD98059) with a to ta l suppression 
of phosphorylation of both Akt and P44/P42 MAPK respectively. However, in 
this study, MEK inhibitor and W ortmannin (100 and 300nM respectively) failed 
to inhibit the transm igration of T  cells in response to chemotactic gradients of 
CXCR3 agonist. Although the involvement of MAPK and Akt in controlling T 
cell chemotaxis is controversial, it is clear th a t CXCR3 agonists induce activation 
of M APK and Akt.
Xia et al. (2000) showed in human brain th a t astrocytes expressed CXCL10 
and neurons expressed CXCR3. Morevover, they showed in vitro th a t E rk l and 2 
were activated by CXCL10 in murine neurons. Although they did not look a t the 
functional effect of CXCL10 on neurons, they concluded th a t a novel mechanism 
of cell-cell communication between neurons and astrocytes existed. Although two 
studies investigated the mechanism of CXCLlO-mediated neurotoxicity [van Marie 
et al., 2004, Sui et al., 2004], the mechanism was not fully elucidated. Recently, 
Sui et al. (2006) showed in an in vitro study th a t CXCL10 induced an increase in 
intracellular calcium th a t resulted in foetal neuronal cell death due to  activation 
of caspase 3.
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Since vascular pericytes express CXCR3, Bonacchi et al. (2001) looked at 
signalling pathways activated by CXCR3. They showed th a t Erk 1 and 2 and 
PI3K induced migration and proliferation of pericytes which are critical biologic 
actions for wound healing and repair. These findings suggest th a t CXCR3 might 
be involved in tissue repair.
CXCR3 also binds other members of the CXC chemokine family, which induce 
signalling events when bound to CXCR3. It was shown th a t both  CXCL9 and 
CXCL11 induced transient phosphorylation of Erk 1 and 2 in activated peripheral 
blood leukocytes [Kouroumalis et al., 2005] and p44/p42 MAPK specifically on 
activated T  cells [Smit et al., 2003].
4.1.3.1 Aim of the study
Since astrocytes actively synthesise and secrete CXCL10, the effect of CXCL10 
on astrocytes was determined in vitro. This aim was addressed by the following 
objectives:
1 . the rate of synthesis and expression of CXCR3 under pro-inflammatory 
conditions was investigated using qRT-PCR, flow cytom etry and immunocyto- 
chemistry.
2 . the functional effect of CXCL10 binding to astrocytes was investigated by 
measuring phosphorylation of E rk l and 2  and Akt and calcium flux following 
CXCL1 0  treatm ent.
165
4.2 M aterials and m ethods
4.2.1 D eterm ination  of CXCR3 m R N A  expression by as­
trocytes following pro-inflam m atory stim ulation  us­
ing qR T -PC R
The same procedure was followed as described in section 2.2.6 .5. Primers used 
for CXCR3 are given below:
Forward: 5’-CTTCGCCAAAGTCAGCCAAG-3’ (Tm, 60.3°C)
Reverse: 5’-TGGTAGAGGAATCGGGAGGT-3’ (Tm, 59.8°C)
Briefly, 2.5/d of cDNA was combined with 0.5/dVI of each primer, 3mM MgCl2 
and IX  absolute SybrGreen. qRT-PCR conditions were as follows: hold 95°C 15 
min; 40 cycles of 95°C 15s, 60°C 15s, 72°C 30s; 1 cycle 95°C 30s; 1 cycle 50°C 
30s and the melt ramp from 50°C to 95°C at l°C /10s to  determine the product 
specificity. All samples were run on the iCycler (Biorad). Prim er efficency was 
determined following the procedure described in section 2.3.2.2 with 5 dilutions 
(neat, 1 :2 , 1:4, 1:5 and 1:8). qRT-PCR was performed in duplicate on each mRNA 
sample from astrocytes (SMS-12) stimulated for 24 and 48 h w ith IL1-/?, TNF 
and IFN 7  from 0 to  lOOng/ml (n=3) following the procedure described in section 
2.2.6.5.
4.2.2 D etection  o f CXCR3 expression by prim ary human  
adult astrocytes using im m unocytochem istry
CXCR3 expression by unstim ulated astrocytes (B327/01) was assessed by im­
munocytochemistry following the procedure described in section 2.2.2.2. Incuba­
tion with monoclonal antibody IgGi anti human CXCR3 (R&D Systems, UK) 
a t 1:100 dilution in PBS-1%BSA for 1.5 h at RT was followed by FITC-labelled 
goat anti mouse IgG (Chemicon, UK) at a dilution of 1:100 in PBS-1%BSA for
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1 h a t RT in the dark. CXCR3 expression was visualized with the Axiovert 200 
M (Zeiss) confocal microscope and LSM 510 laser module as described in section
2.2.3.1.
4.2.3 Q uantitation  o f CXCR3 chem okine receptor expres­
sion by prim ary human adult astrocytes using flow  
cytom etry
The same procedure was followed for CXCR3 staining as described in section 
3.2.2.7. Briefly, 0.25 x 106 astrocytes (B327/01) were stim ulated in triplicate with 
0, 10 and lOOng/ml of IL1-/3, TNF and IFN 7  for 24 h (n=3). Astrocytes were 
harvested by trypsinization and incubated with 10/d of PE-labelled IgG mouse 
anti-hum an CXCR3 antibody (R&D Systems) for 1.5 h in dark on ice. Astrocytes 
were stained in parallel with the corresponding isotype control (PE-labelled mouse 
IgGi) to evaluate background staining. For intracellular staining, cells were fixed 
with 4% paraformaldehyde for 15 min a t RT and permeabilized for 5 min in PBS-
0.5% TritonXlOO at RT. CXCR3 expression under pro-inflammatory stim ulation 
was quantitated  by FACScalibur flow cytom etry and Cell Q uest™  software (BD 
Biosciences, UK) as described in sections 3.2.2.5 and 3.2.2.6 .
4.2 .4  A nalysis o f CXCLlO-induced calcium  flux in pri­
m ary hum an adult astrocytes
The same procedure was performed as described in section 3.2.5. Briefly, 
3x l04 astrocytes (B327/01)/200/d/well in a black wall 96 well plate (Nunc, UK) 
were incubated for 30 min in the dark a t RT with 5/iM Fluo-4AM (Molecular 
Probes, UK) in Krebs HEPES buffer with 0.25mM sulfinpyrazone (Sigma, UK), 
1% F12 pluronic (Sigma, UK). Cells were washed twice with Krebs-HEPES buffer 
supplemented with sulfinpyrazone (0.25mM) and 0.1%BSA to remove the excess of 
dye, th a t was not associated with cells. CXCL10 and ionomycin were respectively 
injected a t 20 and 150s (volume injected corresponded to one fifth of the volume of
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media). Measurement of the calcium signal was taken every second for 5 min using 
an excitation filter of 485 ±  12nm and an emission filter of 520nm. The amplitude 
of the response following CXCL10 addition was expressed as a percentage of the 
maximum response with ionomycin (Sigma Aldrich, UK), which corresponds to 
the internal positive control (n=3).
4.2.5 Erk and A kt phosphorylation analysis following CXCL10 
stim ulation  of primary hum an adult astrocytes
The same procedure for determination of the level of phosphorylation of Erk 
and Akt was followed as described in section 3.2.6. Briefly, astrocytes (B327/01 
and E pl5) were plated in 6  well-plates (0.25xl06 cells/lm l/w ell) and allowed to 
adhere for 24 h. Media was removed and cells were cultured for 24h in SFM and 
stim ulated for 15 min with CXCL10 at 0 to lOOng/ml (Peprotech, UK) and FCS 
(10%) used as a positive control. Western blotting was performed using the same 
antibodies used in section 3.2.6 .3. Experiments were done in duplicate.
4.2.6 S tatistica l analysis
D ata are shown as mean ±  SEM. For experiments on CXCR3 mRNA level 
expression, CXCR3 expression and phosphorylation of Erk and Akt, level of sig­
nificance for comparisons between samples was determined using the ANOVA 
param etric test w ith D unnett’s test. In all cases, P<0.05 was considered signifi­
cant.
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4.3 R esults
4.3.1 C X C R 3 expression by stim ulated  prim ary human  
adult astrocytes at b oth  m R N A  and protein  level
4.3.1.1 CXCR3 mRNA expression by stimulated astrocytes using qRT- 
PCR
CXCR3 mRNA was constitutively expressed in prim ary hum an adult astro­
cytes (SMS-12). No increase in CXCR3 mRNA expression was observed following 
IL1-/? or TN F stimulation. Although IFN 7  induced a dose dependent increase 
in CXCR3 mRNA expression following 24 and 48 h stimulation, it did not reach 
statistical significance.
4.3.1.2 CXCR3 protein expression by primary human adult astrocytes 
following pro-inflammatory cytokine stimulation
CXCR3 immunostaining on unstim ulated astrocytes (B327/01) was assessed 
by immunocytochemistry (figure 4.2a-d). Permeabilized astrocytes showed strong 
staining (Figure 4.2b-d) compared to  the negative control (Figure 4.2a).
Similar findings were observed with flow cytom etry experiments. Astrocytes 
(B327/01) constitutively expressed CXCR3 (figure 4.3). However, only a small 
fraction of CXCR3 was expressed at the cell surface (MFI value of 3, green line) 
compared to  the to ta l staining (MFI value of 101.2, blue line). Thus, CXCR3 
surface expression represents 3% of the to tal cellular CXCR3. Following 24 h 
stimulation, the expression of cell surface CXCR3 did not show a significant dif­
ference following treatm ent with IL1-/? (3.7 ±  0.6 MFI), TNF-o: (3.3 ±  1 MFI) 
and IFN 7  (3.4 ±  0.4 MFI) a t lOng/ml, compared to the unstim ulated astrocytes 
(4.6 ±  1.1 MFI).
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Fig. 4.1: E ffec t o f  p ro - in f la m m a to ry  c y to k in e s  o n  C X C R 3  m R N A  ex­
p re s s io n  b y  p r im a ry  h u m a n  a d u lt  a s tro c y te s  u s in g  q R T -P C R .
Astrocytes (SMS-12) were stim ulated three times with IL1-/3 (white), TN F (grey) 
and IFN 7  (dark grey) at 0 to lOOng/ml for 24h (a) and 48h (b) with qRT-PCR 
performed in duplicate. CXCR3 was increased but did not reach the statistical 
significance using ANOVA followed by D unnett’s test bu t no significance difference 
was observed.
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Following 48 h stim ulation with IL1-/?, TN F and IFN 7 , no difference was ob­
served compared to  the baseline using ANOVA followed by D unnett’s test (SFM,
6.2 ±  0.2 MFI; IL1 /?, 4.8 ±  0.6 MFI; TNF, 4.6 ±  0.8; IFN 7 , 6 .6  ±  0.7).
Total expression of CXCR3 on permeabilised astrocytes was assessed follow­
ing 24 h stim ulation with IL1-/?, TNF and IFN 7  a t lOOng/ml. No difference was 
observed in to ta l CXCR3 expression following 24 h stim ulation a t lOOng/ml stim­
ulation using ANOVA followed by D unnett’s test (data not shown).
4.3.2 E ffect o f CXCL10 treatm ent on intracellular calcium  
increase in astrocytes
The effect of stim ulation of astrocytes (B327/01) with CXCL10 at 0 and 
lOOng/ml (n=3) on Ca2+ flux was assessed using the Fluostar plate reader. No 
difference in the calcium flux in astrocytes was observed following CXCL10 stim ­
ulation (100 ng/m l) and the control. Indeed, Ca2+ response from unstim ulated 
astrocytes (n=3) represents 22.23 ±  4.9% of the maximal response (ionomycin) 
whereas Ca2+ response from astrocytes treated with CXCL10 (100 ng/m l) repre­
sents 26.67 ±  1% (n=3) of the maximal response (data not shown).
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Fig. 4.2: D e te c tio n  o f a s tro c y te  ex p re ss io n  o f C X C R 3  u s in g  im m u n o cy - 
to c h e m is try .
Astrocytes (B327/01) were permeablized and stained with monoclonal IgGi an­
tibody against human CXCR3 followed by FITC-labelled goat anti mouse (b-d). 
Omission of the prim ary antibody was used as negative control (a). Nuclei were 
counterstained with DAPI (blue). CXCR3 staining was visualized with the Ax- 
iovert 200M (Zeiss) confocal microscope with LSM 510 laser module as described 
in section 2.2.3
PE-CXCR3
Fig. 4.3: D etec tio n  of C X C R 3 expression  a t th e  cell surface an d  in tra - 
cellu larly  on p rim ary  ad u lt a s tro cy te s  using flow cy tom etry .
Histogram representation of CXCR3 protein expression by flow cytom etry on 
unstim ulated astrocytes (B327/01). Astrocytes were stained directly with PE- 
labelled IgGi monoclonal antibody against human CXCR3 with (blue histogram) 
and without fixation/permeabilization (green histogram). The negative control 
was run in parallel by incubating astrocytes with PE-labelled IgG i isotype control 
(filled histogram). Staining was quantitated by flow cytom etry and Cell Q uest™  
sot ware.
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Fig. 4.4: E ffec t o f  p ro - in f la m m a to ry  c y to k in e s  o n  C X C R 3  cell su rface  
e x p re ss io n  b y  p r im a ry  h u m a n  a d u l t  a s tro c y te s  u s in g  flow  c y to m e try .
Astrocytes (B327/01) were stimulated with IL1/3, TN F and IFN 7  a t lOng/ml for 
24 h (white histogram) and 48 h (grey histogram). Experiments were done in 
triplicate and the effect on CXCR3 expression following stim ulation was analyzed 
by ANOVA followed by D unnett’s test. No significant difference in CXCR3 cell 
surface expression following cytokine stim ulation at 24 and 48 h stim ulation was 
observed compared to  the baseline using ANOVA followed by D unnett’s test.
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4.3.3 M easurem ent of phosphorylation of Erk and A kt fol­
low ing CXCL10 stim ulation of astrocytes
To confirm the lack of Ca2+ flux following CXCR3 ligand binding, the effect 
of CXCL10 stim ulation on astrocytes (SMS-1 2 , B327/01 and E pl5) on down­
stream  signalling pathways was assessed. No difference was observed in the level 
of phosphorylation of Erk in E pl5  (n=2), SMS-12 (n=2) and in B327/01 astro­
cytes (n = l)  (figure 4.5). Q uantitative analysis by densitometry of E p l5  showed 
th a t there was no difference in the phosphorylation between CXCL10 stim ulated 
and unstim ulated cells. The absence of phosphorylation of Erk following CXCL10 
stim ulation was not due to a technical problem as FCS, used as a positive con­
trol, induced a significant increase in expression of phosphorylated forms of Erk 
(P<0.01, n=2).
Similarly to  Erk, CXCL10 stimulation of E p l5  (n = 2 ) and B327/01 (n = l)  did not 
induce any increase in the phosphorylated form of Akt, compared to unstim ulated 
cells. However, although FCS increased the level of phosphorylation of Akt it did 
not reach statistical significance (figure 4.6).
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Fig. 4.5: E ffec t o f  C X C L 10  t r e a tm e n t  o n  E rk  1  a n d  2  p h o s p h o ry la t io n  
b y  p r im a ry  h u m a n  a d u l t  a s tro c y te s  u s in g  SD S P A G E  a n d  w e s te rn  b lo t­
tin g .
CXCLlO-induced intracellular signalling was assessed on prim ary human adult 
astrocytes (Epl5, SMS-1 2  and B327/01). Astrocytes were serum starved for 24 
h and stim ulated with CXCL10 a t 0-100ng/ml or FCS (1 0 %) as a positive con­
trol. (a) Erk 1 and 2 (pTpY 185/187) as well as the to ta l am ount of Erk were 
assessed by SDS PAGE and western blotting, (b) To compare phosphorylation 
following pro-inflammatory stimulation, IOD values of Erk 1 and 2 (pTpY 185/ 187) 
were normalized to the IOD values of Erk to ta l (Epl5, n = 2 ). ANOVA followed by 
D unnett’s test was performed and p<0.01 was considered as significantly different.
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Fig. 4.6: E ffec t o f C X C L 10 t r e a tm e n t  on  A k t p h o sp h o ry la t io n  b y  p r i­
m a ry  h u m a n  a d u l t  a s tro c y te s  u s in g  SD S P A G E  a n d  w e s te rn  b lo t t in g . 
CXCL10 induced intracellular signalling was assessed on prim ary human adult 
astrocytes (Epl5, SMS-12 and B327/01). Astrocytes were serum starved for 24 h 
and stim ulated with CXCL10 at 0 -1 0 0 ng/m l or FCS (10%) as a positive control, 
(a) Akt (pS473) as well as the to tal amount of Akt were assessed by western blot­
ting. (b) To compare phosphorylation following pro-inflammatory stimulation, 
IOD values of Akt (pS473) were normalized to the IOD values of Akt to ta l (Epl5, 
n=2). Although there is an apparent increase for FCS, ANOVA followed by Dun­
n e tt’s test was performed and no significant difference in the phosphorylation of 
Akt was obtained.
177
4.4 D iscussion
Post-m ortem  tissue analysis using immunohistochemistry has dem onstrated 
the accumulation of CXCR3+ T  cells in active MS lesions [Balashov et al., 1999, 
Sorensen et al., 1999]. The Expression of CXCR3 on CD3+ T  cells correlates with 
the evolution of the severity of MS determined by quantitative immunohistochem-- 
istry on MS brain tissue sections [Sorensen et al., 2 0 0 2 ]. Expression of CXCR3 
was also found on microglia and astrocytes within the plaques in active MS lesions 
[Simpson et al., 2000b, Sorensen et al., 2 0 0 2 ].
Astrocytes have been previously shown to express CXCL10 under IFN 7  stim­
ulation (section 2.3.5). To assess whether CXCL10 had any functional effects on 
astrocytes, CXCR3 expression as well as CXCL10 effects on downstream signalling 
were assessed on prim ary human adult astrocytes.
4.4.1 C X CR3 m R N A  expression by astrocytes following  
pro-inflam m atory cytokine treatm ent
CXCR3 mRNA expression was assessed by qRT-PCR following stim ulation of 
cells for 24 and 48 h with IL1/?, TNF or IFN 7  from 0 to  100 ng/m l. Astrocytes 
constitutively expressed CXCR3 mRNA, which confirmed previous in vitro stud­
ies on simian adult and human foetal astrocytes [Croitoru-Lamoury et al., 2003] 
or mouse and hum an adult astrocytes [Biber et al., 2002] using semi quantitative 
PCR. In this study, CXCR3 mRNA expression was unaffected by stim ulation with 
IL1 /?, TN F and IFN 7  (0 to lOOng/ml) by prim ary hum an adult astrocytes. Again 
Croitoru-Lamoury et al. (2003) also reported th a t CXCR3 was unchanged in 
adult simian and foetal human astrocytes following stim ulation with IL1/3, TNF 
and IFN 7  (lOOIU/ml). These results are contradictory to those of Flynn et al. 
(2003) where prim ary human adult astrocytes stim ulated with TN F (25ng/ml) 
increased expression of CXCR3 mRNA using non quantitative RT-PCR.
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4.4.2 C X CR 3 protein expression by astrocytes following  
pro-inflam m atory cytokine treatm ent
CXCR3 protein was constitutively detected in astrocytes using flow cytome­
try and immunocytochemistry. This finding is in agreement with previous studies 
where it was reported that astrocytes expressed CXCR3 in vivo by immunohis- 
tochemistry [Goldberg et al., 2001, Simpson et al., 2000b]. However, CXCR3 cell 
surface expression was largely unaffected following 24 and 48 h stimulation with 
IL1-/5, TNF and IFN7  (10 and 100 ng/ml). Similarly, cytoplasmic CXCR3 expres­
sion level on astrocytes did not show any difference following stimulation with the 
three pro-inflammatory cytokines. Cytoplasmic CXCR3 level of expression was 
similar to that reported by Flynn et al. (2003) who reported a level of expression 
of CXCR3 around 100 MFI. However, the level of expression of CXCR3 following 
stimulation is in contradiction with their study using the same antibody against 
CXCR3 where they found that TNF (25ng/ml) and IFN7  (200UI/ml) significantly 
increased the expression of CXCR3 in permeabilized astrocytes by 6 fold and 2 
fold respectively. Although primary human adult astrocytes used in both studies 
were isolated using the same procedure, discrepancies could be explained by dif­
ferent donors of astrocytes.
In this study the proportion of CXCR3 expressed at the cell surface was low 
compared to the total amount of CXCR3 and represented only 3% of the total 
expression (permeabilized astrocytes) for unstimulated astrocytes.
Similar findings were observed with the IFN7 R2 , one chain of the IFN7  receptor. 
Rigamonti et al. (2000) showed that the expression of IFN7 R2 was low at the cell 
surface but highly expressed and stored in the cytoplasm of resting and activated 
T cells. The low expression of IFN7 -R2 makes T h l cells resistant to IFN7  reduc­
ing their apoptosis [Rigamonti et al., 2000]. Thus, low expression of CXCR3 at 
the astrocyte cell surface (3% of the total CXCR3) might be a regulatory mecha-
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nism th a t makes astrocytes non responsive to CXCL10.
4.4.3 M easurem ent of signalling pathways induced by CXCL10 
in astrocytes
To validate this hypothesis, CXCL10 effects on intracellular calcium levels 
in prim ary hum an adult astrocytes was assessed. No increase in calcium was 
detected following CXCL10 stimulation a t lOOng/ml. To confirm this finding, 
phosphorylation of Erk and Akt was assessed. No increase in the phosphorylation 
of either Erk or Akt was observed. This was not due to technical issues as FCS 
significantly increased the phosphorylation of Erk. Akt phosphorylation was also 
increased with CXCL10 bu t it did not reach statistical significance. These findings 
are in contradiction with Flynn et al. (2003) who reported th a t CXCL10 induced 
Erk phosphorylation in astrocytes. The fact th a t in our study no calcium flux or 
phosphorylation of Erk or Akt was detected could be explained by a low expres­
sion of CXCR3 at the cell surface (less than  3% of to ta l CXCR3), which would 
not be sufficient to  induce any functional activity. Although Flynn et al. (2003) . 
only assessed CXCR3 expression on permeabilised astrocytes but not a t the cell 
surface, the difference in signalling between this study and the Flynn study might 
result from a differential expression of CXCR3 a t the cell surface between different 
astrocyte preparations.
Indeed, the level of expression of the cell surface receptor is an im portant factor 
for measurement of successful signalling. I t was shown th a t in a dendritic cell 
line (D1 cells) treated  with LPS (1 0 /zg/ml) for 2-3 h a decrease in CCR1 expres­
sion was seen. The expression of CCR1 was dramatically decreased following 24 
h stim ulation [Foti et al., 1999]. Interestingly, the levels of calcium increase fol­
lowed the pa ttern  of CCR1 expression with a decrease after 2-3 hours and to tal 
loss of calcium flux after 24 h stimulation with LPS. Similar findings were ob­
tained from Salentin et al. (2003) where it was shown th a t CCR2 was markedly 
down-regulated in monocytes following incubation with Influenza A virus strain
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A /P R / 8  (H1N1). The calcium flux correlated with the level of expression of CCR2 
with an absence of calcium flux with A /P R / 8  [Salentin et ah, 2003].
Thus, although astrocytes express CXCR3, CXCL10 did not have any effect on 
Ca2+ flux, Erk and Akt phosphorylation in the astrocyte preparations used in this 
study. Therefore, CXCL10 secreted by astrocytes in vitro would appear not to 
have autocrine effects. However, CXCL10 might bind to cell surface proteogly­
can to establish a chemotactic gradient for immune cells. Further experiments on 
CXCL1 0  binding to  astrocytes are required to validate this hypothesis as discussed 
in the chapter 6 . However, no CXCL10 biotinylated is yet available. Binding of 
CXCL10 can be performed only with radiolabelled 125I-CXCL10. Therefore the 
direct comparison with CCL2 binding to astrocytes using another methodology 
would be difficult.
4.4 .4  E ffect o f CXCL10 on other CNS resident cells
CXCL10 acts on other CNS cell types including microglia and neurons. For 
example, CXCL10 acts on microglia to recruit these cells to the axonal injury site 
in the entorhinal cortex mouse model. In CXCR3-/- mice, a marked reduction in 
the recruitm ent of microglia compared to the W T mice was seen especially in the 
outer molecular layer in the brain of the KO animal, with only a few microglia 
cells recruited compared to  the W T, which presented a full layer of microglia 
[Rappert et al., 2004]. A similar finding was also reported by Biber et al. (2 0 0 2 ) 
where they showed th a t in vitro microglia expressed CXCR3 and responded to 
CXCL10 by increasing intracellular calcium transients and chemotaxis. Studies 
have shown th a t neurons express CXCR3 in brain tissue in CNS disease [Goldberg 
et al., 2001, Xia et al., 2000]. Isolation of prim ary mouse cortical neurons and 
in vitro stim ulation with rodent CXCL10 (25nM) for 15 min induced a strong 
phosphorylation of Erk 1 and 2  compared to unstim ulated neurons. This finding 
suggests a possible mechanism of neuronal-glia cell interaction through CXCL10 
derived from astrocytes.
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Taken together, this in vitro data  and published data, suggests th a t astrocyte 
derived CXCL10 acts in a paracrine way on CXCR3+ cells, including microglia 
and neurons rather than  in an autocrine way on astrocytes w ithin the CNS.
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CHAPTER 5
Expression of decoy chemokine
receptor D6
5.1 Introduction
Since chemokines play an im portant role in recruitment of immune cells to 
sites of inflammation, mechanisms exist to control their expression level in tis­
sues. Decoy receptors are well characterized in mammalian cells as regulators 
of chemokine levels in tissues [Mantovani et al., 2001]. IL1 type II receptor was 
the first cytokine decoy receptor to be reported [Colotta et al., 1993]. There 
are three different types of chemokine decoy receptor th a t have been described 
to  date, namely Duffy antigen receptor chemokine (DARC) [Neote et al., 1994], 
CCX CKR [Gosling et al., 2000] and D6  receptor [Nibbs et al., 1997]. Since D6 
exhibits specificity for the CC family and is expressed by astrocytes [Neil et al., 
2005], the work in this chapter examined the expression of D6  receptor in vitro in 
prim ary hum an adult astrocytes and in vivo in hum an brain tissue sections.
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5.1.1 D 6 decoy receptor: characteristics
The D6  decoy receptor is a typical 7 transm em brane chemokine receptor [Nibbs 
et al., 1997]. However, it lacks the cytoplasmic sequence motif th a t is required for 
the induction of chemokine signalling i.e. the DRY (Asp-Arg-Tyr) m otif in the 
second intracellular loop and the TXP (Thr-Xaa-Pro) in the second transm em­
brane domain [Mantovani et al., 2001, Nibbs et al., 1997, Borroni et al., 2006]. 
It binds a wide range of CC chemokines including CCL2  [Mantovani et al., 2006, 
Locati et al., 2005, Fra et al., 2003]. However, D6  exhibits some specificity and 
does not bind homeostatic chemokines or other chemokine families such as CXC 
[Nibbs et al., 1997].
Because D6  binds chemokines but does not induce any signalling, studies were 
performed to  assess the function of D6 . Fra et al. (2003) investigated the internal- 
ization rate for 125I labelled CCL2 bound to  L I.2 lymphoma cell line transfected 
with D6 . After 2-4 min a t 37°C, 70% of the bound ligand was internalized, 5% 
was still attached to the membrane and 25% was released into the supernatant. 
These findings dem onstrate the ability of D6  to  internalize chemokines. This find­
ing was confirmed in a study by Weber et al. (2004) where they showed th a t D6 
internalized CCL3, which trafficked from the cell surface to  the cytoplasm through 
the endosome. W hen bound to the D6  receptor, ligands are recycled into the cy­
toplasm and degraded by an NH4CI sensitive pathway suggesting lysosomes are 
involved [Weber et al., 2004]. Indeed, NH4CI is a specific inactivator of the proton 
pump vacuolar ATPase th a t inhibits acidification of early endosomes and impairs 
the transport between early and late endosomes [Bowman et al., 1988].
In another study, D 6  was shown to be phosphorylated in the absence of lig­
and, and this was unaffected when adding the ligand [Blackburn et al., 2004]. 
Since phosphorylation is required-for receptor internalisation [Ferguson, 2001], 
it is not surprising th a t D6  was shown to be constitutively internalized through 
clathrin-coat pits and was rapidly recycled to  the cell surface [Galliera et al., 2004].
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D 6  has the characteristic of a scavenger receptor for CC chemokine family 
members, which could thus serve an im portant role in the regulation of inflam­
m ation in the CNS in MS.
5.1.2 R o le o f D 6 receptor in inflam m ation
Evidence for an effect of D6  in the regulation of inflammation was obtained by 
Jamieson et al. (2005) using the well characterized model of cutaneous inflamma­
tion, induced by adm inistration of the phorbol ester 1 2 -O-tetradecanoylphorbol- 
13-acetate (TPA) to dorsal skin. Injection of TPA in D6  deficient mice resulted in 
a rapid increase in mRNA expression for CCL2, CCL3, CCL4, CCL5 and CCL11 
similar to the control [Jamieson et al., 2005]. However, 24 h after TPA injec­
tion, D6  deficient mice had an elevated level of CC chemokines compared to the 
W T suggesting th a t D6  deficient mice failed to clear the CC chemokine. Similar 
findings showed th a t in the TPA model, mice lacking D6  expression resulted in 
an increase in leukocyte invasion, necrosis and angiogenesis [Martinez de la Torre 
et al., 2005].
5.1.3 D 6 in EAE
There is a single report on the role of D 6  in EAE. In EAE, induced in mice 
deficient for D 6 , an unexpected reduction in the severity of EAE was observed 
due to impaired encephalitogenic responses, compared to  the W T litterm ate [Liu 
et al., 2006a]. These findings were confirmed by examination of the inflammation 
and demyelination level in the spinal cord of D6  deficient mice and W T mice 
using anti-CD45 and anti-M BP antibodies. It was shown th a t inflammation and 
demyelination were more extensive in W T mice compared to D 6  deficient mice. 
Therefore, D 6  was not involved in the clearance of CC chemokines in the CNS in 
this model [Liu et al., 2006a]. In adoptive transfer studies, no difference in the 
EAE disease course in D 6 -/-  and W T was seen when T  cells injected from EAE
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D6 + / -  animals [Liu et al., 2006a]. They further showed th a t transfer of T  cells 
from EAE mice deficient for D 6  into D6 + / -  animals resulted in a weak induction 
of EAE compared to T  cells from WT. This suggests th a t D 6  could be involved 
in the priming of T  cells but not clearance of CC chemokine in this model. This 
finding was confirmed by a lower IFN7  production in D 6  deficient mice compared 
to the W T mice and a lower proliferative effect of T  cells in response to MOG 
restimulation. Further studies on EAE are needed to  fully assess D 6  involvement.
5.1.4 D 6 in M S
No study has yet investigated the expression and distribution of D 6  within the 
human CNS.
5.2 Aim  of the study
The aim of this chapter was to  determine whether astrocytes have the ability 
to regulate CC chemokine levels in the CNS, through the expression of D 6  recep­
tors. It was addressed by the following objectives:
1. Determine D6  expression on astrocytes in vitro a t the mRNA (qRT-PCR) 
and protein level (flow cytometry and western blot).
2. Measure D6  expression in vivo in normal and MS CNS tissue at the mRNA 
(qRT-PCR), and protein level (immunohistochemistry and western blot) and de­
term ine the cell type expressing D6  receptor.
3. Determine the ability of D 6  to bind biotinylated CCL2 in vivo.
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5.3 M aterials and m ethods
5.3.1 M easurem ent of D 6 m R N A  expression by astrocytes  
following pro-inflam m atory cytokine stim ulation  us­
ing qR T -PC R
The set of primers used for the amplification of D6  were designed with Primer3 
software, and are presented below:
Forward- 5’-AACCAGCTCAATTGGGTGTC-3’ (Tm, 57.3°C)
Reverse- 5’-GAAAGCGTGGTATCCTGGAA-3’ (Tm, 57.3°C)
cDNA was amplified as follows: hold 95°C 15 min; 40 cycles of 95°C 15s, 60°C 
15s, 72°C 30s; 1 cycle 95°C 30s; 1 cycle 50°C 30s and the melt ram p from 50°C 
to 95°C at l ° C / 1 0 s to determine the product specificity. All samples were run on 
the iCycler (Biorad). The relative expression of D 6  against the HK gene UBC, 
was performed using the Pfaffl equation, described in section 2.2.6.1.
5.3.2 D etection  of D6 receptor expression by prim ary hu­
m an adult astrocytes using w estern b lotting
5.3.2.1 Protein extraction
Protein was extracted using the Tri-Reagent method. Confluent astrocytes 
(Epl5) from a 75cm2 flask were resuspended in 1ml of Tri-reagent, transferred 
into an eppendorf tube and 0 .2 ml of chloroform (Sigma,UK) added to  samples, 
mixed and incubated for 10 min at RT. Samples were centrifuged for 15 min a t 12, 
000 g a t 4°C (mini spin plus, Eppendorf, UK) and the protein, in the pink phase, 
was precipitated by adding 1.5ml isopropanol. Samples were mixed, incubated 
for 10 min a t RT and centrifuged at 12, 000 g for 10 min at 4°C. Supernatants 
were removed and pellets were washed 3 x 20 min in 1 ml of 0.3M guanidine 
hydrochloride/95% ethanol solution. A centrifugation step was performed for 5 
min a t 7, 500 g at 4°C between washes. Pellets were further washed in 1 ml
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of 100% ethanol for 20 min a t RT. Samples were centrifuged, supernatants were 
discarded and pellets were air-dried for 5 min and resuspended in 200[A PBS-1% 
SDS. Proteins were stored at -2 0 °C until used.
5.3.2.2 Protein estimation: bicinchoninic acid (BCA) assay
Protein estim ation was performed using the bicinchoninic acid (BCA) assay. 
20 [A of bovine serum albumin (BSA) proteins standards in PBS-1% SDS (ranging 
from 0  to  2 m g/m l) as well as 2 0  {A of extracted protein sample in duplicate were 
loaded in a 96 well plate. 200fA of copper II BCA solution (24.5ml BCA (Sigma 
Aldrich, UK) plus 500/d of copper (II) sulfate pentahydrate 4% (W /V ) solution 
(Sigma Aldrich, UK)) was added to  the samples. The plate was incubated for 30 
min a t RT and the absorbance was read with a Victor Wallac2 plate reader a t 
570nm. A standard  curve was drawn and protein concentration was determined 
using the trend line of the equation of the standard curve :
Y = aX + b  where Y corresponds to absorbance, a corresponds to  the trend line, X 
corresponds to the concentration of protein in the sample and b corresponds to 
the intercept point with curve and the X-axis.
5.3.2 .3 Sample preparation for western blotting analysis
100/d of protein extract sample was mixed with 50/d of NuPAGE LDS sample 
buffer (Invitrogen, UK), 20/d of reducing agent (InVitrogen, UK) and 30/d of 
water. Samples were heated at 60°C for 30 min or 3 min a t 95°C and stored at 
-2 0 °C until analysis.
5.3.2.4 SDS-PAGE and western blotting forT>6 expression in primary 
human adult astrocytes
Optim al dilution for the primary antibody directed against human D6  (1:250, 
1:500 and 1:1000) was determined by dot plot (10/zg of protein, 10/d loaded). 
Staining was performed as described previously described in section 3.2.6 .3 using 
rabbit polyclonal antibody directed against human D6  (Abeam, UK) for 90 min
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at RT and HRP-goat antibody directed against rabbit IgG (1:2000, Dako, UK) 
for 1 h ar RT. Omission of the prim ary antibody allowed determ ination of the 
background level.
Protein (8 , 16 and 32 fig) from E pl5  and 5.5 fi\ of marker Seeblue plus 2 (In­
vitrogen, UK), to  determine the molecular weight of the protein of interest, were 
loaded and run on pre-cast NuPAGE 10% Bis-Tris gel (Invitrogen, UK) in MOPS 
SDS running buffer-0.05% antioxidant (Invitrogen, UK) as described in section
3.2.6 .3, for 1 h a t 120V and 300mA. To improve the separation of the protein, 
migration was performed for 2  h at 100V in some experiments. W estern blotting 
was performed as described in section 3.2.6 .3 for lh  at 100V and 300mA. The 
detection of D6  on the blot was performed as described in section 3.2.6 .3 using 
rabbit polyclonal antibody directed against human D6  (1:250, Abeam, UK) for 
90 min a t RT and HRP-goat antibody directed against rabbit IgG (1:2000, Dako, 
UK) for 1 h ar RT. Three washes of 10 min each were performed after each anti­
body incubation. Immunoreactivity was detected as described in section 3.2.6 .3.
5.3.2.5 Detection of D6 receptor by primary human adult astrocytes 
using flow cytometry
D 6  staining was assessed on primary human adult astrocytes (SMS-12 and 
B327/01) a t the cell surface and intracellularly as described in section 3.2.2. An­
tibody used was PE  conjugated ra t IgG2a directed against human D 6  (R&D Sys­
tems, UK). Non specific binding was assessed by incubating astrocytes with PE- 
labelled ra t IgG2a isotype control antibody (R&D Systems, UK). D 6  cell surface 
expression was also assessed under pro-inflammatory conditions. Briefly, 0.25xl06 
astrocytes/2m l/w ell were plated in 6  well-plates and allowed to adhere for 24 
h in astrocyte cell culture media. Astrocytes were stim ulated with IL1/?, TNF 
and IFN 7  stim ulation (lOOng/ml) for 24 h in SFM. Staining was performed as 
described in section 3.2.2.
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5.3.3 A na lysis o f D6 expression on hum an brain tissue
Six different MS cases were obtained from the UK MS Tissue Bank London 
and used for the determ ination of the cell type expressing D 6 . Case details for the 
different donors are summarised in Table 5.1. Eight blocks were obtained includ­
ing: four MS lesions (LI to L4), two normal appearing white m atter (NAWM) 
(N1 and N2) and two normal control white m atter (C l and C2). Ajiother case 
(MS 122 A4E5) was used for optimisation of D6  staining and CCL2 binding as 
well as colocalisation with D6  and CCL2 . MS1 2 2  A4E5 brain tissue sample (pro­
vided by the UK MS Tissue Bank London) was obtained from a 59 year old male 
diagnosed w ith MS who died from bronchial pneumoniae.
5.3.3.1 Tissue characterisation: Oil red O (ORO) staining
All MS and control blocks were provided snap-frozen and stored a t -80° C 
until used. Blocks were sectioned (10/im) using a cryostat and placed onto poly­
lysine slides (BDH Laboratories, UK). ORO staining, th a t is routinely used to 
detect areas of myelin breakdown and demyelination, was performed on these 
sections [Van Der Voorn et al., 1999]. ORO solution was prepared by adding 1 g 
of ORO (Acros Organics, UK) to 60% solution of triethyl phosphate (TEP, BDH 
Laboratories, UK) in distilled water. The solution was heated a t 100°C for 5 min 
with constant stirring. The solution was filtered when hot and again prior to  the 
staining procedure. Tissue for ORO staining was fixed for 1 h in 4%-PFA a t 4°C 
and incubated in 60% TE P solution for 2 min. Sections were stained with filtered 
ORO solution for 20 min a t RT and washed in 60% T E P  solution until all the 
excess stain was removed. Sections were further washed in distilled water for 5 
min. Cell nuclei were counter stained with 20% Harris’s haematoxylin (Sigma 
Aldrich, UK) for 1 min. Sections were washed in distilled water and mounted 
in glycerin jelly (kept in water bath a t 37°C, Fisher Scientific, UK). Sections 
were visualized using an Olympus BX60 micoscope. Sections were classified as 
(+ + ) for strong demyelination, (+) for low level of demyelination and (-) for no 
demyelination. Similar classification was performed for the level of inflammation.
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Case No Sex Age Block Characteristic D TPI
0 0
Cause of death
C l l male 77 C o ll A1B5 control 26 Carcinoma of the 
lung metastasis
C14 female 64 Col4 P2C3 control 18 Cardiac failure
MS74 female 64 MS74 A1E77 
MS74 A1C6
NAWM
Lesion
7 Gastrointestinal 
bleed/obstruction, 
aspiration pneu­
monia
MS90 male 62 MS90 P2E3 Lesion 17 MS (secondary 
progressive)
MS130 female 57 MS130 P2F4 
MS130 P2E3
NAWM
Lesion
2 2 MS (secondary 
progressive)
MS100 male 46 MS100 A2D2 Lesion 7 Pneumonia
Tab. 5.1: C ase  d e ta ils  o f  d o n o rs  u sed  to  s tu d y  D 6  e x p re ss io n  in  th e  C N S . 
D TPI (h) =  D eath to  tissue preservation interval (hours)
NAWM =  Normal appearing white m atter
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5.3.3.2 Measurement of D6 mRNA expression in human brain tissue 
using qRT-PCR
Five sections of 30 //m from each block were collected in an eppendorf tube. 1 
ml of Tri-reagent (Sigma Aldrich, UK) was added to each tube and sections were 
homogenized using a loosely fitting homogenizer (Sigma Aldrich, UK). Since the 
brain has a high content of lipid, an extra spin was performed at 1 2  0 0 0  g for 10  
min a t 4°C prior to mRNA extraction and cDNA synthesis procedure as described 
in sections 2 .2 .6 .2  and 2.2.6 .3. mRNA extraction was performed twice for each 
block and each of these samples run twice on the iCycler as described in section
5.3.1. '
5.3.3.3 Detection of D6 in human brain tissue using SDS-PAGE and 
western blotting
Proteins were extracted using Tri-Reagent (Sigma Aldrich, UK) and quantified 
as described in section 5.3.2. D6  expression was assessed on six different donors 
(N1 to  N4, NAWM 1 and 2, C 1 and 2) as described in section 5.3.2. To compare 
the level of expression of D6  in the different blocks, membranes were stripped as 
described in section 3.2.6 .3 and reprobed with polyclonal goat antibody directed 
against actin (Sigma Aldrich, UK) at 1:1000 for 90 min a t RT followed by HRP 
rabbit anti-goat IgG (whole molecule) 1:80 000 (Sigma Aldrich, UK) for 1 h a t 
RT. IOD values of D6  were normalized to  the IOD values of actin, considered as
1. Each protein extraction (n=2) was analysed in duplicate by western blotting.
5.3.3.4 Detection of D 6 on human brain sections by immunohisto- 
chemistry: optimisation
Optim al dilution for the primary antibody directed against human D 6  was 
initially determined (1:50, 1:75, 1:100 and 1:250). 10/xm sections (MS122 A4E5) 
were air-dried for 30 min a t RT and blocked in PBS-5% BSA (blocking buffer) 
for lh  a t RT. Sections were stained overnight a t 4°C with a polyclonal rabbit 
antibody directed against the D6  receptor (Genetex, USA) diluted a t 1:50, 1:75,
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1:100 and 1:250 in the blocking buffer. Sections were washed 3 x 5  min with 
PBS and stained with Alexa-568 goat anti rabbit antibody (1:500, Molecular 
Probes, UK). Sections were washed and incubated in 0.15% Sudan Black B (SBB) 
in 70% ethanol (Appendix) to quench lipofuscin autofluorescence in the brain 
[Romijn et al., 1999]. Sections were washed in PBS until excess SSB dye was 
removed, mounted with DAPI medium (Vector laboratories, UK) and sealed with 
nail varnish to avoid drying out. D6  expression was visualized with the Axiovert 
200 M (Zeiss) confocal microscope and LSM 510 laser module as described in 
section 2.2.3.1.
5.3.3.5 Determination of the cell type expressing D6 by double indi­
rect immunofluorescence staining
To determine the cell type expressing D6 , sections were double stained for 
D6  and cellular markers including Neuronal Nuclei (Neu-N), GFAP (Chemicon, 
UK), HLA-DR (Novastra, UK), for the detection of neurons, astrocytes and 
macrophages respectively (table 5.2), following the same procedure as described in 
section 5.3.3.4. F irst, sections were stained overnight a t 4°C with the polyclonal 
rabbit antibody directed against D6 (Genetex, USA) diluted a t 1:75 in blocking 
buffer. Sections were washed 3 x 5  min with PBS and stained with Alexa 488 
goat anti rabbit antibody (1:500, Molecular Probes, UK). Sections were washed 
and prim ary antibody directed against the appropriate cellular marker (GFAP, 
Neu-N or HLA-DR) was applied for 3 h a t RT in the dark (table 5.2). Sections 
were washed 3 x 5  min and Alexa 568 goat anti mouse (1:500) was applied for 1 
h at RT in the dark for GFAP and HLA-DR staining. For the Neu-N staining, 
prim ary antibody was directly conjugated with Alexa-488. Background level was 
assessed by incubating prim ary antibody with the secondary antibody th a t should 
not bind to  it. Cross reactivity between the two secondary antibodies was also 
assessed by incubating sections with the two secondary antibody. Sections were 
washed 3 x 5  min and fluorescent background signal was quenched with 0.15% 
SBB in 70% ethanol for 10 min at RT. Sections were washed in PBS, mounted
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with DAPI media (Vector laboratories, UK) and sealed with nail varnish. 
Colocalisation with D6  and the cell markers was assessed using the Zeiss 510 
CSLM software. This software analysed each individual pixel of each fluorescent 
channel used and produces a composite picture with white pixels when colocali­
sation occurs.
5.3.4 CCL2 b inding to  hum an brain tissue sections by im­
munofluorescence: optim isation  o f concentration of 
biotinylated  CCL2 and avidin-FITC
Human brain tissue sections (10 fim) were air-dried for 30 min a t RT and 
blocked with PBS-5%BSA (blocking buffer) for 1 h a t RT. Different dilutions of 
biotinylated CCL2 (1:4,1:10 and 1:20) in blocking buffer were performed overnight 
at 4°C. A negative control was included by om itting biotinylated CCL2. Sections 
were washed 3 x 5  min and avidin-FITC (neat), provided by the manufacturer, 
was added to  the cells and incubated 1 h at RT in the dark. Sections were washed 
as described previously and fluorescent signal was quenched as described in section
5 .3 .3 .4. CCL2 binding was visualized with the Axiovert 200 M (Zeiss) confocal 
microscope and LSM 510 laser module as described in section 2.2.3.1.
To reduce the background level of bound biotinylated CCL2 to hum an brain 
tissue sections, the optimal dilution of avidin-FITC was determined. The same 
procedure was followed as described above. Biotinylated CCL2 was diluted at 1:4 
in blocking buffer and avidin-FITC was used a t either 1:2, 1:4 or 1:10 in PBS.
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Prim ary antibody working dilution Secondary anti­
body (Molecu­
lar Probes, UK)
Supplier
Polyclonal rabbit anti 
D6
1:75 Alexa 488 or 
Alexa 588 goat 
anti rabbit anti­
body (1:500)
Genetex, USA
Monoclonal mouse anti 
GFAP
1 :1 0 0 0 Alexa 568 goat 
anti mouse 
(1:500)
Chemicon, UK
Monoclonal mouse anti 
Alexa fluor 488 Neu-N
1 :1 0 0 0 “ Chemicon, UK
Monoclonal mouse anti 
HLA-DR
1:500 Alexa 568 goat 
anti mouse 
(1:500)
Novastra, UK
Tab. 5.2: S u m m a ry  ta b le  o f  p r im a ry  a n d  se c o n d a ry  a n tib o d ie s  u sed  for 
th e  d e c te c t io n  o f  th e  c e llu la r  o rig in  o f D 6  b y  im m u n o h is to c h e m is try  on  
h u m a n  b ra in  sec tio n s .
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5.3.5 D eterm ination  of the cell typ e binding b iotinylated  
CCL2 in hum an brain sections: dual stain ing w ith  
D 6
CCL2 binding was first performed as described in section 5.3.4. Sections were 
washed 3 x 5  min and D6  staining was performed as described in section 5 .3.3.4. 
Colocalisation was assessed as described in section 5.3.3.5.
5.3.6 S tatistica l analysis
D ata are shown as mean ±  SEM. For experiments on D6  mRNA level expres­
sion and D6  expression, level of significance for comparison between samples was 
determined using the ANOVA param etric test w ith D unnett’s test. In all cases, 
P<0.05 was considered significant.
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5.4 R esults
5.4.1 D 6 expression on prim ary hum an adult astrocytes
5.4.1.1 Measurement of D6 mRNA expression by astrocytes using 
qRT-PCR
Astrocytes (SMS-12) constitutively expressed D 6  mRNA (figure 5.1). The 
expression was increased following pro-inflammatory stim ulation (24 h) with IL1/3, 
TN F and IFN 7  a t 100 ng/m l reaching 33.5 ±  7.6 fold increase, 12 ±  5.2 fold 
increase and 28.1 ±  13.9 fold increase respectively. However, only the effect of 
IL1/? and IFN 7  reached statistical significance (p<0.01). Lower dilutions of the 
three cytokines were assessed (1  and 10  ng/m l) but did not affect the level of 
expression of D6  mRNA (figure 5.1).
5.4.1.2 Measurement of D6 protein expression by astrocytes using 
SDS-PAGE and western blotting
Optim isation of the dilution of the antibody directed against D 6  (1:250, 1:500 
and 1:1000) was performed by dot plot. 1:250 showed the optimal immunoreactiv- 
ity compared to 1:500 and 1:1000. The negative control showed no immunoreac- 
tivity (data  not shown). Western blotting experiments were performed on protein 
from non-stim ulated astrocytes (Epl5) using different protein amounts (8 , 16 and 
32/zg). Two bands a t 53KDa and 60 KDa were observed.
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Fig. 5.1: M e a su re m e n t o f  D 6  m R N A  ex p re ss io n  in  a s tro c y te s  by  qR T - 
P C R  fo llow ing  p ro - in f la m m a to ry  c y to k in e  s tim u la tio n .
Cells (SMS-12) were stim ulated with IL1-/5 (white), TN F (grey) and IFN 7  (dark 
grey) a t 0 to  lOOng/ml for 24h (n=4). ANOVA followed by D unnett’s test was 
performed. **p< 0 .0 1  was considered as significant.
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Protein concentration (ug/ml) 
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64—  L  
51 —
KDa 
Lane 1 2
Fig. 5.2: D e te c tio n  o f D 6  re c e p to r  on  a s tro c y te s  u s in g  S D S -P A G E  a n d  
w e s te rn  b lo tt in g : o p tim is a tio n  o f p ro te in  c o n c e n tra tio n .
Different amounts of protein extracted from astrocytes (Epl5) were loaded on to a 
NuPAGE 10% bis tris acrylamide gel (8 , 16 and 32/zg) in lanes 2, 3 and 4. Proteins 
were transferred on to  a nitrocellulose membrane and incubated sequentially with 
a rabbit polyclonal antibody directed against human D 6  (Abeam, UK) and HRP- 
goat anti rabbit IgG. Molecular weight markers (RMM) lane 1, Seeblue plus 2 
(Invitrogen, UK), was used to determine the molecular weight of the bands (KDa). 
Imm unoreactivity was detected by chemiluminescence using the ECL Reagent Kit 
Plus and UVP imager.
16 32
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Fig. 5.3: Detection of D6 receptor on astrocytes using western blotting: 
optimisation of the sample preparation.
Sample preparation times, tem perature and range of protein loading concentra­
tions were compared. Protein extracts from astrocytes (Epl5) were loaded onto 
a NuPAGE 10% bis tris acrylamide gel (4, 8  and 12/ig). The gel was run for 2 
h a t 110 V. Proteins were transferred onto a nitrocellulaose membrane and in­
cubated sequentially with a polyclonal antibody directed against human D 6  and 
HRP-goat anti rabbit IgG. (RMM) Relative molecular mass marker, see blue plus 
2 (Invitrogen, UK), was used to determine the molecular weight of the bands of 
interest (KDa). Immunoreactivity was detected by chemiluminescence using ECL 
Reagent K it Plus and UVP imager.
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Proteins were smeared a t the top of the gel which could interfere with the 
band analysis which was due to over loading of protein (figure 5.2). Thus a lower 
amount of protein was loaded onto the gel (ranging from 4 up to 16 fig of protein) 
and a longer tim e for migration with a lower voltage was performed to improve the 
separation of the proteins. Two different sample preparations (either heated for 
30 min a t 60°C or heated for 3 min at 95°C) were compared. No difference in the 
resolution of the band was observed between the two different sample preparations. 
Although the smear was still present a t the top of the blot, it did not interfere 
w ith the two specific bands (figure 5.3).
5.4.1.3 Measurement of D 6 protein expression by astrocytes using flow 
cytometry
D 6  was constitutively expressed by astrocytes (B327/01). Histogram repre­
sentation of D6  expression by flow cytometry showed th a t D6 was expressed both 
at the cell surface (green line) and in the cytoplasmic com partm ent (blue line) 
(figure 5.4). The filled histogram corresponds to the negative control (PE la­
belled IgG isotype control). Q uantitation of D 6  expression was determined both 
a t the cell surface and in the cytoplasmic com partment in two astrocyte prepa­
rations (B327/01 and SMS-12) (figure 5.5). Both astrocyte preparations mainly 
expressed D 6  in the cytoplasmic com partment (SMS-12, 12.25 ± 1 .1  MFI and 
B327/01, 12.7± 0.6 MFI) compared to  the cell surface (SMS-12, 2 ±  0.4 MFI 
and B327/01, 1.4± 0.1 MFI). D6  cell surface expression represented only 11 and 
16 % of the to tal D6  expression in B327/01 and SMS-12 astrocyte preparation 
respectively.
Following 24 h stimulation with pro-inflammatory cytokines, the expression of 
D 6  a t the astrocyte cell surface was unaffected with IL1-/3 (2.4 ± 0 .2  MFI) , TN F 
(3.1 ±  0.8 MFI) and IFN 7  (2.6 ±  0.4 MFI) at 100 ng/m l compared to the control 
(2.9 ±  0.4 MFI).
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FL-2 PE-labelled
Fig. 5.4: H is to g ra m  re p re s e n ta t io n  o f D 6  ex p re ss io n  a t  th e  cell su rface  
a n d  in tra c e llu la r ly  in  p r im a ry  h u m a n  a d u l t  a s tro c y te s  u s in g  flow cy­
to m e try .
Astrocytes (B32/01) were stained directly with PE-labelled rat IgG2a antibody 
against human D6 (R&D Systems) with (blue histogram) and w ithout fixa- 
tion/perm eabilization (green histogram). A negative control was run in parallel 
by incubating astrocytes with PE-labelled ra t IgG2a isotype control (filled his­
togram). Staining was quantitated by flow cytometry.
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Fig. 5.5: M e a su re m e n t o f D 6  e x p re ss io n  level a t  th e  cell su rface  a n d  in- 
t r a c e llu la r ly  o n  p r im a ry  h u m a n  a d u lt  a s tro c y te s  u s in g  flow  c y to m e try .
D 6  expression level was assessed at the cell surface (white) and in the cytoplasmic 
com partm ent (grey) of two astrocyte preparations using using directly labelled 
D 6  antibody (R&D Systems, UK)(n=3). A negative control was run in parallel 
by incubating astrocytes with PE-labelled ra t IgG2Q isotype control and the back­
ground was subtracted from each value. ANOVA followed by D unnett’s test was 
performed to determine significant differences between the cell surface and the 
cytoplasmic D6  expression. *** p <  0.01 was considered significant.
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Fig. 5.6: E ffec t o f  p ro - in f la m m a to ry  c y to k in e  s tim u la t io n  o n  cell su rface  
D 6  e x p re ss io n  b y  p r im a ry  h u m a n  a d u l t  a s tro c y te s  u s in g  flow c y to m e try .
Astrocytes (B327/01) were stimulated with IL1-/?, TN F and IFN 7  a t 100 ng/m l 
for 24 h. D6  expression was assessed at the astrocyte cell surface using directly 
labelled D 6  antibody (R&D Systems, UK). Stimulations were done in triplicate 
and the effect on D6  expression following stim ulation was analyzed by ANOVA 
followed by D unnett’s test. No significant difference was seen.
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5.4.2 A na lysis o f D 6 expression on hum an brain tissue sec­
tions
5.4.2.1 Characterisation of brain tissue sections using ORO staining
Eight blocks were stained for ORO to measure the extent of demyelination 
(figure 5.7). MS90 P2E3 showed strong demyelination ORO (+ + ) compared to 
MS74 A1C6 and MS100 A2 D2  ORO (+ ) and the remainder of blocks were ORO 
(-) (no demyelination). Harris’s haematoxylin staining, which is commonly used 
to  detect the cellular infiltration, was able to  detect perivascular inflammatory 
cells synonymous with inflammation (MS90 P2E3 and MS130 P2F4). Levels of 
demyelination and inflammation for the eight blocks are summarised in table 5.3.
5.4.2.2 Measurement of D6 mRNA expression in brain tissue using 
qRT-PCR.
D 6  mRNA expression was assessed in the eight different blocks (figure 5.8). 
C t values for the two controls were averaged and the mRNA expression for the 
control was normalized to 1. The level of expression of D 6  mRNA was slightly 
decreased in the N1 and 2 compared to  the control (0.8 ± 0 .1  fold increase and 
0.3 ±  0.1 fold increase) but it did not reach statistical significance. D6  mRNA 
was increased for L2 (1.6 ±  0.4 fold increase) and L4 (3.3 ±  0.5 fold increase). 
However only L4 was statistical significant (p<0.01). For LI and L3, a slight but 
non significant decrease was observed (0.2 ±0.04 fold increase and 0.3 ± 0 .1  fold 
increase) compared to  the control.
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Fig. 5.7: A ssessm ent of dem yelination  and  in flam m ation  in  h u m an  b ra in  
tissue  sections: Oil R ed  O (O RO ) sta in ing .
Sections were stained with ORO and haematoxylin. Different grades were given to 
the sections depending on the extent of demyelination, characterized by red stain­
ing due to the accumulation of myelin. MS90 P2E3 (LI) had strong demyelination 
(O R O ++) , compared to MS100 A2D2 (L4) which had low demyelination level 
(ORO+) and C14 P2C3 (C2) which had no demyelination (ORO-). Inflam mation 
was also assessed and MS130 P2F4 (N l) was shown to have strong perivascular 
cell infiltration (inflammation). Sections were visualized with the an Olympus 
BX60 microscope.
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Tissue block type Code ORO inflammation
MS90 P2E3 lesion LI 4—h +
MS130 P2E3 lesion L2 - -
MS74 A1C6 lesion L3 + -
MS100 A2D2 lesion L4 + -
MS130 P2F4 NAWM N1 - + +
MS74 A1E7 NAWM N2 - -
C o ll A1B5 Control C l - -
Col4 P2C3 Control C2 - -
Tab. 5.3: C h a ra c te r is a t io n  o f e ig h t tis s u e  b lo ck s  u sed  in  th is  s tu d y  by  
O R O  a n d  h a e m a to x y lin  s ta in in g .
Grading of demyelination was assessed by ORO staining corresponding to strong 
demyelination (+ + + ) , low level of demyelination (+ ) and absence of demyeli­
nation (-) respectively. Inflammation corresponds to  the presence of perivascular 
cuffs visualized with haematoxylin staining. Different grades in inflammation were 
observed (+ +  strong, +  low and - absent).
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Control NAWM LESION
Fig. 5.8: D 6  m R N A  ex p re ss io n  in  M S , N A W M  a n d  c o n tro l b ra in  tis su e  
b y  q R T -P C R .
Extraction of brain tissue mRNA was done in duplicate and cDNA amplification 
was performed twice per sample (n=4). The HK gene UBC was used as an internal 
control. Expression of D6  mRNA was normalised to 1 for the control. ANOVA 
followed by D unnett’s test was performed. **p< 0.01 is considered significantly 
different.
5.4.2.3 Detection of D6 protein expression in brain tissue using SDS- 
PAGE and western blotting
Two bands of 49KDa and 58 KDa were observed for D 6 . D6  was expressed 
in all the samples (figure 5.9). To determine the level of expression in the eight 
different blocks, IOD values of D6  were normalized to the IOD values of actin, 
considered as 1. D 6  was shown to be expressed in all the lesions but no significant 
difference in D6  expression level was observed (figure 5.10).
5.4.2.4 Optimisation of D6 staining on human brain sections by im- 
munohisto chemistry
Optim isation of the D6  antibody concentration was performed by incubating 
brain sections (MS122 A4E5) with four different dilutions (1:50, 1:75, 1:100 and 
1:250) (figure 5.11). The negative control showed absence of immunoreactivity. 
1:50 and 1:75 gave a good signal for detection of D6  compared to  1:100 and 1:250 
dilutions, which gave a weak or to tal absence of staining respectively. 1:75 dilution 
was selected for further use to determine the cellular origin of D6  in brain tissue 
sections. D6  staining was associated with the cell body, as indicated by the white 
arrows. Pictures taken at higher magnification confirmed this finding and further 
showed th a t the D6  staining pattern  was vesicular (figure 5.11).
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Fig. 5.9: D e te c tio n  o f  D 6  r e c e p to r  in  M S , N A W M  a n d  c o n tro l h u m a n  
b ra in  tis su e  u s in g  S D S -P A G E  a n d  w e s te rn  b lo t t in g .
Proteins extracted from brain were loaded onto a NuPAGE 10% bis tris acry- 
lamide gel and run for 2 h a t 110 V. Proteins were transferred onto a nitrocellulose 
membrane and incubated sequentially with a rabbit polyclonal antibody directed 
against human D6  (Abeam, UK) and HRP-goat anti rabbit IgG (a). (RMM) 
Marker, Seeblue plus 2 (Invitrogen, UK), was used to determine the molecular 
weight of the bands of interest (KDa). To assess protein loading for the different 
samples, membranes were stripped and reprobed with polyclonal goat antibody 
directed against actin followed by HRP rabbit anti-goat IgG (b). Immunoreac- 
tivity  was detected by chemiluminescence using ECL Reagent K it Plus and UVP 
imager.
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Fig. 5.10: Q u a n ti ta t iv e  co m p a riso n  o f  D 6  e x p re ss io n  b e tw e e n  M S ,
N A W M  a n d  c o n tro l h u m a n  b ra in  tissu e .
To compare D6  expression in the eight different blocks, a normalization step was 
performed. W estern blots were analysed with UVP bioimaging software. IOD 
values of D6  were normalized with the IOD values of actin. D 6  was expressed in 
all the different sections. However, no significant difference was observed between 
the different samples (ANOVA followed by D unnett’s test, n=4).
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Fig. 5.11: D e te c tio n  o f D 6  r e c e p to r  in  h u m a n  b ra in  tis su e  sec tio n s  u s in g  
im m u n o flu o rescen ce .
Sections (MS122 A4E5) were stained with polyclonal goat antibody directed 
against D6 at different dilutions (1:50, 1:75 and 1:100) and PE-labelled rabbit 
anti goat antibody IgG. Negative control was performed by om itting the prim ary 
antibody. Autofluorescence was quenched with 0.15%SBB-70% ethanol solution. 
Nuclei were counter stained with DAPI (blue). Immunofluorescence was visualized 
with the CSLM following the procedure described in section 2.2.3.1. Fluorescence 
was associated with the cell body as shown by the white arrows. Higher magnifi­
cation images are shown in the red frame.
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5.4.2.5 Cell phenotype expressing D6 in brain using immunohisto- 
chemistry
Dual labelling for D6  and cellular markers, including GFAP (astrocytes), Neu- 
N (neurons) and HLA-DR (activated microglia/macrophages), was used to deter­
mine the cell type expressing D6  in human brain tissue sections. Utilisation of the 
Zeiss 510 software enabled pixels to be scanned in the different channels and were 
designated as a white colour when colocalisation was observed. Strong colocalisa­
tion was observed with D6  and the neuronal marker (Neu-N) as shown in lesion 
tissue sections LI (figure 5.12) indicated with the white arrows. The staining for 
D 6  appeared to be mainly on the grey m atter compared to  the absence of reac­
tivity  for D6  in the white m atter. Some Neu-N-  cells (green) were positive for 
D6  (red). A low level of colocalisation was observed with D6  (green)and HLA-DR 
(red) in LI lesion (figure 5.13). No staining for HLA-DR was observed in con­
trol tissue sections. Complete absence of colocalisation for D 6  (green) and GFAP 
(red) was observed as shown in lesion tissue sections L4 (figure 5.14). Therefore, 
colocalisation experiments provided evidence for strong D6  neuronal expression, 
low level expression on microglia/macrophages and no expression by astrocytes.
5.4.3 CCL2 binding to  human brain tissue sections
5.4.3.1 Optimisation of the binding of biotinylated CCL2 to brain tis­
sue sections
Three different dilutions of biotinylated CCL2 were tested (1:4, 1:10 and 1:20). 
Figure 5.15a shows the absence of fluorescence background when biotinylated 
CCL2 was omitted. The strongest fluorescent signal was observed for the 1:4 
dilution (b) compared to 1:10 (c) and 1:20 (d). CCL2 binding was associated 
with cell nuclei (white arrows). To reduce the fluorescent background, different 
dilutions of avidin-FITC were tested (1:2, 1:4 and 1:10) with biotinylated CCL2 
at 1:4. Figure 5.16 shows th a t the background level decreased with the lower 
concentration of avidin-FITC. The three dilutions gave a good signal for detection
213
Fig. 5.12: D e te rm in a t io n  o f th e  n e u ro n a l ex p re ss io n  o f D 6  in  h u m a n  
b ra in  tissu e .
Brain tissue sections (LI) were sequentially stained with antibody directed against 
B 6 (a, red) and Neu-N (b, green). Immunofluorescence was visualized with the 
CSLM following the procedure described in section 2.2.3.1. The two channels were 
overlayed (c) and colocalisation (white colour pixels) was observed using the Zeiss 
510 software (d).
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aFig. 5.13: Determination of the microglia expression of D6 in human 
brain tissue.
Brain tissue sections (LI) were sequentially stained with antibody directed against 
D6  (a, green) and HLA-DR (b, red). Immunofluorescence was visualized with the 
CSLM following the procedure described in section 2.2.3.1. The two channels were 
overlayed (c) and colocalisation (white colour pixels shown by the white arrows) 
was observed using the Zeiss 510 software (d).
215
Fig. 5.14: D e te rm in a t io n  o f th e  a s tro c y t ic  e x p re ss io n  o f D 6  in  h u m a n  
b ra in  tissu e .
Brain tissue sections (L4) were sequentially stained with antibody directed against 
D6 (a, green) and GFAP (b, red). Immunofluorescence was visualized with the 
CSLM following the procedure described in section 2.2.3.1. The two channels 
(red and green) were overlayed (c). No colocalisation between D6 and GFAP was 
observed using the Zeiss 510 software.
Fig. 5.15: O p tim is a tio n  o f b in d in g  o f b io tin y la te d  C C L 2  to  h u m a n  b ra in  
tis su e  sec tio n s: d e te rm in a tio n  o f o p tim a l c o n c e n tra tio n  fo r b io t in y la te d  
C C L 2
Brain tissue sections (MS122 A4E5) were incubated with increasing dilution of 
biotinylated CCL2 (b, 1:4 c, 1:10 d, 1:20) followed by incubation with avidin- 
FITC. (a) The background level was observed by omitting biotinylated CCL2 
(a). Immunofluorescence was visualized with the CSLM following the procedure 
described in section 2.2.3.1.
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of binding of biotinylated CCL2. However, the background level was lowest 
w ith avidin FITC  diluted a t 1:10. This dilution was used for the further ex­
periments. CCL2 binding was shown to  be associated with cell nuclei. Higher 
magnification showed th a t biotinylated binding was associated with vesicles (fig­
ure 5.16c).
5.4.3.2 Determination of the ability of D6 to bind CCL2 in brain tissue 
sections
Dual labelling on MS lesion sections (MS1 2 2  A4E5) showed th a t D 6  (red) 
and CCL2 (green) showed a strong colocalization represented by the white pixels 
(figures (5.17). However, some cells were positive for CCL2 and negative for D6 .
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Fig. 5.16: O p tim is a tio n  o f b in d in g  o f b io tin y la te d  C C L 2 to  h u m a n  b ra in  
tis su e  sec tio n s: d e te rm in a tio n  o f th e  o p tim a l c o n c e n tra tio n  fo r a v id in  
F IT C .
Brain tissue sections (MS122 A4E5) were incubated with biotinylated CCL2 (1:4) 
followed by incubation with increasing dilution of avidin-FITC (a, 1:2 b, 1:4 c, 
1:10). (c) Picture at higher magnification shows the vesicular staining for CCL2 
binding. Immunofluorescence was visualized with the CSLM following the proce­
dure described in section 2.2.3.1.
219
Fig. 5.17: D e te rm in a t io n  o f th e  a b ility  o f D 6  to  b in d  C C L 2  in  h u m a n  
b ra in  tissu e .
10/im brain tissue section (MS122 A4E5) was incubated with biotinylated CCL2 
and avidin FITC (a, green) followed by D6 antibody (b, red). Immunofluores­
cence was visualized with the CSLM following the procedure described in section 
2.2.3.1. The two channels (red and green) were overlayed (c) with high magnifi­
cation in the frame. Colocalisation (white colour pixels) was observed using the 
Zeiss 510 software (d) at low and high magnification (frame). Arrow indicates 
cell with colocalised biotinylated CCL2 and D6 which appears to be of neuronal 
morphology.
5.5 D iscussion
The decoy receptor D6  shares some similarities w ith conventional chemokine 
receptors. I t is a 7 transm em brane receptor th a t can bind chemokines [Fra et al., 
2003, Locati et al., 2005, Mantovani et al., 2006]. The D6  decoy receptor has 
some specificity in ligand binding, it binds only pro-inflammatory CC chemokines 
bu t not homeostatic CC chemokines or other chemokine families such as CXC 
chemokines [Fra et al., 2003, Locati et al., 2005, Mantovani et al., 2006]. How­
ever, the D 6  decoy receptor lacks motifs in the second intracellular loop th a t 
transduce signalling events [Borroni et al., 2006, Mantovani et al., 2001, Nibbs 
et al., 1997]. I t has been shown to be constitutively internalized to the cytoplasm 
independently of CC chemokine binding [Blackburn et al. 2004]. It was further 
dem onstrated th a t the decoy receptor internalized CC chemokines and lead to 
their degradation in lysosomes [Galliera et al., 2004, Weber et al., 2004]. 
Evidence in mice has shown a role for D6  in regulating inflammation. A model 
of cutaneous inflammation in mice deficient for the D6  gene, suffered from aggra­
vated inflammation due to  increased leukocyte invasion, necrosis and angiogenesis 
[Jamieson et al., 2005, M artinez de la Torre et al., 2007]. However, an unexpected 
resistance to EAE in D6  KO mice was observed due to an impaired encephalito- 
genic response [Liu et al., 2006a],
The D6  decoy receptor serves a regulatory function for CC chemokine ex­
pression a t sites of inflammation. D 6  was shown to  be strongly expressed by 
endothelial cells in the lymphatic afferent vessels in the skin, gut and placenta 
as well as on circulating leukocytes at low levels [McKimmie and Graham, 2006, 
Nibbs et al., 2001]. No studies to date have examined the expression of D6  in 
human brain. To determine if D6  was expressed in the CNS, it was assessed on 
astrocytes in vitro as well as on human brain tissue sections.
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5.5.1 D 6 m R N A  expression by unstim ulated astrocytes  
using qR T -PC R
In this study, astrocytes have been shown to constitutively express D6  mRNA. 
Two reports on constitutive D 6  mRNA expression by astrocytes were previously 
published [Zuurman et al., 2003, Neil et al., 2005]. Zuurman et al. (2003) showed 
th a t murine astrocytes did not express D6  mRNA using RT-PCR experiments 
whereas Neil et al. (2005) showed th a t prim ary human astrocytes constitutively 
expressed D6  mRNA using qRT-PCR. The discrepancy might be explained by 
the difference in the species of astrocytes. Indeed, Zuurman et al. (2003) isolated 
astrocytes from cortex of mouse pups (<  day 1 ) whereas in this study and in the 
study by Neil et al. (2005), astrocytes were isolated from human brain.
5.5.2 D 6 m R N A  expression by astrocytes following pro- 
inflam m atory cytokine treatm ent using qR T -PC R
In this study, under pro-inflammatory conditions, astrocyte D 6  mRNA was 
significantly increased following IL1/? (33.5 ±  7.6 fold increase) and IFN 7  (28.1 ±  
13.9 fold increase) a t lOOng/ml compared to unstim ulated cells. Although TNF 
induced a 12 =L 5.2 fold increase in D6  mRNA expression it did not reach statis­
tical significance. No modulation of D6  mRNA was observed a t lower cytokine 
concentration. Since D6  has been shown to be involved in the clearance of CC 
chemokines, it is not surprising to observe an increase in D6  mRNA expression 
following cytokine stimulation, which also increased CCL2 mRNA expression as 
described in chapter 2. However, there was a large difference in D 6  mRNA expres­
sion between cytokine stimulation a t 10 ng/m l and 100 ng/m l . This difference 
might be due to the fact th a t the characteristic dose response might be between 
these two concentrations. Thus further cytokine treatm ents (20 ng/m l, 40 ng/m l, 
60 ng/m l and 80 ng/m l) should be performed to determine if D6  mRNA expression 
has a gradual increase in expression with increasing concentration of cytokines.
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5.5.3 D 6 protein  expression by astrocytes using w estern  
b lottin g  and flow cytom etry
To confirm the previous finding th a t astrocytes express D6  and to check if 
protein expression mirrored mRNA expression, western blotting as well as flow 
cytom etry experiments were performed on astrocytes. We report in this study 
th a t astrocytes expressed D6  using both methods. In western blot experiments 
for D 6  receptor on proteins extracted from astrocytes, two bands of 53KDa and 
60KDa with similar intensity were obtained. The expected size for D6  receptor 
was 50 KDa [Blackburn et al., 2004] which supports the finding here of astrocyte 
expression of D 6 . Since N-terminal sulphation of chemokine receptors has been 
reported and this post-translational modification is believed to  be im portant for 
chemokine binding [Farzan et al., 1999, 2002], D6  receptor might be modified in  
vivo which would yield a band at higher molecular weight (possibly 60KDa). Fur­
ther experiments to sequence proteins in these bands are required.
D6  expression by astrocytes was quantitated by flow cytometry. Astrocytes ex­
pressed D 6  receptor a t both  the cell surface and in the cytoplasmic compartment. 
However, only a small fraction of the to tal D6  was expressed at the cell surface (10 
and 16% for B327/01 and SMS-12 astrocyte preparations). This finding was also 
observed in other published studies. Blackburn et al. (2004) showed in transfected 
L I.2 pre B cells and human embryonic kidney (HEK) cells th a t only between 10 
to 20 % of D 6  was expressed at the cell surface. Similarly, Weber et al. (2004), 
investigating trafficking of D6  from the cell surface to the cytoplasm in HEK cells, 
found th a t only 5% of the to tal D6  was expressed a t the cell surface.
Astrocytes stim ulated with pro-inflammatory cytokines (lOOng/ml) showed no 
m odulation of the level of expression (IL1/5, 2.4 ±0.2 MFI, TNF, 3.1 ±  0.9 MFI 
and IFN 7 : 2.6 ±  0.3 MFI) compared to unstim ulated astrocytes (2.9 ±  0.4 MFI). 
We previously dem onstrated in Chapter 2 th a t pro-inflammatory cytokine stimula­
tion (lOOng/ml) induced an increase in CCL2 secretion, therefore D6  cell surface 
expression is unaffected by increasing concentrations of CCL2. These findings 
agreed with the study by Weber et al. (2004) where they showed th a t D6  cell
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surface expression was unaffected following incubation with recombinant CCL3 
compared to CCR5 which showed strong internalization. The ability of decoy 
receptors to actively remove CC chemokines from the extracellular milieu is due 
to  a faster rate  of internalisation and recycling to  the cell surface compared to 
functional receptors [Weber et al., 2004]. These findings suggest th a t the internal­
isation rate is an im portant factor in the regulation of the level of CC chemokines 
rather than  the actual cell surface expression which is unaffected following pro- 
inflammatory treatm ent.
The da ta  reported here are consistent with the fact th a t in vitro astrocytes ex­
press D 6  (mRNA and protein level). Moreover, for the detection of D 6  protein, two 
different antibodies and two different staining procedures were used. The antibody 
used for flow cytom etry (R&D Systems) was a monoclonal antibody raised against 
human D6  transfected RBL-1 cells whereas the antibody for the western blot was 
obtained by injecting a synthetic peptide (C-LATEDADSENSSFYYYDYLDEVAFML), 
corresponding to  N term inal amino acids 10-35 of human D 6  in goat.
To relate these in vitro findings to in vivo, expression of D 6  was assessed 
in hum an brain tissue. Real time PCR as well as western blotting showed the 
presence of D6  a t the mRNA and protein level in the brain of control, NAWM 
and MS lesions.
5.5.4 D 6 m R N A  expression in vivo using qR T -PC R
At the mRNA level, only L2 and L4 showed an increase in D 6  expression com­
pared to control w ith a 1.6 ±  0.4 fold increase and 3.3 ±  0.5 fold increase. L4 block 
was shown to have limited demyelination and no apparent inflammation. Surpris­
ingly, L3 which showed a similar level of demyelination and no inflammation did 
not show any difference in D6  mRNA expression compared to the control. At 
the protein level, the band pattern  for western blotting was similar to th a t found 
for the astrocytes in vitro. Two bands of 49 and 58 KDa were detected, which
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suggested post-translational modification of D6 . The quantitative analysis of the 
blots, using actin to  normalize D6  expression, did not show any difference between 
control, MS and NAWM brain.
5.5.5 D 6 protein  expression in vivo using w estern b lotting
In this study, D6  was shown to be strongly expressed by neurons, present in 
the grey m atter (GM). Absence of staining was observed in the white m atter. It 
is therefore difficult to  relate D6  expression with the level of inflammation in the 
white m atter (WM). I t was traditionally considered th a t MS is a demyelinating 
disease characterized by demyelinated plaques in the WM. However, pathology 
can be found in the deep cerebral nuclei and cerebral cortex [Cifelli et al., 2 0 0 2 , 
Kidd et al., 1999, Kutzelnigg et al., 2007]. Cortical lesions differ from the WM le­
sions by having demyelination w ithout an increase in lymphocyte count or altered 
distributions of subsets of lymphocytes compared to control. The authors con­
cluded th a t inflammation in the cortex is independent of lymphocytes [Bo et al., 
2003].
In this study, no assumption can be made on the comparison of the level of expres­
sion of D6  in the WM between control, NAWM and lesion since the proportion 
of W M /G M  was not assessed. We can only conclude th a t D 6  was detected at the 
mRNA and protein level within the brain and th a t D6  was mainly detected in the 
GM. To be able to  accurately compare the level of expression of D6  in control, 
lesions and NAWM, the composition of W M /GM  should be determined as well 
as including a greater number of brains for each category (control, NAWM and 
lesion).
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5.5.6 D eterm ination  of cell types expressing D6 in vivo 
using im m unohisto chem istry
The fact th a t neurons express D6  might be a protective mechanism against 
CCL2 actions. I t was shown in an in vitro study th a t hippocampal neurons incu­
bated with CCL2 were subjected to apoptosis, which was inhibited by prior trea t­
ment w ith caspase 1 inhibitor [Kalehua et ah, 2004]. This finding was confirmed in  
vivo by intrahippocam pal injection of CCL2 th a t induced neuronal death. There­
fore D 6  expression would render neurons less sensitive to CCL2 by removing CCL2 
in their close environment.
Images obtained by immunohistochemistry showed th a t D 6  labelling was mainly 
associated with the cell body which seemed to be, at higher magnification, a 
vesicular pattern , which may mean th a t it is mainly endoplasmic reticulum or an 
endosomal com partment. Similar staining was observed in studies by Blackburn 
et al. (2003) and Weber et al. (2003) where they found th a t bo th  the L I.2 cell 
line and HEK cells th a t expressed GFP-D 6  presented a granular distribution in 
the cells. Weber et al. (2003) further showed th a t the fusion protein, G FP-D 6 , 
colocalised with rab 5 and the transferrin receptor, which are markers for early 
and recycling endosomes.
We report here th a t D6  expression was also associated with HLA-DR+ activated 
microglia/macrophages. Microglia have been shown to play a central role in MS 
pathogenesis. They are able to sense danger signals through the ligation of con­
served innate receptors such as Toll-like receptors (TLRs), which result in in­
creased expression of pro-inflammatory mediators such as chemokines [Jack et al., 
2005]. Microglia activate immune cells through their expression of MHC class 
II and co-stimulatory molecules [Rezaie and Male, 1999, Bechmann et al., 2001] 
resulting in an amplification of the inflammatory response in the CNS. Microglia 
cells have been shown to clear apoptotic cells and downregulate their APC abil­
ity, representing an active mechanism to limit the inflammatory response th a t is 
characteristic of acute MS lesions [Magnus et al., 2001, Chan et al., 2003]. The 
fact th a t microglia express D6  would further support the finding th a t microglia
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cells act in controlling inflammation by regulating the level of pro-inflammatory 
CC chemokines.
Surprisingly, D 6  expression was not associated with astrocytes. Although our in 
vitro da ta  are consistent with the fact th a t astrocytes express D 6  a t the mRNA 
level and protein level (using two different procedures), it did not correlate with 
the in vivo findings. The discrepancy might be due to  an in vitro artefact. In­
deed, evidence has been published on the discrepancy between in vitro and in 
vivo findings. T ian et al. (2004) compared gene expression of retinal pigment 
epithelial cells grown in different conditions and native R PE using laser microdis­
section, using microarray analysis, which was further confirmed by qRT-PCR. 
They showed th a t cells grown in vitro had a significantly different overall gene 
expression compared to native cells [Tian et al., 2004]. To confirm the fact th a t 
astrocytes express D6  in vivo, laser microdissection with qRT-PCR would be the 
ideal procedure.
5.5.7 D eterm ination  of D6 ability to  bind CCL2 in vivo 
using im m unohistochem istry
Many reports have shown th a t D6  binds various CC chemokines. We report 
in this study th a t CCL2 binding on human brain tissue sections showed a strong 
colocalisation with D6  expression (white pixels). However, some D 6 _ cells also 
had bound CCL2. Further investigation is needed to identify these cells by doing 
dual labelling with cellular markers such as GFAP, HLA-DR, CD3 (T-cells).
In C hapter 3, CCL2 binding was shown to be CCR2-independent in prim ary 
adult hum an astrocytes. The absence of activation of the common signal trans­
duction pathways for chemokine receptors and the expression of the D6  receptor in  
vitro might suggest a new regulatory function for human adult astrocytes during 
inflammation in MS by sequestration of chemokines released during inflamma­
tory cell recruitm ent . In vivo, microglia and neurons expressed D 6 , which could 
contribute to  the removal of CCL2 from the extracellular space, providing some
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explanation for the decrease in CCL2 in the CSF at the time of relapse in MS 
patients [Mahad et al., 2002b, Narikawa et al., 2004, Scarpini et al., 2002]. D6 
expression on astrocytes has to be further investigated in vivo due to  the failure 
to detect it on astrocytes in the current preliminary study.
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CHAPTER 6
General discussion
6.1 General discussion
The research question addressed in this thesis was the possible contribution of 
astrocytes to the differential expression of CCL2  and CXCL10 in the CSF in MS 
patients [Mahad et al., 2002b, Narikawa et al., 2004, Scarpini et al., 2002]. Since 
both  chemokines are highly expressed in the CNS in active lesions, it was sur­
prising th a t CCL2  was decreased whereas CXCL10 was increased in MS patients. 
Thus the differences in relation to  synthesis of the 2 chemokines in response to 
inflammatory cytokines was investigated.
In this study, astrocytes were found to  respond to  pro-inflammatory cytokine 
treatm ent by increasing synthesis and secretion of both  CCL2 and CXCL10. CCL2 
was more highly expressed than  CXCL10 both a t the mRNA and protein level. 
Thus, the reduced levels of CCL2 in the CSF during relapse in MS patients cannot 
be explained by an differential expression of CCL2 and CXCL10 by astrocytes. 
A second possible explanation may relate to the sequestration of CCL2 within 
the brain parenchyma. Thus CCR2 expression and CCL2 binding to  astrocytes 
in vitro was assessed. Although CCR2 mRNA was expressed by astrocytes, no 
protein was detected either a t the cell surface nor in the cytoplasmic com part­
ment. Since astrocytes showed the ability to bind CCL2 , which was unaffected
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following cytokine treatm ent, and showed a complete absence of activation of both 
calcium flux and phosphorylation of Erk and Akt, it would appear th a t the bind­
ing of CCL2 was CCR2-independent. Therefore, CCL2 could bind either to decoy 
chemokine receptors or to  proteoglycans known ligand for CCL2 [Proudfoot et al., 
2003]. Astrocytes were shown to constitutively express D6  receptor a t the mRNA 
(qRT-PCR) and protein (flow cytometry and western blot) level. The expression 
a t the cell surface was not modulated by pro-inflammatory cytokine treatm ent. 
Therefore in vitro da ta  might suggest th a t astrocytes regulate the level of CC 
chemokines through binding to the decoy chemokine receptor. Although mRNA 
and protein were not affected by cytokines, it remains to be investigated whether 
the rate  of recycling of D6  to  the surface is modulated.
Levels of chemokines can also be regulated by storage in intracellular stores 
th a t can be released rapidly following cell activation. It was shown th a t CD8 + T 
cells were able to  release CCL5 from small vesicles following activation through 
the T  cell receptor [Catalfamo et al., 2004]. Similar findings were obtained with 
peripheral blood eosinophils [Lacy et al., 1999] who found th a t CCL5 released by 
eosinophils under IFN 7  stimulation was quicker than  expected reaching its max­
imal effect following 60 to 120 min treatm ent. Subcellular fractionation demon­
strated  th a t CCL5 was associated with small secretory vesicles, suggesting the 
presence of intracellular stores of CCL5.
Not only T  cells and eosinophils, ECs have also been shown to store several 
chemokines such as CXCL8 , CXCL1 and CCL2 to  allow them  to respond quickly 
to stim ulation [Oynebraten et al., 2005]. It was proposed th a t CXCL8  storage in 
EC corresponds to a memory mechanism of preceding inflammatory conditions 
[Wolff et al., 1998]. Therefore, EC can respond to  the next inflammatory insult 
w ithout the delay of de novo synthesis. These findings illustrate the existence 
of mechanisms th a t rapidly regulate the level of chemokines in the extracellular 
milieu.
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W hen chemokines are secreted, their diffusion is limited by GAGs. As previ­
ously said in section 1.4.6, GAGs are composed of long linear polysaccharides and 
a protein core [Johnson et al., 2005]. Since chemokines are prim arily basic and 
proteoglycans are highly negatively charged, it is not surprising to  observe inter­
action between chemokines and proteoglycans. The interaction of chemokines and 
proteoglycans have been under investigation to  understand their role in chemokine 
regulation. I t was hypothesised th a t this interaction provides a mechanism th a t 
concentrates chemokine in a close environment, from the site of synthesis, to re­
cruit immune cells to the site of inflammation [Rot, 1992], I t was further demon­
strated  th a t this interaction is fundamental for chemokine function. M utations in 
the binding site for CCL2, CCL4 and CCL5 have been assessed in vitro and in vivo 
to  determine the effect of proteoglycan on chemokine function. The chemotactic 
activity of the m utated chemokines was retained only in vitro and were unable to 
recruit any cells when injected intraperitoneally [Proudfoot et al., 2003]. The fact 
th a t chemokines can induce chemotactic effects on immune cells in vitro bu t not in 
vivo is not surprising as in vitro tests solely examine the effect on chemokines on 
recruitm ent of immune cells without consideration of flow conditions. Therefore, 
this study dem onstrates the im portance of proteoglycans for the establishment 
and maintenance of chemokine gradient.
As discussed in section 1.4.6, proteoglycans possess some specificity for chemokines 
[Kuschert et al., 1999]. Therefore, cells th a t are producing proteoglycan might 
favour the formation of a specific gradient of a particular chemokine th a t will 
recruit a certain type of immune cells [W itt and Lander, 1994]. This specificity 
in binding of chemokines to proteoglycans controls the localisation of chemokines 
in tissues.
Existence of soluble GAGs which bind chemokines might m odulate the activity 
of chemokines although the data  to support this is controversial. It was demon­
strated  th a t heparin and heparan sulphate decreased the chemotactic effect of 
CXCL12 in vitro on acute lymphoblastic leukemia cell line [Murphy et al., 2007].
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This finding was confirmed by studies where co-incubation of soluble GAGs (hep­
arin) w ith chemokines resulted in a reduction in binding and a resultant effect on 
their functional effect on neutrophils and Chinese ham ster ovary K1 (CHO-K1) 
cells (CCL5, CCL3 and CXCL8 ) [Kuschert et al., 1999, M artin et al., 2001]. Con­
tradictory results were obtained with heparan sulphate [Netelenbos et al., 2002]. 
Incubation of myeloblastic CD34+ KG-1 cell line with increasing amounts of hep­
aran sulphate resulted in a significant increase in migration. Although there are 
obvious discrepancies in the effect of soluble GAGs on chemokine effects, it would 
appear th a t the chemokine activity can be modulated by soluble GAGs.
Since chemokines exert their biological effect through GPCRs, it is not surpris­
ing th a t chemokine actions can be regulated by the regulation of their receptors. 
GPCRs can be desensitized, following binding of a chemokine receptor agonist and 
activation of signalling inactivation pathways. This mechanism is extremely rapid 
and is followed by endocytosis of the receptor, in less than  1 hour [Steele et al.,
2002]. This mechanism is im portant as it provides a tight mechanism of regulation 
tha t could be necessary during the chemotaxis of immune cells toward the inflam­
mation site to  avoid over-stimulation of the receptor [Ferguson, 2001]. I t was 
shown, for example, .that the mono Mac 1 cell line strongly responded to CCL2 
stim ulation by increasing calcium mobilization. However, a second stim ulation 
with CCL2 induced a decreased in calcium mobilization, suggesting desensitiza­
tion [Aragay et al., 1998]. This mechanism is regulated by the G PC R kinases 
(GRKs) and arrestins. The GRK family is composed of seven family members 
with four of them  ubiquitously expressed (2, 3, 5 and 6 ) whereas the arrestin fam­
ily is composed of two members with one ubiquitously expressed (Arrestin/22). 
The desensitization occurs following phosphorylation of the C term inal domain of 
the receptor by GRKs, inducing an increased affinity for arrestin. This interac­
tion results in the steric inhibition for further coupling of the receptor w ith the 
G protein rendering the receptor unresponsive to its ligand [Vroon et al., 2006, 
Pierce and Lefkowitz, 2001]. The GRK-arrestin complex promotes internalisation
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through clathrin pathways to  the endosome to degrade or resensitise the receptor 
[Pierce and Lefkowitz, 2001]. Thus desensitization is a rapid and effective mecha­
nism for regulating chemokine activity. Binding of chemokines to  a decoy receptor 
is another mechanism th a t can quickly regulate the level of chemokines a t the site 
of inflammation as discussed in the sections 5.1.1 and 1.4.4.1.
Finally, proteolysis of chemokines is another mechanism, which may regulate 
of chemokine activity. The NH2 part of the chemokine is im portant for the bind­
ing, hence why proteolytic cleavage can change the activity of chemokines [Proost 
et al., 2001]. I t was shown th a t the dipeptide peptidase IV (CD26) which cleaved 
CXCL8 , CXCL9 and CXCL10 induced a reduction in both  the migration effect 
and calcium mobilization on CXCR3 transfected CHO-K1 cells. Many other re­
ports have shown modulation of chemokine effects following protease processing. 
It was shown th a t CCL2 was cleaved by MMP1, 3 and 8 , CCL7 was cleaved by 
MMP3 and CCL13 was cleaved by MMP1 and 3 [McQuibban et al., 2002]. These 
authors further showed th a t the proteolytic cleavage took place on the N term inal 
part of the chemokine which resulted in the strong reduction of migration effect for 
CCL2  CCL8  and CCL13 on T H P 1 cells. W hether proteolytic cleavage of CCL2 
in the CNS might explain reduced CSF levels in MS remains to be determined.
All these findings reported in this thesis dem onstrate the complexity of regu­
lation of chemokine actions. This current study has indicated a number of mecha­
nisms which are potentially involved in vivo in MS CNS in controlling chemokine 
expression levels. However, further work is required to fully understand the in  
vivo processes.
6.2 Future work
Further work should include further characterization of D6  expression in vivo. 
The preliminary work performed in this thesis on hum an brain tissue sections
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was only to  determine whether D 6  was expressed in vivo and to  determine the 
cellular localization. To compare the level of D6  expression in lesions, NAWM 
and control brain, the ratio of white m atter/grey  m atter has to be characterised 
using a greater number of brain samples from MS lesion, NAWM and control, to 
quantitate differences in expression level.
The effect of proteases (MMP2, 9 and CD26), which are known to be up regu­
lated in the CNS lesions in MS, on CCL2  and CXCL10 should be determined. It 
would then be interesting to determine whether the affinity of cleaved CCL2 for 
D6  is affected. It would also be interesting to determine whether cleaved CCL2 
has a more potent effect on astrocytes by investigating the calcium mobilization 
and the phosphorylation of E rk l and 2  and Akt.
Study of the binding of CXCL10, as well as the cleaved CXCL10, would also 
give us greater insight into the differential regulation of chemokines by prim ary 
human astrocytes.
Binding of CXCL10 to tissue sections as well as potential binding to  decoy 
receptors such as DARC would also give greater understanding of the regulation 
of CXC chemokines in relation to MS. It would then be possible to compare 
findings for both  CCL2  and CXCL10 to enhance understanding of any differential 
control mechanisms.
234
Appendix
Paraformaldehyde (4 %):
solution A: dissolve 11.36 g Na2H P0 4  in 400 ml deionized water 
solution B: dissolve 3.2 g NaB^PC^. 2 H2O in 200 ml deionized water 
Mix solution A and B and pH was adjusted to 7.2 (0.2M phosphate buffer).
4 g of PFA (Sigma Aldrich, UK) were resuspended in 25 ml of deionized water. 
The solution was heated a t 60°C and NaOH (2 M) was added to  the solution until 
it was clear. Deionized water was added to have a final volume of 50 ml. Solution 
was filtered and 50 ml of 0.2M phosphate buffer was added to the filtered solution 
and the pH was adjusted at 7.2.
RNA loading buffer (6X):
60% Glycerol 
0.03% Bromophenol blue 
0.03% Xylene cyanole FF 
lOmM Tris/H Cl pH 7.6
Krebs HEPES:
Solution was composed of 134 mM NaCl, 4.7 mM KC1, 1.2 mM K H 2P04, 1.2 mM 
MgCU, 2.5 mM CaCU, 0.56 mM ascorbic acid, and 11  mM glucose.
Laemmli buffer
62.5mM Tris/HCL pH 6 .8 , 2%w/v SDS (BDH Chemicals, UK), 10% glycerol, 
50nM D TT, 0.01% w /v  bromophenol blue (Sigma, Aldrich, UK). Working solu­
tion used 2 x SDS sample buffer diluted in distilled water containing InM  ortho­
vanadate (phosphate inhibitor).
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Sudan black B
100ml of 70% ethanol was added to  0.15 g of Sudan black B (Sigma Aldrich, UK) 
and mixed for 1 h a t RT. Solution was incubated overnight at 4°C and filtered 
prior to use. The solution was stored at 4°C for up to 2  months.
Conferences attended
May 2005: MS Frontiers held in Edinburgh. Poster presented entitled: Cytokine 
regulation of CCL2 and CXCL10 expression by prim ary adult human astrocytes 
in vitro.
Dec 2005: British Society for Immunology held in Harrogate. Oral presentation 
was presented in the Neuroimmunology workshop entitled: Cytokine regulation 
of CCL2 and CXCL10 expression by primary human adult astrocytes in vitro.
Sept 2006: EFIS conference held in Paris. Poster presented entitled: In vitro 
characterization of chemokine receptor CCR2  and CXCR3 expression and ligand 
binding by prim ary hum an adult astrocytes.
May 07: National MS conference held in Sheffield. An award oral presentation 
was presented entitled: Chemokine CCL2 to prim ary adult hum an astrocytes is 
CCR2-independent: a new role for astrocytes in the regulation of inflammation.
June 07: MS Frontiers conference held in London. Poster was presented enti­
tled: CCL2 binding to prim ary adult human astrocytes is CCR2 -independent: a 
new role for astrocytes in the regulation of inflammation.
Sept 07: 8 th  European Meeting on Glial Cell Function in Health and Disease 
held in London. Poster presented entitled: Astrocytes regulate CCL2 level in 
CCR2-independent way.
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5.5 D iscussion
The decoy receptor D6  shares some similarities w ith conventional chemokine 
receptors. I t is a 7 transm em brane receptor th a t can bind chemokines [Fra et ah, 
2003, Locati et ah, 2005, Mantovani et al., 2006]. The D6  decoy receptor has 
some specificity in ligand binding, it binds only pro-inflammatory CC chemokines 
but not homeostatic CC chemokines or other chemokine families such as CXC 
chemokines [Fra et ah, 2003, Locati et ah, 2005, Mantovani et ah, 2006]. How­
ever, the D 6  decoy receptor lacks motifs in the second intracellular loop tha t 
transduce signalling events [Borroni et ah, 2006, Mantovani et ah, 2001, Nibbs 
et ah, 1997]. I t has been shown to be constitutively internalized to the cytoplasm 
independently of CC chemokine binding [Blackburn et ah 2004]. I t was further 
dem onstrated th a t the decoy receptor internalized CC chemokines and lead to 
their degradation in lysosomes [Galliera et ah, 2004, Weber et ah, 2004]. 
Evidence in mice has shown a role for D6  in regulating inflammation. A model 
of cutaneous inflammation in mice deficient for the D6  gene, suffered from aggra­
vated inflammation due to increased leukocyte invasion, necrosis and angiogenesis 
[Jamieson et ah, 2005, Martinez de la Torre et ah, 2007]. However, an unexpected 
resistance to EAE in D6  KO mice was observed due to an impaired encephalito- 
genic response [Liu et ah, 2006a].
The D 6  decoy receptor serves a regulatory function for CC chemokine ex­
pression a t sites of inflammation. D6  was shown to  be strongly expressed by 
endothelial cells in the lymphatic afferent vessels in the skin, gut and placenta 
as well as on circulating leukocytes at low levels [McKimmie and Graham, 2006, 
Nibbs et ah, 2001]. No studies to date have examined the expression of D 6  in 
human brain. To determine if D 6  was expressed in the CNS, it was assessed on 
astrocytes in vitro as well as on human brain tissue sections.
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5.5.1 D 6 m R N A  expression by unstim ulated  astrocytes  
using qR T -PC R
In this study, astrocytes have been shown to constitutivelyexpress D6  mRNA. 
Two reports on constitutive D6  mRNA expression by astrocytes were previously 
published [Zuurman et al., 2003, Neil et al., 2005]. Zuurman et al. (2003) showed 
th a t murine astrocytes did not express D6  mRNA using RT-PCR experiments 
whereas Neil et al. (2005) showed th a t prim ary human astrocytes constitutively 
expressed D6  mRNA using qRT-PCR. The discrepancy might be explained by 
the difference in the species of astrocytes. Indeed, Zuurm an et al. (2003) isolated 
astrocytes from cortex of mouse pups (<  day 1 ) whereas in this study and in the 
study by Neil et al. (2005), astrocytes were isolated from hum an brain.
5.5.2 D 6 m R N A  expression by astrocytes following pro- 
inflam m atory cytokine treatm ent using qR T -PC R
In this study, under pro-inflammatory conditions, astrocyte D 6  mRNA was 
significantly increased following IL1/? (33.5 ±  7.6 fold increase) and IFN 7  (28.1 ±  
13.9 fold increase) a t lOOng/ml compared to unstim ulated cells. Although TNF 
induced a 12 ±  5.2 fold increase in D6  mRNA expression it did not reach statis­
tical significance. No modulation of D6  mRNA was observed a t lower cytokine 
concentration. Since D6  has been shown to be involved in the clearance of CC 
chemokines, it is not surprising to observe an increase in D6 mRNA expression 
following cytokine stimulation, which also increased CCL2  mRNA expression as 
described in chapter 2. However, there was a large difference in D6  mRNA expres­
sion between cytokine stim ulation at 10 ng/m l and 100 ng/m l . This difference 
might be due to the fact th a t the characteristic dose response might be between 
these two concentrations. Thus further cytokine treatm ents (20 ng/m l, 40 ng/m l, 
60 ng/m l and 80 ng/m l) should be performed to determine if D 6  mRNA expression 
has a gradual increase in expression with increasing concentration of cytokines.
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5.5.3 D 6 protein  expression by astrocytes using w estern  
b lottin g  and flow cytom etry
To confirm the previous finding th a t astrocytes express D6  and to check if 
protein expression mirrored mRNA expression, western blotting as well as flow 
cytom etry experiments were performed on astrocytes. We report in this study 
th a t astrocytes expressed D6  using both methods. In western blot experiments 
for D6  receptor on proteins extracted from astrocytes, two bands of 53KDa and 
60KDa with similar intensity were obtained. The expected size for D6  receptor 
was 50 KDa [Blackburn et al., 2004] which supports the finding here of astrocyte 
expression of D6 . Since N-terminal sulphation of chemokine receptors has been 
reported and this post-translational modification is believed to be im portant for 
chemokine binding [Farzan et al., 1999, 2002], D 6  receptor might be modified in 
vivo which would yield a band at higher molecular weight (possibly 60KDa). Fur­
ther experiments to sequence proteins in these bands are required.
D6  expression by astrocytes was quantitated by flow cytometry. Astrocytes ex­
pressed D6  receptor at both  the cell surface and in the cytoplasmic compartment. 
However, only a small fraction of the to tal D6  was expressed at the cell surface (10 
and 16% for B327/01 and SMS-12 astrocyte preparations). This finding was also 
observed in other published studies. Blackburn et al. (2004) showed in transfected 
L I.2 pre B cells and human embryonic kidney (HEK) cells th a t only between 10 
to 20 % of D 6  was expressed at the cell surface. Similarly, Weber et al. (2004), 
investigating trafficking of D6  from the cell surface to the cytoplasm in HEK cells, 
found th a t only 5% of the to tal D6  was expressed a t the cell surface.
Astrocytes stim ulated with pro-inflammatory cytokines (lOOng/ml) showed no 
m odulation of the level of expression (IL1/?, 2.4 ±0.2 MFI, TNF, 3.1 ±  0.9 MFI 
and IFN 7 : 2.6 ±  0.3 MFI) compared to unstim ulated astrocytes (2.9 ±  0.4 MFI). 
We previously dem onstrated in Chapter 2  th a t pro-inflammatory cytokine stimula­
tion (lOOng/ml) induced an increase in CCL2 secretion, therefore D6  cell surface 
expression is unaffected by increasing concentrations of CCL2. These findings 
agreed with the study by Weber et al. (2004) where they showed th a t D 6  cell
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surface expression was unaffected following incubation with recombinant CCL3 
compared to  CCR5 which showed strong internalization. The ability of decoy 
receptors to actively remove CC chemokines from the extracellular milieu is due 
to a faster rate  of internalisation and recycling to the cell surface compared to 
functional receptors [Weber et al., 2004]. These findings suggest th a t the internal­
isation rate is an im portant factor in the regulation of the level of CC chemokines 
rather than  the actual cell surface expression which is unaffected following pro- 
inflammatory treatm ent.
The da ta  reported here are consistent with the fact th a t in vitro astrocytes ex­
press D 6  (mRNA and protein level). Moreover, for the detection of D6  protein, two 
different antibodies and two different staining procedures were used. The antibody 
used for flow cytom etry (R&D Systems) was a monoclonal antibody raised against 
human D6  transfected RBL-1 cells whereas the antibody for the western blot was 
obtained by injecting a synthetic peptide (C-LATEDADSENSSFYYYDYLDEVAFML), 
corresponding to  N term inal amino acids 10-35 of human D6  in goat.
To relate these in vitro findings to in vivo, expression of D6  was assessed 
in human brain tissue. Real time PC R  as well as western blotting showed the 
presence of D6  a t the mRNA and protein level in the brain of control, NAWM 
and MS lesions.
5.5.4 D 6 m R N A  expression in vivo using qR T -PC R
At the mRNA level, only L2  and L4 showed an increase in D 6  expression com­
pared to  control w ith a 1.6 ±  0.4 fold increase and 3.3 ±  0.5 fold increase. L4 block 
was shown to have limited demyelination and no apparent inflammation. Surpris­
ingly, L3 which showed a similar level of demyelination and no inflammation did 
not show any difference in D6  mRNA expression compared to the control. At 
the protein level, the band pattern  for western blotting was similar to th a t found 
for the astrocytes in vitro. Two bands of 49 and 58 KDa were detected, which
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suggested post-translational modification of D6 . The quantitative analysis of the 
blots, using actin to  normalize D6  expression, did not show any difference between 
control, MS and NAWM brain.
5.5.5 D 6 protein  expression in vivo using w estern b lotting
In this study, D6  was shown to be strongly expressed by neurons, present in 
the grey m atter (GM). Absence of staining was observed in the white m atter. It 
is therefore difficult to relate D6  expression with the level of inflammation in the 
white m atter (WM). I t was traditionally considered th a t MS is a demyelinating 
disease characterized by demyelinated plaques in the WM. However, pathology 
can be found in the deep cerebral nuclei and cerebral cortex [Cifelli et al., 2 0 0 2 , 
Kidd et al., 1999, Kutzelnigg et al., 2007]. Cortical lesions differ from the WM le­
sions by having demyelination w ithout an increase in lymphocyte count or altered 
distributions of subsets of lymphocytes compared to control. The authors con­
cluded th a t inflammation in the cortex is independent of lymphocytes [Bo et al., 
2003].
In this study, no assumption can be made on the comparison of the level of expres­
sion of D 6  in the WM between control, NAWM and lesion since the proportion 
of W M /G M  was not assessed. We can only conclude th a t D6 was detected at the 
mRNA and protein level within the brain and th a t D 6  was mainly detected in the 
GM. To be able to  accurately compare the level of expression of D6  in control, 
lesions and NAWM, the composition of W M /GM  should be determined as well 
as including a greater number of brains for each category (control, NAWM and 
lesion).
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5.5.6 D eterm ination  of cell types expressing D 6 in vivo 
using im m unohistochem istry
The fact th a t neurons express D6  might be a protective mechanism against 
CCL2 actions. I t was shown in an in vitro study th a t hippocampal neurons incu­
bated with CCL2 were subjected to apoptosis, which was inhibited by prior trea t­
ment w ith caspase 1 inhibitor [Kalehua et al., 2004]. This finding was confirmed in 
vivo by intrahippocam pal injection of CCL2 th a t induced neuronal death. There­
fore D 6  expression would render neurons less sensitive to CCL2 by removing CCL2 
in their close environment.
Images obtained by immunohistochemistry showed th a t D6  labelling was mainly 
associated with the cell body which seemed to  be, at higher magnification, a 
vesicular pattern , which may mean th a t it is mainly endoplasmic reticulum or an 
endosomal com partment. Similar staining was observed in studies by Blackburn 
et al. (2003) and Weber et al. (2003) where they found th a t both  the L I.2 cell 
line and HEK cells th a t expressed G FP-D 6  presented a granular distribution in 
the cells. Weber et al. (2003) further showed th a t the fusion protein, G FP-D 6 , 
colocalised w ith rab 5 and the transferrin receptor, which are markers for early 
and recycling endosomes.
We report here th a t D 6  expression was also associated w ith HLA-DR+ activated 
microglia/macrophages. Microglia have been shown to play a central role in MS 
pathogenesis. They are able to sense danger signals through the ligation of con­
served innate receptors such as Toll-like receptors (TLRs), which result in in­
creased expression of pro-inflammatory mediators such as chemokines [Jack et al., 
2005]. Microglia activate immune cells through their expression of MHC class 
II and co-stimulatory molecules [Rezaie and Male, 1999, Bechmann et al., 2001] 
resulting in an amplification of the inflammatory response in the CNS. Microglia 
cells have been shown to clear apoptotic cells and downregulate their APC abil­
ity, representing an active mechanism to limit the inflamm atory response th a t is 
characteristic of acute MS lesions [Magnus et al., 2001, Chan et al., 2003]. The 
fact th a t microglia express D6  would further support the finding th a t microglia
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cells act in controlling inflammation by regulating the level of pro-inflammatory 
CC chemokines.
Surprisingly, D6  expression was not associated with astrocytes. Although our in 
vitro da ta  are consistent with the fact th a t astrocytes express D 6  a t the mRNA 
level and protein level (using two different procedures), it did not correlate with 
the in vivo findings. The discrepancy might be due to  an in vitro artefact. In­
deed, evidence has been published on the discrepancy between in vitro and in 
vivo findings. T ian et al. (2004) compared gene expression of retinal pigment 
epithelial cells grown in different conditions and native R PE  using laser microdis­
section, using microarray analysis, which was further confirmed by qRT-PCR. 
They showed th a t cells grown in vitro had a significantly different overall gene 
expression compared to  native cells [Tian et al., 2004]. To confirm the fact th a t 
astrocytes express D 6  in vivo, laser microdissection with qRT-PCR would be the 
ideal procedure.
5.5.7 D eterm ination  of D 6 ability to  bind CCL2 in vivo 
using im m unohistochem istry
Many reports have shown th a t D6  binds various CC chemokines. We report 
in this study th a t CCL2  binding on human brain tissue sections showed a strong 
colocalisation with D6  expression (white pixels). However, some D 6 _ cells also 
had bound CCL2. Further investigation is needed to identify these cells by doing 
dual labelling with cellular markers such as GFAP, HLA-DR, CD3 (T-cells).
In C hapter 3, CCL2 binding was shown to be CCR2-independent in prim ary 
adult hum an astrocytes. The absence of activation of the common signal trans­
duction pathways for chemokine receptors and the expression of the D6  receptor in 
vitro might suggest a new regulatory function for hum an adult astrocytes during 
inflammation in MS by sequestration of chemokines released during inflamma­
tory cell recruitm ent . In  vivo, microglia and neurons expressed D 6 , which could 
contribute to the removal of CCL2 from the extracellular space, providing some
227
explanation for the decrease in CCL2 in the CSF at the tim e of relapse in MS 
patients [Mahad et al., 2002b, Narikawa et al., 2004, Scarpini et al., 2002], D6 
expression on astrocytes has to  be further investigated in vivo due to the failure 
to detect it on astrocytes in the current preliminary study.
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CHAPTER 6
General discussion
6.1 General discussion
The research question addressed in this thesis was the possible contribution of 
astrocytes to the differential expression of CCL2 and CXCL10 in the CSF in MS 
patients [Mahad et al., 2002b, Narikawa et a l ,  2004, Scarpini et al., 2 0 0 2 ]. Since 
both  chemokines are highly expressed in the CNS in active lesions, it was sur­
prising th a t CCL2  was decreased whereas CXCL10 was increased in MS patients. 
Thus the differences in relation to  synthesis of the 2 chemokines in response to 
inflammatory cytokines was investigated.
In this study, astrocytes were found to respond to  pro-inflammatory cytokine 
treatm ent by increasing synthesis and secretion of both  CCL2 and CXCL10. CCL2 
was more highly expressed than CXCL10 both at the mRNA and protein level. 
Thus, the reduced levels of CCL2 in the CSF during relapse in MS patients cannot 
be explained by an differential expression of CCL2  and CXCL10 by astrocytes. 
A second possible explanation may relate to the sequestration of CCL2  within 
the brain parenchyma. Thus CCR2 expression and CCL2 binding to  astrocytes 
in vitro was assessed. Although CCR2 mRNA was expressed by astrocytes, no 
protein was detected either a t the cell surface nor in the cytoplasmic com part­
ment. Since astrocytes showed the ability to bind CCL2, which was unaffected
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following cytokine treatm ent, and showed a complete absence of activation of both 
calcium flux and phosphorylation of Erk and Akt, it would appear th a t the bind­
ing of CCL2 was CCR2-independent. Therefore, CCL2 could bind either to decoy 
chemokine receptors or to  proteoglycans known ligand for CCL2 [Proudfoot et al.,
2003]. Astrocytes were shown to constitutively express D6  receptor at the mRNA 
(qRT-PCR) and protein (flow cytometry and western blot) level. The expression 
a t the cell surface was not modulated by pro-inflammatory cytokine treatm ent. 
Therefore in vitro da ta  might suggest th a t astrocytes regulate the level of CC 
chemokines through binding to the decoy chemokine receptor. Although mRNA 
and protein were not affected by cytokines, it remains to be investigated whether 
the rate  of recycling of D6  to  the surface is modulated.
Levels of chemokines can also be regulated by storage in intracellular stores 
th a t can be released rapidly following cell activation. It was shown th a t CD8 + T  
cells were able to release CCL5 from small vesicles following activation through 
the T  cell receptor [Catalfamo et al., 2004]. Similar findings were obtained with 
peripheral blood eosinophils [Lacy et al., 1999] who found th a t CCL5 released by 
eosinophils under IFN 7  stimulation was quicker than  expected reaching its max­
imal effect following 60 to 120 min treatm ent. Subcellular fractionation demon­
strated  th a t CCL5 was associated with small secretory vesicles, suggesting the 
presence of intracellular stores of CCL5.
Not only T  cells and eosinophils, ECs have also been shown to  store several 
chemokines such as CXCL8 , CXCL1 and CCL2 to  allow them  to respond quickly 
to stim ulation [Oynebraten et al., 2005]. It was proposed th a t CXCL8  storage in 
EC corresponds to a memory mechanism of preceding inflammatory conditions 
[Wolff et al., 1998]. Therefore, EC can respond to the next inflammatory insult 
w ithout the delay of de novo synthesis. These findings illustrate the existence 
of mechanisms th a t rapidly regulate the level of chemokines in the extracellular 
milieu.
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W hen chemokines are secreted, their diffusion is limited by GAGs. As previ­
ously said in section 1.4.6, GAGs are composed of long linear polysaccharides and 
a protein core [Johnson et al., 2005]. Since chemokines are prim arily basic and 
proteoglycans are highly negatively charged, it is not surprising to observe inter­
action between chemokines and proteoglycans. The interaction of chemokines and 
proteoglycans have been under investigation to  understand their role in chemokine 
regulation. I t was hypothesised th a t this interaction provides a mechanism th a t 
concentrates chemokine in a close environment, from the site of synthesis, to  re­
cruit immune cells to  the site of inflammation [Rot, 1992]. It was further demon­
strated  th a t this interaction is fundamental for chemokine function. M utations in 
the binding site for CCL2, CCL4 and CCL5 have been assessed in vitro and in vivo 
to determine the effect of proteoglycan on chemokine function. The chemotactic 
activity of the m utated chemokines was retained only in vitro and were unable to 
recruit any cells when injected intraperitoneally [Proudfoot et al., 2003]. The fact 
th a t chemokines can induce chemotactic effects on immune cells in vitro bu t not in  
vivo is not surprising as in vitro tests solely examine the effect on chemokines on 
recruitm ent of immune cells without consideration of flow conditions. Therefore, 
this study dem onstrates the importance of proteoglycans for the establishment 
and maintenance of chemokine gradient.
As discussed in section 1.4.6, proteoglycans possess some specificity for chemokines 
[Kuschert et al., 1999]. Therefore, cells th a t are producing proteoglycan might 
favour the formation of a specific gradient of a particular chemokine th a t will 
recruit a certain type of immune cells [Witt and Lander, 1994]. This specificity 
in binding of chemokines to proteoglycans controls the localisation of chemokines 
in tissues.
Existence of soluble GAGs which bind chemokines might m odulate the activity 
of chemokines although the data  to support this is controversial. It was demon­
strated  th a t heparin and heparan sulphate decreased the chemotactic effect of 
CXCL12 in vitro on acute lymphoblastic leukemia cell line [Murphy et al., 2007].
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This finding was confirmed by studies where co-incubation of soluble GAGs (hep­
arin) w ith chemokines resulted in a reduction in binding and a resultant effect on 
their functional effect on neutrophils and Chinese ham ster ovary K1 (CHO-K1) 
cells (CCL5, CCL3 and CXCL8 ) [Kuschert et al., 1999, M artin et al., 2001]. Con­
tradictory results were obtained with heparan sulphate [Netelenbos et al., 2002]. 
Incubation of myeloblastic CD34+ KG-1 cell line with increasing amounts of hep­
aran sulphate resulted in a significant increase in migration. Although there are 
obvious discrepancies in the effect of soluble GAGs on chemokine effects, it would 
appear th a t the chemokine activity can be m odulated by soluble GAGs.
Since chemokines exert their biological effect through GPCRs, it is not surpris­
ing th a t chemokine actions can be regulated by the regulation of their receptors. 
G PCRs can be desensitized, following binding of a chemokine receptor agonist and 
activation of signalling inactivation pathways. This mechanism is extremely rapid 
and is followed by endocytosis of the receptor, in less than  1 hour [Steele et al., 
2002]. This mechanism is im portant as it provides a tight mechanism of regulation 
th a t could be necessary during the chemotaxis of immune cells toward the inflam­
m ation site to  avoid over-stimulation of the receptor [Ferguson, 2001]. It was 
shown, for example, th a t the mono Mac 1 cell line strongly responded to  CCL2 
stim ulation by increasing calcium mobilization. However, a second stim ulation 
with CCL2 induced a decreased in calcium mobilization, suggesting desensitiza­
tion [Aragay et al., 1998]. This mechanism is regulated by the G PC R kinases 
(GRKs) and arrestins. The GRK family is composed of seven family members 
with four of them  ubiquitously expressed (2, 3, 5 and 6 ) whereas the arrestin fam­
ily is composed of two members with one ubiquitously expressed (Arrestin/22). 
The desensitization occurs following phosphorylation of the C term inal domain of 
the receptor by GRKs, inducing an increased affinity for arrestin. This interac­
tion results in the steric inhibition for further coupling of the receptor w ith the 
G protein rendering the receptor unresponsive to its ligand [Vroon et al., 2006, 
Pierce and Lefkowitz, 2001]. The GRK-arrestin complex promotes internalisation
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through clathrin pathways to  the endosome to degrade or resensitise the receptor 
[Pierce and Lefkowitz, 2001]. Thus desensitization is a rapid and effective mecha­
nism for regulating chemokine activity. Binding of chemokines to a decoy receptor 
is another mechanism th a t can quickly regulate the level of chemokines at the site 
of inflammation as discussed in the sections 5.1.1 and 1.4.4.1.
Finally, proteolysis of chemokines is another mechanism, which may regulate 
of chemokine activity. The NH2 part of the chemokine is im portant for the bind­
ing, hence why proteolytic cleavage can change the activity of chemokines [Proost 
et al., 2001]. I t was shown th a t the dipeptide peptidase IV (CD26) which cleaved 
CXCL8 , CXCL9 and CXCL10 induced a reduction in both  the migration effect 
and calcium mobilization on CXCR3 transfected CHO-K1 cells. Many other re­
ports have shown modulation of chemokine effects following protease processing. 
It was shown th a t CCL2  was cleaved by M M P1 , 3 and 8 , CCL7 was cleaved by 
MMP3 and CCL13 was cleaved by MMP1 and 3 [McQuibban et al., 2002]. These 
authors further showed th a t the proteolytic cleavage took place on the N term inal 
part of the chemokine which resulted in the strong reduction of migration effect for 
CCL2 CCL8  and CCL13 on THP1 cells. W hether proteolytic cleavage of CCL2 
in the CNS might explain reduced CSF levels in MS remains to be determined.
All these findings reported in this thesis dem onstrate the complexity of regu­
lation of chemokine actions. This current study has indicated a number of mecha­
nisms which are potentially involved in vivo in MS CNS in controlling chemokine 
expression levels. However, further work is required to fully understand the in  
vivo processes.
6.2 Future work
Further work should include further characterization of D6  expression in vivo. 
The preliminary work performed in this thesis on hum an brain tissue sections
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was only to determine whether D6  was expressed in  vivo and to  determine the 
cellular localization. To compare the level of D 6  expression in lesions, NAWM 
and control brain, the ratio of white m atter/grey  m atter has to be characterised 
using a greater number of brain samples from MS lesion, NAWM and control, to 
quantitate differences in expression level.
The effect of proteases (MMP2, 9 and CD26), which are known to be up regu­
lated in the CNS lesions in MS, on CCL2  and CXCL10 should be determined. It 
would then be interesting to  determine whether the affinity of cleaved CCL2 for 
D 6  is affected. I t would also be interesting to  determine whether cleaved CCL2 
has a more potent effect on astrocytes by investigating the calcium mobilization 
and the phosphorylation of E rk l and 2  and Akt.
Study of the binding of CXCL10, as well as the cleaved CXCL10, would also 
give us greater insight into the differential regulation of chemokines by prim ary 
human astrocytes.
Binding of CXCL10 to tissue sections as well as potential binding to decoy 
receptors such as DARC would also give greater understanding of the regulation 
of CXC chemokines in relation to MS. It would then be possible to  compare 
findings for both  CCL2 and CXCL10 to enhance understanding of any differential 
control mechanisms.
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A ppendix
Paraformaldehyde (4 %):
solution A: dissolve 11.36 g Na2H P0 4  in 400 ml deionized water 
solution B: dissolve 3.2 g NaH2P 0 4 . 2 H2O in 200 ml deionized water 
Mix solution A and B and pH was adjusted to 7.2 (0.2M phosphate buffer).
4 g of PFA (Sigma Aldrich, UK) were resuspended in 25 ml of deionized water. 
The solution was heated a t 60° C and NaOH (2M) was added to  the solution until 
it was clear. Deionized water was added to  have a final volume of 50 ml. Solution 
was filtered and 50 ml of 0.2M phosphate buffer was added to  the filtered solution 
and the pH was adjusted a t 7.2.
RNA loading buffer (6X):
60% Glycerol 
0.03% Bromophenol blue 
0.03% Xylene cyanole FF  
lOmM Tris/H Cl pH 7.6
Krebs HEPES:
Solution was composed of 134 mM NaCl, 4.7 mM KC1, 1.2 mM K H 2P04, 1.2 mM 
MgCU, 2.5 mM CaCU, 0.56 mM ascorbic acid, and 11  mM glucose.
Laemmli buffer
62.5mM Tris/HCL pH 6 .8 , 2%w/v SDS (BDH Chemicals, UK), 10% glycerol, 
50nM D TT, 0.01% w /v  bromophenol blue (Sigma, Aldrich, UK). Working solu­
tion used 2  x SDS sample buffer diluted in distilled water containing InM  ortho­
vanadate (phosphate inhibitor).
235
Sudan black B
100ml of 70% ethanol was added to  0.15 g of Sudan black B (Sigma Aldrich, UK) 
and mixed for 1 h a t RT. Solution was incubated overnight at 4°C and filtered 
prior to  use. The solution was stored at 4°C for up to  2  months.
Conferences attended
May 2005: MS Frontiers held in Edinburgh. Poster presented entitled: Cytokine 
regulation of CCL2 and CXCL10 expression by prim ary adult hum an astrocytes 
in vitro.
Dec 2005: British Society for Immunology held in Harrogate. Oral presentation 
was presented in the Neuroimmunology workshop entitled: Cytokine regulation 
of CCL2 and CXCL10 expression by primary human adult astrocytes in vitro.
Sept 2006: EFIS conference held in Paris. Poster presented entitled: In vitro 
characterization of chemokine receptor CCR2 and CXCR3 expression and ligand 
binding by prim ary human adult astrocytes.
May 07: National MS conference held in Sheffield. An award oral presentation 
was presented entitled: Chemokine CCL2 to prim ary adult hum an astrocytes is 
CCR2 -independent: a new role for astrocytes in the regulation of inflammation.
June 07: MS Frontiers conference held in London. Poster was presented enti­
tled: CCL2 binding to  prim ary adult human astrocytes is CCR2 -independent: a 
new role for astrocytes in the regulation of inflammation.
Sept 07: 8 th  European Meeting on Glial Cell Function in Health and Disease 
held in London. Poster presented entitled: Astrocytes regulate CCL2 level in 
CCR2-independent way.
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